{
  "usdmVersion": "4.0",
  "generatedAt": "2026-01-23T04:53:20.824154",
  "generator": "Protocol2USDM v6.5.0",
  "study": {
    "id": "c183d153-d18c-422f-8bf8-17726152abf0",
    "instanceType": "Study",
    "versions": [
      {
        "id": "a00103f4-627a-4d3a-9dbe-b3a022c61057",
        "instanceType": "StudyVersion",
        "versionIdentifier": "1.0",
        "studyDesigns": [
          {
            "id": "e0f1ec09-2ae6-4c75-b756-7db5bb3034d6",
            "name": "Study Design",
            "rationale": "Protocol-defined study design for investigating efficacy and safety",
            "instanceType": "InterventionalStudyDesign",
            "blindingSchema": {
              "id": "6789eede-ad58-4d81-8a53-e05e46c7088b",
              "standardCode": {
                "id": "37e96bf4-8919-4cb0-b47a-61417b7b789c",
                "code": "Single Blind",
                "codeSystem": "http://www.cdisc.org",
                "codeSystemVersion": "2024-09-27",
                "decode": "Single Blind",
                "instanceType": "Code"
              },
              "instanceType": "AliasCode"
            },
            "randomizationType": {
              "code": "Randomized"
            },
            "arms": [
              {
                "id": "c0aa64c9-d5f7-450b-842a-615016999ed8",
                "name": "Brolucizumab 6 mg",
                "instanceType": "StudyArm",
                "dataOriginDescription": "Collected",
                "description": "Intravitreal injection of 6 mg brolucizumab. Loading phase: 3 injections every 6 weeks (q6w) at Baseline, Week 6, and Week 12. Maintenance phase: q12w injections through Week 90, with potential extension up to q24w after Week 48.",
                "type": {
                  "id": "C174266",
                  "code": "C174266",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Investigational Arm",
                  "instanceType": "Code"
                },
                "dataOriginType": {
                  "id": "456d4cd3-aa7e-4c3b-ac68-f4580cbf8dd3",
                  "code": "C70793",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Collected",
                  "instanceType": "Code"
                }
              },
              {
                "id": "3422c1dd-4422-41f7-a0af-151afec761ab",
                "name": "Panretinal Photocoagulation (PRP)",
                "instanceType": "StudyArm",
                "dataOriginDescription": "Collected",
                "description": "Initial laser treatment in 1-4 sessions up to Week 12, followed by additional PRP treatment as needed up to Week 90.",
                "type": {
                  "id": "C174267",
                  "code": "C174267",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.12e",
                  "decode": "Active Comparator Arm",
                  "instanceType": "Code"
                },
                "dataOriginType": {
                  "id": "82f5782d-1d2b-491b-9c1c-4505139924a0",
                  "code": "C70793",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Collected",
                  "instanceType": "Code"
                }
              }
            ],
            "studyCohorts": [],
            "studyCells": [
              {
                "id": "7d7fb81e-542e-413d-b2c9-e93161ec6093",
                "armId": "c0aa64c9-d5f7-450b-842a-615016999ed8",
                "epochId": "5164e538-0f16-463b-bed3-624da550c9dd",
                "elementIds": [
                  "f2a1cd34-d33a-4147-b513-c59e7cc38831"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "5a8d85dd-bc3f-433b-bdb7-2eebcfab30f3",
                "armId": "c0aa64c9-d5f7-450b-842a-615016999ed8",
                "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e",
                "elementIds": [
                  "ccee3923-da07-4c3a-b0e7-e9355535894b"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "222c24e0-85f3-4bd7-9182-c4e55850153b",
                "armId": "c0aa64c9-d5f7-450b-842a-615016999ed8",
                "epochId": "93243f35-6c06-4826-af42-d53b369c07a4",
                "elementIds": [
                  "20d041d1-f7ae-4d13-8dea-6d437c603f5a"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "9c2df032-8e74-41ec-b76d-36ef481c030e",
                "armId": "3422c1dd-4422-41f7-a0af-151afec761ab",
                "epochId": "5164e538-0f16-463b-bed3-624da550c9dd",
                "elementIds": [
                  "6508be24-9923-4b3d-8aec-1a07bc8f8e57"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "539e7c3e-7833-4c90-9fa4-9d1bd42ad8c5",
                "armId": "3422c1dd-4422-41f7-a0af-151afec761ab",
                "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e",
                "elementIds": [
                  "fea30a1c-808d-488a-85a1-bf80f556a19c"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "51a6bf2a-ac8c-4e43-936c-f7cd67e67007",
                "armId": "3422c1dd-4422-41f7-a0af-151afec761ab",
                "epochId": "93243f35-6c06-4826-af42-d53b369c07a4",
                "elementIds": [
                  "2979ed45-903c-41ce-bf83-128b862fc4c1"
                ],
                "instanceType": "StudyCell"
              }
            ],
            "studyElements": [
              {
                "id": "f2a1cd34-d33a-4147-b513-c59e7cc38831",
                "name": "Brolucizumab 6 mg - Screening period",
                "instanceType": "StudyElement",
                "description": "Treatment period for Brolucizumab 6 mg during Screening period"
              },
              {
                "id": "ccee3923-da07-4c3a-b0e7-e9355535894b",
                "name": "Brolucizumab 6 mg - Single-masked treatment period",
                "instanceType": "StudyElement",
                "description": "Treatment period for Brolucizumab 6 mg during Single-masked treatment period"
              },
              {
                "id": "20d041d1-f7ae-4d13-8dea-6d437c603f5a",
                "name": "Brolucizumab 6 mg - Post-treatment follow-up period",
                "instanceType": "StudyElement",
                "description": "Treatment period for Brolucizumab 6 mg during Post-treatment follow-up period"
              },
              {
                "id": "6508be24-9923-4b3d-8aec-1a07bc8f8e57",
                "name": "Panretinal Photocoagulation (PRP) - Screening period",
                "instanceType": "StudyElement",
                "description": "Treatment period for Panretinal Photocoagulation (PRP) during Screening period"
              },
              {
                "id": "fea30a1c-808d-488a-85a1-bf80f556a19c",
                "name": "Panretinal Photocoagulation (PRP) - Single-masked treatment period",
                "instanceType": "StudyElement",
                "description": "Treatment period for Panretinal Photocoagulation (PRP) during Single-masked treatment period"
              },
              {
                "id": "2979ed45-903c-41ce-bf83-128b862fc4c1",
                "name": "Panretinal Photocoagulation (PRP) - Post-treatment follow-up period",
                "instanceType": "StudyElement",
                "description": "Treatment period for Panretinal Photocoagulation (PRP) during Post-treatment follow-up period"
              }
            ],
            "maskingRoles": [
              {
                "id": "b03f0ca9-6993-4570-bec6-250fbde3e235",
                "text": "Subject is masked in this Single Blind study",
                "isMasked": true,
                "instanceType": "Masking"
              },
              {
                "id": "8fe7a5e5-a642-4be1-9289-e017debabd99",
                "text": "Outcome Assessor is masked in this Single Blind study",
                "isMasked": true,
                "instanceType": "Masking"
              },
              {
                "id": "73e6f86e-9173-475b-bb46-aaed65874c20",
                "text": "Data Analyst is masked in this Single Blind study",
                "isMasked": true,
                "instanceType": "Masking"
              }
            ],
            "eligibilityCriteria": [
              {
                "id": "0c9160e7-ee07-4f84-9fe5-d731ab7d50b7",
                "identifier": "1",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "801ca5a1-1309-49ed-be97-a7f860a24030",
                "instanceType": "EligibilityCriterion",
                "name": "Informed Consent",
                "nextId": "57d469fc-33d4-4282-9d1c-18a224678f81"
              },
              {
                "id": "57d469fc-33d4-4282-9d1c-18a224678f81",
                "identifier": "2",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "fa564fe5-b1c7-4bfb-9d32-fa2ae6dff957",
                "instanceType": "EligibilityCriterion",
                "name": "Age Requirement",
                "previousId": "0c9160e7-ee07-4f84-9fe5-d731ab7d50b7",
                "nextId": "321297ab-416a-4271-8681-0adca39f47a4"
              },
              {
                "id": "321297ab-416a-4271-8681-0adca39f47a4",
                "identifier": "3",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "8358db14-fa05-42ae-9cb9-f0deb96f22e7",
                "instanceType": "EligibilityCriterion",
                "name": "Participant Cooperation",
                "previousId": "57d469fc-33d4-4282-9d1c-18a224678f81",
                "nextId": "cb649bf8-7bb6-4e29-b9d9-d7b11425e5e8"
              },
              {
                "id": "cb649bf8-7bb6-4e29-b9d9-d7b11425e5e8",
                "identifier": "4",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "d7a5342f-db3f-41ba-a50e-56ebf7bdb2c9",
                "instanceType": "EligibilityCriterion",
                "name": "Diabetes Diagnosis and HbA1c",
                "previousId": "321297ab-416a-4271-8681-0adca39f47a4",
                "nextId": "6e7cfd80-8a1b-433a-a89e-fc239d6e8a62"
              },
              {
                "id": "6e7cfd80-8a1b-433a-a89e-fc239d6e8a62",
                "identifier": "5",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "ae7cc9f5-dbb2-481e-976b-bb5bc85218bb",
                "instanceType": "EligibilityCriterion",
                "name": "Stable Diabetes Medication",
                "previousId": "cb649bf8-7bb6-4e29-b9d9-d7b11425e5e8",
                "nextId": "980a07f7-727f-495e-9d7e-b68c2352bd51"
              },
              {
                "id": "980a07f7-727f-495e-9d7e-b68c2352bd51",
                "identifier": "6",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "dbbc7db9-9e3b-491d-bdcb-c2e492f7eb96",
                "instanceType": "EligibilityCriterion",
                "name": "PDR Diagnosis Study Eye",
                "previousId": "6e7cfd80-8a1b-433a-a89e-fc239d6e8a62",
                "nextId": "d479763a-eb70-48f9-acb3-9b4e1d5c53f2"
              },
              {
                "id": "d479763a-eb70-48f9-acb3-9b4e1d5c53f2",
                "identifier": "7",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "d418a177-46ad-457f-b2f9-db4cbc05f744",
                "instanceType": "EligibilityCriterion",
                "name": "BCVA Requirement Study Eye",
                "previousId": "980a07f7-727f-495e-9d7e-b68c2352bd51"
              },
              {
                "id": "0643c5da-cc05-43df-9ca1-251d7f8b69ab",
                "identifier": "E1",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "b2fa5285-288b-4bf4-8084-90570630c4fb",
                "instanceType": "EligibilityCriterion",
                "name": "Concomitant Ocular Disorders",
                "nextId": "753cbeda-6a8d-440b-b9fd-a4c5d5287699"
              },
              {
                "id": "753cbeda-6a8d-440b-b9fd-a4c5d5287699",
                "identifier": "E2",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "1076ddfa-02b2-47e9-ba66-415244111151",
                "instanceType": "EligibilityCriterion",
                "name": "Center-involved DME",
                "previousId": "0643c5da-cc05-43df-9ca1-251d7f8b69ab",
                "nextId": "b7f3828e-8db4-40ad-a91f-c89e630e1373"
              },
              {
                "id": "b7f3828e-8db4-40ad-a91f-c89e630e1373",
                "identifier": "E3",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "ae05010b-184f-4d02-9195-3f3bf7f648b6",
                "instanceType": "EligibilityCriterion",
                "name": "Active Infection or Inflammation",
                "previousId": "753cbeda-6a8d-440b-b9fd-a4c5d5287699",
                "nextId": "b56c7b41-06d1-4ba6-b9e2-ef002972fff4"
              },
              {
                "id": "b56c7b41-06d1-4ba6-b9e2-ef002972fff4",
                "identifier": "E4",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "7a8837e9-879a-4c53-967d-712131c52339",
                "instanceType": "EligibilityCriterion",
                "name": "Uncontrolled Glaucoma",
                "previousId": "b7f3828e-8db4-40ad-a91f-c89e630e1373",
                "nextId": "0b020df8-89e1-4215-830f-9d3cbf92a7ef"
              },
              {
                "id": "0b020df8-89e1-4215-830f-9d3cbf92a7ef",
                "identifier": "E5",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "ffece53e-27cb-4136-9ed9-e028469c6e1a",
                "instanceType": "EligibilityCriterion",
                "name": "Vitreous Hemorrhage",
                "previousId": "b56c7b41-06d1-4ba6-b9e2-ef002972fff4",
                "nextId": "87d15599-8c39-4d1b-9e5a-f19c59cc3cc3"
              },
              {
                "id": "87d15599-8c39-4d1b-9e5a-f19c59cc3cc3",
                "identifier": "E6",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "ac6c1990-5f27-42c4-9d95-480732119ebd",
                "instanceType": "EligibilityCriterion",
                "name": "Vitreoretinal Proliferation",
                "previousId": "0b020df8-89e1-4215-830f-9d3cbf92a7ef",
                "nextId": "8606acc0-9f9c-4b2a-91ed-dd046d957da5"
              },
              {
                "id": "8606acc0-9f9c-4b2a-91ed-dd046d957da5",
                "identifier": "E7",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "8458b860-459c-4f86-99d5-0e79328c89d5",
                "instanceType": "EligibilityCriterion",
                "name": "Neovascularization",
                "previousId": "87d15599-8c39-4d1b-9e5a-f19c59cc3cc3",
                "nextId": "8c6143f3-cd56-4f17-a9fa-60ad2b322019"
              },
              {
                "id": "8c6143f3-cd56-4f17-a9fa-60ad2b322019",
                "identifier": "E8",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "6f57b856-4e64-45b2-a0e5-8fda06b858eb",
                "instanceType": "EligibilityCriterion",
                "name": "Fellow Eye Condition",
                "previousId": "8606acc0-9f9c-4b2a-91ed-dd046d957da5",
                "nextId": "f5fb821e-bd74-48b7-8a0b-6d13b1e23807"
              },
              {
                "id": "f5fb821e-bd74-48b7-8a0b-6d13b1e23807",
                "identifier": "E9",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "23fc461f-ef85-4d86-a4d6-7cee150e8f5c",
                "instanceType": "EligibilityCriterion",
                "name": "Prior PRP",
                "previousId": "8c6143f3-cd56-4f17-a9fa-60ad2b322019",
                "nextId": "688b7e5d-d9c8-4090-92d5-1ab14660c192"
              },
              {
                "id": "688b7e5d-d9c8-4090-92d5-1ab14660c192",
                "identifier": "E10",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "a0ce49be-2c41-4650-9a16-87062b8e691e",
                "instanceType": "EligibilityCriterion",
                "name": "Prior Anti-VEGF",
                "previousId": "f5fb821e-bd74-48b7-8a0b-6d13b1e23807",
                "nextId": "e13bcaf3-9af5-45ef-9c1e-7a98ee8cd5ed"
              },
              {
                "id": "e13bcaf3-9af5-45ef-9c1e-7a98ee8cd5ed",
                "identifier": "E11",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "757cda8d-6358-4055-af1c-55c9c7f1d04d",
                "instanceType": "EligibilityCriterion",
                "name": "Vitreoretinal Surgery",
                "previousId": "688b7e5d-d9c8-4090-92d5-1ab14660c192",
                "nextId": "0b023a90-7c0b-4d08-a167-9a93b620bc2e"
              },
              {
                "id": "0b023a90-7c0b-4d08-a167-9a93b620bc2e",
                "identifier": "E12",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "1b06ca6a-fada-4861-b245-2ace242ab601",
                "instanceType": "EligibilityCriterion",
                "name": "Macular Laser",
                "previousId": "e13bcaf3-9af5-45ef-9c1e-7a98ee8cd5ed",
                "nextId": "9e7628e1-c5ab-44bb-8fab-7e0f0441fba9"
              },
              {
                "id": "9e7628e1-c5ab-44bb-8fab-7e0f0441fba9",
                "identifier": "E13",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "771f2a2d-ffc2-40b6-817c-efd7c47d2fac",
                "instanceType": "EligibilityCriterion",
                "name": "Corticosteroid Implants",
                "previousId": "0b023a90-7c0b-4d08-a167-9a93b620bc2e",
                "nextId": "1b59378d-3aab-444e-b8cf-f81a3c11e8bc"
              },
              {
                "id": "1b59378d-3aab-444e-b8cf-f81a3c11e8bc",
                "identifier": "E14",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "e3969fc0-56fc-4059-bcdd-b015bbdf9ae3",
                "instanceType": "EligibilityCriterion",
                "name": "Aphakia",
                "previousId": "9e7628e1-c5ab-44bb-8fab-7e0f0441fba9",
                "nextId": "dd7db6ae-b064-4336-9274-fd1eabcb901b"
              },
              {
                "id": "dd7db6ae-b064-4336-9274-fd1eabcb901b",
                "identifier": "E15",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "13d33052-011e-4d39-a881-104f718b63c6",
                "instanceType": "EligibilityCriterion",
                "name": "Intraocular Surgery",
                "previousId": "1b59378d-3aab-444e-b8cf-f81a3c11e8bc",
                "nextId": "583619fb-6fa2-4128-8383-9b38ba05f258"
              },
              {
                "id": "583619fb-6fa2-4128-8383-9b38ba05f258",
                "identifier": "E16",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "59644ecb-2a92-4a9d-b93f-4819bb43ad2f",
                "instanceType": "EligibilityCriterion",
                "name": "Stroke or MI",
                "previousId": "dd7db6ae-b064-4336-9274-fd1eabcb901b",
                "nextId": "37df5861-70b1-40c0-a497-b082140d3486"
              },
              {
                "id": "37df5861-70b1-40c0-a497-b082140d3486",
                "identifier": "E17",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "36c1363e-a5d4-40e1-8f0d-e1ff0d0539b7",
                "instanceType": "EligibilityCriterion",
                "name": "Renal Disease",
                "previousId": "583619fb-6fa2-4128-8383-9b38ba05f258",
                "nextId": "56654c37-e355-4115-b283-95b01578e6e3"
              },
              {
                "id": "56654c37-e355-4115-b283-95b01578e6e3",
                "identifier": "E18",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "83155406-a857-4e94-9940-8de01d932d76",
                "instanceType": "EligibilityCriterion",
                "name": "Uncontrolled Blood Pressure",
                "previousId": "37df5861-70b1-40c0-a497-b082140d3486",
                "nextId": "6fabc5be-5416-4632-bc1b-8b3d9b7ab082"
              },
              {
                "id": "6fabc5be-5416-4632-bc1b-8b3d9b7ab082",
                "identifier": "E19",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "2ae12695-0378-41cc-8f04-fe10352c9e3b",
                "instanceType": "EligibilityCriterion",
                "name": "Systemic Anti-VEGF",
                "previousId": "56654c37-e355-4115-b283-95b01578e6e3",
                "nextId": "c43fcf08-e5f0-4955-99fb-ad524acbb6a4"
              },
              {
                "id": "c43fcf08-e5f0-4955-99fb-ad524acbb6a4",
                "identifier": "E20",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "1092f6b5-34ca-451d-b857-dbaa0a844be3",
                "instanceType": "EligibilityCriterion",
                "name": "Toxic Systemic Medications",
                "previousId": "6fabc5be-5416-4632-bc1b-8b3d9b7ab082",
                "nextId": "ba0828e2-5bb4-4ae7-92ba-f937f3e34c22"
              },
              {
                "id": "ba0828e2-5bb4-4ae7-92ba-f937f3e34c22",
                "identifier": "E21",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "0240fe08-4453-4251-9ceb-98528d0a5387",
                "instanceType": "EligibilityCriterion",
                "name": "Hypersensitivity",
                "previousId": "c43fcf08-e5f0-4955-99fb-ad524acbb6a4",
                "nextId": "ee49aa8b-e669-498c-8d4f-451b7c699477"
              },
              {
                "id": "ee49aa8b-e669-498c-8d4f-451b7c699477",
                "identifier": "E22",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "a75064ff-fb75-4c0a-8647-92286325b106",
                "instanceType": "EligibilityCriterion",
                "name": "History of Malignancy",
                "previousId": "ba0828e2-5bb4-4ae7-92ba-f937f3e34c22",
                "nextId": "a5756ceb-3fd2-4bbd-b282-b961dfdde60b"
              },
              {
                "id": "a5756ceb-3fd2-4bbd-b282-b961dfdde60b",
                "identifier": "E23",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "a96d22bb-7edd-44a4-91cc-9e5f9bdc643d",
                "instanceType": "EligibilityCriterion",
                "name": "General Medical Condition",
                "previousId": "ee49aa8b-e669-498c-8d4f-451b7c699477",
                "nextId": "f573374a-5ec9-45bb-bb9d-284e3c96c41f"
              },
              {
                "id": "f573374a-5ec9-45bb-bb9d-284e3c96c41f",
                "identifier": "E24",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "fcf26105-865f-497e-abe2-b3425d2d7b1e",
                "instanceType": "EligibilityCriterion",
                "name": "Investigational Drugs",
                "previousId": "a5756ceb-3fd2-4bbd-b282-b961dfdde60b",
                "nextId": "f9230ca8-12ab-4621-bf1e-c7b4c01ba646"
              },
              {
                "id": "f9230ca8-12ab-4621-bf1e-c7b4c01ba646",
                "identifier": "E25",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "11d668c1-025e-4b20-9d22-eb58097d8e43",
                "instanceType": "EligibilityCriterion",
                "name": "Pregnancy and Nursing",
                "previousId": "f573374a-5ec9-45bb-bb9d-284e3c96c41f",
                "nextId": "73b7e37e-984d-489d-a054-8f4896763b46"
              },
              {
                "id": "73b7e37e-984d-489d-a054-8f4896763b46",
                "identifier": "E26",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "2a7626b1-cd8c-4643-9e93-3bdf3a983169",
                "instanceType": "EligibilityCriterion",
                "name": "Contraception Requirements",
                "previousId": "f9230ca8-12ab-4621-bf1e-c7b4c01ba646"
              }
            ],
            "population": {
              "id": "773b74d2-0f25-40f4-9381-17ec2898db34",
              "name": "Study Population",
              "includesHealthySubjects": false,
              "criterionIds": [
                "0c9160e7-ee07-4f84-9fe5-d731ab7d50b7",
                "57d469fc-33d4-4282-9d1c-18a224678f81",
                "321297ab-416a-4271-8681-0adca39f47a4",
                "cb649bf8-7bb6-4e29-b9d9-d7b11425e5e8",
                "6e7cfd80-8a1b-433a-a89e-fc239d6e8a62",
                "980a07f7-727f-495e-9d7e-b68c2352bd51",
                "d479763a-eb70-48f9-acb3-9b4e1d5c53f2",
                "0643c5da-cc05-43df-9ca1-251d7f8b69ab",
                "753cbeda-6a8d-440b-b9fd-a4c5d5287699",
                "b7f3828e-8db4-40ad-a91f-c89e630e1373",
                "b56c7b41-06d1-4ba6-b9e2-ef002972fff4",
                "0b020df8-89e1-4215-830f-9d3cbf92a7ef",
                "87d15599-8c39-4d1b-9e5a-f19c59cc3cc3",
                "8606acc0-9f9c-4b2a-91ed-dd046d957da5",
                "8c6143f3-cd56-4f17-a9fa-60ad2b322019",
                "f5fb821e-bd74-48b7-8a0b-6d13b1e23807",
                "688b7e5d-d9c8-4090-92d5-1ab14660c192",
                "e13bcaf3-9af5-45ef-9c1e-7a98ee8cd5ed",
                "0b023a90-7c0b-4d08-a167-9a93b620bc2e",
                "9e7628e1-c5ab-44bb-8fab-7e0f0441fba9",
                "1b59378d-3aab-444e-b8cf-f81a3c11e8bc",
                "dd7db6ae-b064-4336-9274-fd1eabcb901b",
                "583619fb-6fa2-4128-8383-9b38ba05f258",
                "37df5861-70b1-40c0-a497-b082140d3486",
                "56654c37-e355-4115-b283-95b01578e6e3",
                "6fabc5be-5416-4632-bc1b-8b3d9b7ab082",
                "c43fcf08-e5f0-4955-99fb-ad524acbb6a4",
                "ba0828e2-5bb4-4ae7-92ba-f937f3e34c22",
                "ee49aa8b-e669-498c-8d4f-451b7c699477",
                "a5756ceb-3fd2-4bbd-b282-b961dfdde60b",
                "f573374a-5ec9-45bb-bb9d-284e3c96c41f",
                "f9230ca8-12ab-4621-bf1e-c7b4c01ba646",
                "73b7e37e-984d-489d-a054-8f4896763b46"
              ],
              "instanceType": "StudyDesignPopulation",
              "description": "Target population defined by eligibility criteria"
            },
            "objectives": [
              {
                "id": "aae7a136-0669-45d6-9124-2666d4488f4b",
                "name": "Primary Efficacy Objective",
                "text": "To demonstrate that brolucizumab is non-inferior to PRP with respect to the change from Baseline in visual acuity at Week 54 by assessing the change from Baseline in best corrected visual acuity (BCVA) at Week 54",
                "level": {
                  "id": "C85826",
                  "code": "C85826",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Primary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "edecd821-b3e5-488a-a04c-775a3ebdc222"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "b8338579-d1dd-4b43-afe8-c5887f08717a",
                "name": "Secondary Efficacy Objective - DR Severity",
                "text": "To demonstrate that brolucizumab is superior to PRP in reducing diabetic retinopathy (DR) severity after 54 weeks of treatment by assessing the proportion of subjects with no PDR at Week 54",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "f89a855e-7968-45d1-945a-94eccb167877"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "a2e25a11-e75d-43b0-a952-a4078b847003",
                "name": "Secondary Efficacy Objective - DME Prevention",
                "text": "To demonstrate that brolucizumab is superior to PRP in preventing the development of center-involved diabetic macular edema (DME) up to Week 54 by assessing the proportion of subjects with center-involved DME up to Week 54",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "51573948-eb72-42be-8804-024e145fd136"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "9b0d6b17-60e3-4a91-bc10-f07f52ee74cd",
                "name": "Secondary Efficacy Objective - Visual Acuity AUC",
                "text": "To compare the effect of brolucizumab relative to PRP with respect to visual acuity by assessing the area under the curve in change from Baseline in BCVA up to Week 54 and Week 96",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "b866a553-5bdf-442a-9807-b68c4e61f498"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "d5d59f30-e738-44e6-86ef-af8a3e8f4717",
                "name": "Secondary Efficacy Objective - DR Status",
                "text": "To compare the effect of brolucizumab relative to PRP on DR status by assessing the change from Baseline in ETDRS diabetic retinopathy severity scale (DRSS) score at Week 54 and Week 96 and the proportion of subjects with no PDR at Week 96",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "bed8e368-7a42-4380-ae0f-7a5de94db6d5",
                  "7bc2b811-a606-480c-980f-9fa0d985bd7c"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "b097dcfd-12db-4867-9bfb-efc1f9cbcd7d",
                "name": "Secondary Efficacy Objective - Ocular Complications",
                "text": "To compare the effect of brolucizumab relative to PRP on ocular complications by assessing the proportion of subjects developing vision-threatening complications associated with DR up to Week 54 and Week 96 and the proportion of subjects with center-involved DME up to Week 96",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "9d976ae2-ad28-4faa-82cb-10e468339705",
                  "d426023c-fb83-41ae-8070-1538fc287881"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "325f9f11-5832-45b7-a881-669f6ad7e6ca",
                "name": "Secondary Safety Objective",
                "text": "To assess the safety and tolerability of brolucizumab relative to PRP",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "7d35a4a8-a5e7-4808-b838-99237ddce2ac"
                ],
                "instanceType": "Objective"
              }
            ],
            "endpoints": [
              {
                "id": "edecd821-b3e5-488a-a04c-775a3ebdc222",
                "name": "Primary Efficacy Endpoint",
                "text": "Change from Baseline in BCVA at Week 54",
                "level": {
                  "id": "C98772",
                  "code": "C98772",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Primary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "f89a855e-7968-45d1-945a-94eccb167877",
                "name": "Secondary Efficacy Endpoint - No PDR at Week 54",
                "text": "Proportion of subjects with no PDR at Week 54",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "51573948-eb72-42be-8804-024e145fd136",
                "name": "Secondary Efficacy Endpoint - DME up to Week 54",
                "text": "Proportion of subjects with center-involved DME up to Week 54",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "b866a553-5bdf-442a-9807-b68c4e61f498",
                "name": "Secondary Efficacy Endpoint - BCVA AUC",
                "text": "Area under the curve in change from Baseline in BCVA up to Week 54 and Week 96",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "bed8e368-7a42-4380-ae0f-7a5de94db6d5",
                "name": "Secondary Efficacy Endpoint - DRSS Score",
                "text": "Change from Baseline in ETDRS Diabetic Retinopathy Severity Scale (DRSS) score at Week 54 and Week 96",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "7bc2b811-a606-480c-980f-9fa0d985bd7c",
                "name": "Secondary Efficacy Endpoint - No PDR at Week 96",
                "text": "Proportion of subjects with no PDR at Week 96",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "9d976ae2-ad28-4faa-82cb-10e468339705",
                "name": "Secondary Efficacy Endpoint - Vision-threatening Complications",
                "text": "Proportion of study eyes developing vision-threatening complications associated with diabetic retinopathy up to Week 54 and Week 96",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "d426023c-fb83-41ae-8070-1538fc287881",
                "name": "Secondary Efficacy Endpoint - DME up to Week 96",
                "text": "Proportion of subjects with center-involved DME up to Week 96",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "7d35a4a8-a5e7-4808-b838-99237ddce2ac",
                "name": "Secondary Safety Endpoint",
                "text": "Incidence of ocular and non-ocular adverse events (AE) up to Week 54 and Week 96",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Safety"
              }
            ],
            "estimands": [
              {
                "id": "870c5840-3d8d-4602-be6a-f320aef82a32",
                "name": "Primary Efficacy Estimand",
                "populationSummary": "Adult patients with proliferative diabetic retinopathy (PDR) and BCVA â‰¥ 34 ETDRS letters Summary measure: Difference in least squares means.",
                "analysisPopulationId": "f6d624fe-effd-400e-b464-440d30df826a",
                "variableOfInterestId": "edecd821-b3e5-488a-a04c-775a3ebdc222",
                "interventionIds": [
                  "17539617-1604-4114-8d46-c38f793dbac7"
                ],
                "intercurrentEvents": [
                  {
                    "id": "004bf071-d52b-4661-89b8-c9fad9b20ddf",
                    "name": "Alternative DR/DME treatment",
                    "text": "Application of alternative diabetic retinopathy or diabetic macular edema treatments to the study eye",
                    "strategy": "Hypothetical",
                    "instanceType": "IntercurrentEvent"
                  },
                  {
                    "id": "4733b243-cce9-41b2-8ffa-71a68d5601bc",
                    "name": "Treatment discontinuation",
                    "text": "Permanent discontinuation of study treatment prior to Week 54",
                    "strategy": "Treatment Policy",
                    "instanceType": "IntercurrentEvent"
                  }
                ],
                "instanceType": "Estimand",
                "treatment": "Brolucizumab 6 mg (3 x q6w loading then q12w maintenance) vs Panretinal photocoagulation (PRP)",
                "analysisPopulation": "Adult patients with proliferative diabetic retinopathy (PDR) and BCVA â‰¥ 34 ETDRS letters",
                "variableOfInterest": "Change from Baseline in BCVA at Week 54",
                "summaryMeasure": "Difference in least squares means"
              },
              {
                "id": "e9efa19a-95a4-4c3b-9aa3-d47ca0c740b1",
                "name": "First Key Secondary Estimand",
                "populationSummary": "Adult patients with proliferative diabetic retinopathy (PDR) and BCVA â‰¥ 34 ETDRS letters Summary measure: Odds ratio or risk difference.",
                "analysisPopulationId": "80226673-bd3f-4a21-833f-1c720b0bb6d7",
                "variableOfInterestId": "f89a855e-7968-45d1-945a-94eccb167877",
                "interventionIds": [
                  "f483c47a-4d04-4b9f-824a-3020ac88b7b2"
                ],
                "intercurrentEvents": [
                  {
                    "id": "1dc5a841-4463-4d75-8678-ce69231abf85",
                    "name": "Death",
                    "text": "Death of the subject prior to Week 54",
                    "strategy": "Composite",
                    "instanceType": "IntercurrentEvent"
                  }
                ],
                "instanceType": "Estimand",
                "treatment": "Brolucizumab 6 mg vs Panretinal photocoagulation (PRP)",
                "analysisPopulation": "Adult patients with proliferative diabetic retinopathy (PDR) and BCVA â‰¥ 34 ETDRS letters",
                "variableOfInterest": "Proportion of subjects with no PDR (DRSS score < 61) at Week 54",
                "summaryMeasure": "Odds ratio or risk difference"
              },
              {
                "id": "e0c89a60-86f5-47da-b9aa-3d117aeebf26",
                "name": "DME Prevention Estimand",
                "populationSummary": "Adult patients with PDR and no center-involved DME at baseline Summary measure: Odds ratio or risk difference.",
                "analysisPopulationId": "371ce3ce-a26b-46df-b564-ecd5a99292a1",
                "variableOfInterestId": "51573948-eb72-42be-8804-024e145fd136",
                "interventionIds": [
                  "5d67b4a2-0522-499d-94b2-e053ca09f2c2"
                ],
                "intercurrentEvents": [
                  {
                    "id": "71bde386-a23a-4d9a-9be1-39205cb189fb",
                    "name": "Treatment discontinuation due to AE",
                    "text": "Discontinuation of treatment due to adverse events (e.g., retinal vasculitis)",
                    "strategy": "Treatment Policy",
                    "instanceType": "IntercurrentEvent"
                  }
                ],
                "instanceType": "Estimand",
                "treatment": "Brolucizumab 6 mg vs Panretinal photocoagulation (PRP)",
                "analysisPopulation": "Adult patients with PDR and no center-involved DME at baseline",
                "variableOfInterest": "Proportion of subjects with center-involved DME up to Week 54",
                "summaryMeasure": "Odds ratio or risk difference"
              }
            ],
            "scheduleTimelines": [
              {
                "id": "14c4a0c4-2ff1-4801-bb91-8d3b560a21e6",
                "name": "Main Schedule Timeline",
                "mainTimeline": true,
                "instanceType": "ScheduleTimeline",
                "entryCondition": "Subject enrolled in study",
                "entryId": "0db13622-74aa-4c1c-957d-d92cb51da497",
                "instances": [
                  {
                    "id": "0db13622-74aa-4c1c-957d-d92cb51da497",
                    "activityIds": [
                      "0f81063d-2fee-4aa3-9392-16ec686db9c1"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_1@enc_1",
                    "encounterId": "56bcafbc-fd80-4e1a-815f-0a9d35f3ad33",
                    "epochId": "5164e538-0f16-463b-bed3-624da550c9dd"
                  },
                  {
                    "id": "0fef1d17-62f3-4d7f-8a68-95ea00cd770f",
                    "activityIds": [
                      "a93b3967-4d03-4c22-b2ca-9268caa6d32c"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_2@enc_1",
                    "encounterId": "56bcafbc-fd80-4e1a-815f-0a9d35f3ad33",
                    "epochId": "5164e538-0f16-463b-bed3-624da550c9dd"
                  },
                  {
                    "id": "9137fe4c-bfc8-4708-9d50-79dc16b24b57",
                    "activityIds": [
                      "a93b3967-4d03-4c22-b2ca-9268caa6d32c"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_2@enc_2",
                    "encounterId": "454ac12d-e0cc-4fc1-a841-a2f31385e659",
                    "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e"
                  },
                  {
                    "id": "531fd735-a3b5-4268-bf7d-c4b081713689",
                    "activityIds": [
                      "07cd1d20-b48c-4045-81e3-374bb56a2292"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_3@enc_1",
                    "encounterId": "56bcafbc-fd80-4e1a-815f-0a9d35f3ad33",
                    "epochId": "5164e538-0f16-463b-bed3-624da550c9dd"
                  },
                  {
                    "id": "f6b4e857-fa42-4279-bff7-b36e78919476",
                    "activityIds": [
                      "e8583088-9dcd-4e47-93cd-3eaedfcc4d79"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_4@enc_1",
                    "encounterId": "56bcafbc-fd80-4e1a-815f-0a9d35f3ad33",
                    "epochId": "5164e538-0f16-463b-bed3-624da550c9dd"
                  },
                  {
                    "id": "8afd3720-3144-49d8-8cf4-6bd4ced433d3",
                    "activityIds": [
                      "06211281-bfd6-4df3-ae14-1737e96f567b"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_5@enc_1",
                    "encounterId": "56bcafbc-fd80-4e1a-815f-0a9d35f3ad33",
                    "epochId": "5164e538-0f16-463b-bed3-624da550c9dd"
                  },
                  {
                    "id": "18189554-ed33-4311-b6e2-a2b3b051ab89",
                    "activityIds": [
                      "06211281-bfd6-4df3-ae14-1737e96f567b"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_5@enc_2",
                    "encounterId": "454ac12d-e0cc-4fc1-a841-a2f31385e659",
                    "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e"
                  },
                  {
                    "id": "c128342c-fa7d-49cc-92e6-edac19bd9164",
                    "activityIds": [
                      "bdf42c26-c7bc-4de3-bb70-685ff9cd9d69"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_2",
                    "encounterId": "454ac12d-e0cc-4fc1-a841-a2f31385e659",
                    "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e"
                  },
                  {
                    "id": "5a90bf1f-a06e-4651-943a-8cde7134e5b9",
                    "activityIds": [
                      "99549801-e757-4a91-b44f-0aa6fac8d1ca"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_7@enc_1",
                    "encounterId": "56bcafbc-fd80-4e1a-815f-0a9d35f3ad33",
                    "epochId": "5164e538-0f16-463b-bed3-624da550c9dd"
                  },
                  {
                    "id": "a4c081aa-1122-4a9b-9d6b-fb43be538b9f",
                    "activityIds": [
                      "99549801-e757-4a91-b44f-0aa6fac8d1ca"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_7@enc_2",
                    "encounterId": "454ac12d-e0cc-4fc1-a841-a2f31385e659",
                    "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e"
                  },
                  {
                    "id": "0e49e6db-f2cd-4397-a406-2ebe7bd689a9",
                    "activityIds": [
                      "a2af2a6b-8cb9-4630-9af0-8fbf4e0b1a69"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_10@enc_1",
                    "encounterId": "56bcafbc-fd80-4e1a-815f-0a9d35f3ad33",
                    "epochId": "5164e538-0f16-463b-bed3-624da550c9dd"
                  },
                  {
                    "id": "55a6b0b4-2099-4d46-aadc-901e1d26db28",
                    "activityIds": [
                      "a2af2a6b-8cb9-4630-9af0-8fbf4e0b1a69"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_10@enc_2",
                    "encounterId": "454ac12d-e0cc-4fc1-a841-a2f31385e659",
                    "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e"
                  },
                  {
                    "id": "c0264df7-e767-44d3-ab0b-651d208b5317",
                    "activityIds": [
                      "fb2bbbd7-5ddc-40fe-9829-940df3c9e047"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_11@enc_1",
                    "encounterId": "56bcafbc-fd80-4e1a-815f-0a9d35f3ad33",
                    "epochId": "5164e538-0f16-463b-bed3-624da550c9dd"
                  },
                  {
                    "id": "e8779ae7-fe5b-440e-b154-2532c6bdb8d1",
                    "activityIds": [
                      "fb2bbbd7-5ddc-40fe-9829-940df3c9e047"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_11@enc_2",
                    "encounterId": "454ac12d-e0cc-4fc1-a841-a2f31385e659",
                    "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e"
                  },
                  {
                    "id": "be83e78e-463d-4ffe-b791-093cd1c0c5db",
                    "activityIds": [
                      "55a85e0c-efcd-4680-a788-a90f73bb4c24"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_14@enc_1",
                    "encounterId": "56bcafbc-fd80-4e1a-815f-0a9d35f3ad33",
                    "epochId": "5164e538-0f16-463b-bed3-624da550c9dd"
                  },
                  {
                    "id": "85c54cd7-47fb-4c2d-a911-21015a88e300",
                    "activityIds": [
                      "ac513318-abc5-4141-97c6-e922393ca390"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_15@enc_1",
                    "encounterId": "56bcafbc-fd80-4e1a-815f-0a9d35f3ad33",
                    "epochId": "5164e538-0f16-463b-bed3-624da550c9dd"
                  },
                  {
                    "id": "24929f4b-6420-405f-8760-82969bb727f6",
                    "activityIds": [
                      "5d1c5b41-cd18-4a78-b14a-4ef7f70bb526"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_16@enc_1",
                    "encounterId": "56bcafbc-fd80-4e1a-815f-0a9d35f3ad33",
                    "epochId": "5164e538-0f16-463b-bed3-624da550c9dd"
                  },
                  {
                    "id": "ad733d0f-a992-4334-ac2e-2b8e370cef70",
                    "activityIds": [
                      "3cc4c6ef-f64e-40ee-84ee-8225667a3235"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_17@enc_4",
                    "encounterId": "7105a3e9-5dc3-4367-981e-1e6fe115f7e9",
                    "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e"
                  },
                  {
                    "id": "746b4ab5-20f8-49aa-9f0c-f09d4b823254",
                    "activityIds": [
                      "f57dc500-305f-4a92-9cc7-614edab72c86"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_18@enc_2",
                    "encounterId": "454ac12d-e0cc-4fc1-a841-a2f31385e659",
                    "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e"
                  },
                  {
                    "id": "019c3d53-93a2-451c-b2f5-b8d22038bd9e",
                    "activityIds": [
                      "f57dc500-305f-4a92-9cc7-614edab72c86"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_18@enc_3",
                    "encounterId": "11ffdb60-2db0-4639-9254-8e1827bd535e",
                    "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e"
                  },
                  {
                    "id": "911c6522-43c5-4061-a1f0-a139c5156868",
                    "activityIds": [
                      "f57dc500-305f-4a92-9cc7-614edab72c86"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_18@enc_4",
                    "encounterId": "7105a3e9-5dc3-4367-981e-1e6fe115f7e9",
                    "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e"
                  },
                  {
                    "id": "094bdaad-fe4b-49b4-b607-cea0bda8403b",
                    "activityIds": [
                      "a6b93991-ae32-4b7a-b202-4feca0790ead"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_19@enc_2",
                    "encounterId": "454ac12d-e0cc-4fc1-a841-a2f31385e659",
                    "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e"
                  },
                  {
                    "id": "cb4f2e41-616c-468f-a2ad-6cabbac2d7ab",
                    "name": "InformedConsent",
                    "description": "Event anchor: InformedConsent",
                    "activityIds": [
                      "0f81063d-2fee-4aa3-9392-16ec686db9c1"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "2c84fbe4-7343-48c3-b844-6a5d858241d3",
                        "url": "http://example.org/usdm/anchorClassification",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "Event"
                      },
                      {
                        "id": "5ed60d6c-f2de-4c5d-8bbf-db7b08d9cfce",
                        "url": "http://example.org/usdm/intraDayOrder",
                        "instanceType": "ExtensionAttribute",
                        "valueInteger": 10
                      }
                    ],
                    "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e",
                    "scheduledDay": 1
                  },
                  {
                    "id": "a181804b-7308-44f3-85a7-bd2bf4ddafac",
                    "name": "Screening",
                    "description": "Visit anchor: Screening",
                    "encounterId": "454ac12d-e0cc-4fc1-a841-a2f31385e659",
                    "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "2c84fbe4-7343-48c3-b844-6a5d858241d3",
                        "url": "http://example.org/usdm/anchorClassification",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "Visit"
                      },
                      {
                        "id": "5ed60d6c-f2de-4c5d-8bbf-db7b08d9cfce",
                        "url": "http://example.org/usdm/intraDayOrder",
                        "instanceType": "ExtensionAttribute",
                        "valueInteger": 20
                      }
                    ],
                    "scheduledDay": 1
                  },
                  {
                    "id": "8700462d-ad7d-47ab-a161-70460564ee86",
                    "name": "Randomization",
                    "description": "Event anchor: Randomization",
                    "activityIds": [
                      "bdf42c26-c7bc-4de3-bb70-685ff9cd9d69"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "2c84fbe4-7343-48c3-b844-6a5d858241d3",
                        "url": "http://example.org/usdm/anchorClassification",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "Event"
                      },
                      {
                        "id": "5ed60d6c-f2de-4c5d-8bbf-db7b08d9cfce",
                        "url": "http://example.org/usdm/intraDayOrder",
                        "instanceType": "ExtensionAttribute",
                        "valueInteger": 40
                      }
                    ],
                    "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e",
                    "scheduledDay": 1
                  },
                  {
                    "id": "12b02fcd-6733-49fe-9b1e-2ced876d7cc2",
                    "name": "Baseline",
                    "description": "Visit anchor: Baseline",
                    "encounterId": "454ac12d-e0cc-4fc1-a841-a2f31385e659",
                    "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "2c84fbe4-7343-48c3-b844-6a5d858241d3",
                        "url": "http://example.org/usdm/anchorClassification",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "Visit"
                      },
                      {
                        "id": "5ed60d6c-f2de-4c5d-8bbf-db7b08d9cfce",
                        "url": "http://example.org/usdm/intraDayOrder",
                        "instanceType": "ExtensionAttribute",
                        "valueInteger": 50
                      }
                    ],
                    "scheduledDay": 1
                  },
                  {
                    "id": "3fba07a4-75a8-44a9-a43c-e766590a3f53",
                    "name": "Anchor: Standard Visit Window",
                    "activityIds": [],
                    "encounterId": "454ac12d-e0cc-4fc1-a841-a2f31385e659",
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "c29e48df-66fe-4af4-86ff-a3d5492d1b30",
                        "url": "http://example.org/usdm/instanceSource",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "execution_model"
                      },
                      {
                        "id": "8414de39-39ac-4012-b5ff-076145e9b8fe",
                        "url": "http://example.org/usdm/anchorClassification",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "Visit"
                      }
                    ],
                    "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e"
                  },
                  {
                    "id": "16cf7bd7-0dfa-4d22-b730-3b368bdf6eb6",
                    "name": "Anchor: End of Study Visit",
                    "activityIds": [],
                    "encounterId": "454ac12d-e0cc-4fc1-a841-a2f31385e659",
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "5da05231-0fe0-4dc8-a8e5-64d8750fe19b",
                        "url": "http://example.org/usdm/instanceSource",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "execution_model"
                      },
                      {
                        "id": "f4f68715-05ad-4c3a-b171-89fb7fbc1242",
                        "url": "http://example.org/usdm/anchorClassification",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "Visit"
                      }
                    ],
                    "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e"
                  },
                  {
                    "id": "f49b374a-a7e2-428c-a185-f65b5952b1f2",
                    "name": "Anchor: Safety Follow-up Call",
                    "activityIds": [],
                    "encounterId": "454ac12d-e0cc-4fc1-a841-a2f31385e659",
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "7e4e9014-1da5-4804-8459-32208fb9a6fc",
                        "url": "http://example.org/usdm/instanceSource",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "execution_model"
                      },
                      {
                        "id": "836a26e8-ecc9-460a-aaa0-e151fa568a83",
                        "url": "http://example.org/usdm/anchorClassification",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "Visit"
                      }
                    ],
                    "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e"
                  }
                ],
                "timings": [
                  {
                    "id": "ce956b38-8679-4426-a6de-70b04783d652",
                    "name": "Screening Window",
                    "type": {
                      "id": "723ad6bf-ba83-4166-b55c-cdf6e0fb6a76",
                      "code": "C71151",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Within",
                      "instanceType": "Code"
                    },
                    "value": "P21D",
                    "valueLabel": "Day 21",
                    "relativeToFrom": {
                      "id": "728b479c-8ae4-419e-bc5b-bf7ccbfcdf3c",
                      "code": "C71159",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Baseline",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "a181804b-7308-44f3-85a7-bd2bf4ddafac",
                    "instanceType": "Timing",
                    "windowLower": "-P21D",
                    "windowUpper": "-P1D"
                  },
                  {
                    "id": "386a68f3-9a14-4151-a901-252f3c2d24b6",
                    "name": "Standard Visit Window",
                    "type": {
                      "id": "57bf9089-d25a-4a4b-85a9-6d5d21c69cbf",
                      "code": "C71148",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Fixed Reference",
                      "instanceType": "Code"
                    },
                    "value": "P7D",
                    "valueLabel": "Day 7",
                    "relativeToFrom": {
                      "id": "291bab46-63ef-4175-a468-ee2438248cb4",
                      "code": "C71157",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Previous Visit",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "3fba07a4-75a8-44a9-a43c-e766590a3f53",
                    "instanceType": "Timing",
                    "windowLower": "-P7D",
                    "windowUpper": "P7D"
                  },
                  {
                    "id": "24a9048b-df5f-4b29-a026-2c3e1892873f",
                    "name": "Treatment Administration Window",
                    "type": {
                      "id": "6f64c830-5598-487a-b2f3-7c8bb72b6886",
                      "code": "C71150",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "After",
                      "instanceType": "Code"
                    },
                    "value": "P3D",
                    "valueLabel": "Day 3",
                    "relativeToFrom": {
                      "id": "c6abf735-a13b-47ce-8ba0-082999970066",
                      "code": "C71157",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Previous Visit",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "c7eb5cb1-bc06-460c-ba81-ad5625655bed",
                    "instanceType": "Timing",
                    "windowLower": "P0D",
                    "windowUpper": "P3D"
                  },
                  {
                    "id": "23b47344-0018-4af1-bf75-38d0619df0be",
                    "name": "Minimum Brolucizumab Interval",
                    "type": {
                      "id": "1622110c-b2ae-44c1-9083-7fe0c8b51673",
                      "code": "C71150",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "After",
                      "instanceType": "Code"
                    },
                    "value": "P21D",
                    "valueLabel": "Day 21",
                    "relativeToFrom": {
                      "id": "e94c0e7b-195f-4237-b504-56161f4b9130",
                      "code": "C71157",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Previous Visit",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "931f056d-2e03-405b-89d0-cf4edc2ff23a",
                    "instanceType": "Timing",
                    "windowLower": "P21D",
                    "windowUpper": "P0D"
                  },
                  {
                    "id": "b32cc29d-2650-4d2b-96b8-a5865b3fd9ab",
                    "name": "End of Study Visit",
                    "type": {
                      "id": "78fbf9b6-d4be-4098-a4c1-02a8fd4c24e3",
                      "code": "C71148",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Fixed Reference",
                      "instanceType": "Code"
                    },
                    "value": "P6W",
                    "valueLabel": "6 weeks",
                    "relativeToFrom": {
                      "id": "88619572-9b21-48c1-9c40-cc106bac9714",
                      "code": "C71156",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Last Dose",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "16cf7bd7-0dfa-4d22-b730-3b368bdf6eb6",
                    "instanceType": "Timing",
                    "windowLower": "-P7W",
                    "windowUpper": "P7W"
                  },
                  {
                    "id": "6def56dc-2436-462e-9f5a-9692bb231357",
                    "name": "Safety Follow-up Call",
                    "type": {
                      "id": "1b287865-6e21-4145-8822-6dfbf955dcf2",
                      "code": "C71150",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "After",
                      "instanceType": "Code"
                    },
                    "value": "P30D",
                    "valueLabel": "Day 30",
                    "relativeToFrom": {
                      "id": "80739439-dd27-43a5-ba46-e93bc111ea6d",
                      "code": "C71156",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Last Dose",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "f49b374a-a7e2-428c-a185-f65b5952b1f2",
                    "instanceType": "Timing",
                    "windowLower": "P30D",
                    "windowUpper": "P30D"
                  }
                ],
                "exits": [
                  {
                    "id": "88e699a6-e9c0-4038-b0fc-ea30d40cd2c2",
                    "name": "Withdrawal of Consent",
                    "exitType": "Early Termination",
                    "instanceType": "ScheduleTimelineExit",
                    "description": "Participant explicitly requests to stop use of data/samples and stop treatment"
                  },
                  {
                    "id": "eff518c6-24bb-494a-8674-9e2e94687a1d",
                    "name": "Study Completion",
                    "exitType": "Completion",
                    "instanceType": "ScheduleTimelineExit",
                    "description": "Last randomized subject finishes EOS visit at Week 96"
                  },
                  {
                    "id": "f84e8fd0-d599-4d53-9552-98cf88f3ed3d",
                    "name": "Sponsor Termination",
                    "exitType": "Early Termination",
                    "instanceType": "ScheduleTimelineExit",
                    "description": "Novartis may terminate the study at any time for safety, practical, or regulatory reasons"
                  }
                ]
              }
            ],
            "encounters": [
              {
                "id": "56bcafbc-fd80-4e1a-815f-0a9d35f3ad33",
                "name": "Screening (Day -21 to Day -1)",
                "instanceType": "Encounter",
                "type": {
                  "id": "96199f93-3009-4ba3-a581-a59660f434da",
                  "code": "C98779",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Screening Visit",
                  "instanceType": "Code"
                },
                "epochId": "5164e538-0f16-463b-bed3-624da550c9dd",
                "extensionAttributes": [
                  {
                    "id": "2046d392-29a8-42f6-88d9-fc220ebf9f33",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "a04d540b-e305-4928-9516-57345c24d9c1",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "8665567a-a8f3-43d1-a5f0-74235e97e670",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyDay",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": -21
                  }
                ]
              },
              {
                "id": "454ac12d-e0cc-4fc1-a841-a2f31385e659",
                "name": "Day 1 (Baseline)",
                "instanceType": "Encounter",
                "type": {
                  "id": "c2df368f-f7c1-4586-bb0f-5fdfb6ad6cfa",
                  "code": "C142615",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Baseline Visit",
                  "instanceType": "Code"
                },
                "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e",
                "extensionAttributes": [
                  {
                    "id": "15fb72ea-a9a2-418c-9baa-0a1b70f6eb8e",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "26df53ae-d2df-4e5b-852d-df33b8357480",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "4c3da75b-2678-4dfd-bac2-874679f65563",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyDay",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 1
                  }
                ]
              },
              {
                "id": "11ffdb60-2db0-4639-9254-8e1827bd535e",
                "name": "Week 6",
                "instanceType": "Encounter",
                "type": {
                  "id": "20b9573c-bf86-496e-b9a6-289eec92ba88",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e",
                "extensionAttributes": [
                  {
                    "id": "747e8d16-307e-4e21-8e1f-911986f3586e",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "ed15db63-ae58-40b7-8237-034d41059e1f",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "fc304ef1-91f7-4435-bde3-1ba35b27b2b2",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 6
                  }
                ]
              },
              {
                "id": "7105a3e9-5dc3-4367-981e-1e6fe115f7e9",
                "name": "Week 12",
                "instanceType": "Encounter",
                "type": {
                  "id": "08f6f04e-f94f-4668-ae37-c7d78a65ac3a",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e",
                "extensionAttributes": [
                  {
                    "id": "da5672e2-c007-4700-a7fc-f88c4a021d69",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "1698c9ef-e07d-43fc-82ab-27f8b61f1d69",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "857493ab-71fc-4fe6-ae92-d526b2a7e1ec",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 12
                  }
                ]
              },
              {
                "id": "16555e80-7792-49db-ab8e-58feec8df8bb",
                "name": "Week 18",
                "instanceType": "Encounter",
                "type": {
                  "id": "6c68d23f-dac5-45c3-af26-7a8a3c8d9b9b",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e",
                "extensionAttributes": [
                  {
                    "id": "16dd3f6e-759d-4f60-8f8f-83dc63a8f203",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "d53cd233-5865-4f56-ace3-9b7e683474e4",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "c09604f7-8778-48fe-bbe5-bb0229889a64",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 18
                  }
                ]
              },
              {
                "id": "027c9c93-7589-4914-a9e2-b8c8139b947f",
                "name": "Week 24",
                "instanceType": "Encounter",
                "type": {
                  "id": "b1d92733-72bb-4719-8be2-4f65b6b4c900",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e",
                "extensionAttributes": [
                  {
                    "id": "5515b91d-6116-4d00-b572-ca6eb7a1a578",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "3350933a-c36b-436b-a192-b291bb2b43e6",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "c1082b01-1f4b-406b-b346-8599506219ac",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 24
                  }
                ]
              },
              {
                "id": "f715863a-b9dc-4edf-8863-6b99140710ed",
                "name": "Week 30",
                "instanceType": "Encounter",
                "type": {
                  "id": "da26c501-0a61-4204-bd90-830c7a933d2c",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e",
                "extensionAttributes": [
                  {
                    "id": "5597637c-488f-4fa5-a9a2-c19ebf51e6ae",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "ce502df3-0ddb-4e64-9e59-8a67fbf433f0",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "3bc7e91b-6b8c-4e43-97c5-f011aced8932",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 30
                  }
                ]
              },
              {
                "id": "ee199fb4-7b63-4354-b3a6-f52427ba758d",
                "name": "Week 36",
                "instanceType": "Encounter",
                "type": {
                  "id": "229d28b6-658f-4b8d-8517-4f13728045e8",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e",
                "extensionAttributes": [
                  {
                    "id": "247e38d2-05c1-47d8-a072-03d01a62ba3a",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "cac1c3b7-6ccc-4ef9-ae58-6a65b02442b1",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "86de951f-3a52-4951-8820-df63770fb29c",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 36
                  }
                ]
              },
              {
                "id": "d1fd0f89-8c44-4e45-9ade-2983029f6c77",
                "name": "Week 42",
                "instanceType": "Encounter",
                "type": {
                  "id": "9fa03b28-df8f-4b30-970f-5c494c75d2c7",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e",
                "extensionAttributes": [
                  {
                    "id": "32044158-9253-4b81-b70f-ea9e2bea7e09",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "f1a2fcf2-f815-4fec-a717-a90ae1ed26e6",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "7f14c344-c33b-47d3-ad1e-b72a505cffec",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 42
                  }
                ]
              },
              {
                "id": "13d783a6-3ca1-4f04-9d16-b56c5c3ece12",
                "name": "Week 48",
                "instanceType": "Encounter",
                "type": {
                  "id": "d09d156c-2af6-4712-befb-cc96132a7668",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e",
                "extensionAttributes": [
                  {
                    "id": "aa0282d2-1696-4af3-af96-ae0f25039950",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "6938dc78-df85-4fd6-83f6-b98ce662d573",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "d07e1531-232b-4078-905b-eb31dbee4f62",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 48
                  }
                ]
              },
              {
                "id": "6d60bf87-159d-4aa5-99f6-8f51041a4f41",
                "name": "Week 54 (Primary Endpoint)",
                "instanceType": "Encounter",
                "type": {
                  "id": "4bf71f77-c3ce-45cd-8b75-0d7e03ccdd06",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e",
                "extensionAttributes": [
                  {
                    "id": "6fb8fba9-f3dd-43de-ad59-73a46e68312d",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "e49a4008-564a-4ecb-93c2-25b5946c651a",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "30d7b778-364d-4332-a0d9-f07876524201",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 54
                  }
                ]
              },
              {
                "id": "c1f60812-70b0-4ec8-9e6f-063ca1c41935",
                "name": "Week 60",
                "instanceType": "Encounter",
                "type": {
                  "id": "350bfe08-f0ff-4cdd-80d1-c146cce5d603",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e",
                "extensionAttributes": [
                  {
                    "id": "76070968-1ddd-4072-a908-28d3b2e84e6e",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "38ef94ff-e33a-46b4-ad4a-9edfb8f03f31",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "7ff2a739-c0b6-461d-a761-c9adde520d09",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 60
                  }
                ]
              },
              {
                "id": "a5c33cbb-f2bb-4147-8e1e-f1e24f7b0396",
                "name": "Week 66",
                "instanceType": "Encounter",
                "type": {
                  "id": "8e8e4f84-4aa5-4d8e-9c60-4e4d81381679",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e",
                "extensionAttributes": [
                  {
                    "id": "7db678af-8c5e-45b1-9cab-6a58d6466ef0",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "874851c2-d91a-45b6-b62c-1cd38c2c9d3b",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "b2404154-87fd-477a-8f73-207c9b6fca62",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 66
                  }
                ]
              },
              {
                "id": "1106865e-d127-4c51-8c83-f83bab4d3cb9",
                "name": "Week 72",
                "instanceType": "Encounter",
                "type": {
                  "id": "248147ed-01e7-4e68-a0f2-d8e7c8e0593c",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e",
                "extensionAttributes": [
                  {
                    "id": "4a298b5c-79c6-4b83-ac4a-6ba6e4142b49",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "2d36ae58-c38b-4ff6-82bf-5f0a2d113a7a",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "68829d23-bcb6-48e8-aeda-97119060d9c4",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 72
                  }
                ]
              },
              {
                "id": "78de961b-68a5-43a0-8ad5-b4a1783e2a72",
                "name": "Week 78",
                "instanceType": "Encounter",
                "type": {
                  "id": "03b36643-1090-4478-96dd-01c81ec92368",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e",
                "extensionAttributes": [
                  {
                    "id": "ba83f9fe-ec80-483e-84a8-a4965573a088",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "b1911221-36ef-4bbc-a02f-38f70895ff40",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "7cdab870-89e7-40d3-b78d-7d97368dadbc",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 78
                  }
                ]
              },
              {
                "id": "35d151bd-720a-4cc8-b9b1-4c6ffdc1e5f3",
                "name": "Week 84",
                "instanceType": "Encounter",
                "type": {
                  "id": "006c00ff-4767-4872-bf08-a662d6ff24b5",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e",
                "extensionAttributes": [
                  {
                    "id": "694424dc-c6d3-457e-bcae-5dd964b420ab",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "e847900a-666c-48df-b23d-a043f2e86481",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "449c84e3-f029-49d8-ad44-93e6e8d3be32",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 84
                  }
                ]
              },
              {
                "id": "4c965055-884c-44de-9cb7-6388931488d7",
                "name": "Week 90 (End of Treatment)",
                "instanceType": "Encounter",
                "type": {
                  "id": "57a45f09-a1c1-4fc4-baba-7c31695bf112",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Visit",
                  "instanceType": "Code"
                },
                "epochId": "fae44b45-d641-4d65-ae99-44b681ec569e",
                "extensionAttributes": [
                  {
                    "id": "67226ef1-ba38-437a-b4ce-9b4e17878bb6",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "2133c470-2ab2-4976-80b1-ab2ccb8cd391",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "24143f67-2e0d-449a-8ee8-bf7f6c3042cf",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 90
                  }
                ]
              },
              {
                "id": "208fe5e8-df00-47df-b412-ac02044987e1",
                "name": "Week 96 (End of Study)",
                "instanceType": "Encounter",
                "type": {
                  "id": "bc59ae78-eff8-4ff4-a4bc-b83c6f7909ce",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "End of Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "93243f35-6c06-4826-af42-d53b369c07a4",
                "extensionAttributes": [
                  {
                    "id": "93a786c1-bf65-40aa-9091-fe8185db9abd",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "f32b6635-8725-49e1-9aa2-2bae66593073",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "096ee8ac-8379-4d14-8831-a54b1ffa890f",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyWeek",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 96
                  }
                ]
              }
            ],
            "activities": [
              {
                "id": "55a85e0c-efcd-4680-a788-a90f73bb4c24",
                "name": "7-Field CFP",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "80fff0bc-5e2c-456a-9bc3-cbd5961d9912",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "1510239f-0171-4e1f-a341-c85fa329fd3b",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "e36ff14b-9c75-49ce-a2c7-bacc4ecab309",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "1366d19a-c35a-4055-8fce-06d8b10fc6fd",
                "name": "Adverse Events",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "684e894a-b28b-473e-a670-51eb8c29f1cc",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "3d504c51-f8b9-42a8-a9cd-5df8db18be19",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "8906dc61-f870-4940-9764-41673ae82538",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "a2af2a6b-8cb9-4630-9af0-8fbf4e0b1a69",
                "name": "BCVA",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "f9cf5bab-b52b-449b-ab94-21411b59f23e",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "ecef845d-d40c-4815-99bc-6598a6286a6d",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "90f34f6d-7619-43c7-bf4c-f7c1d935a150",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "530993a4-e50d-4de8-9079-3a8f0d8b4057",
                "name": "Best Corrected Visual Acuity",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "530993a4-e50d-4de8-9079-3a8f0d8b4057",
                    "name": "Best Corrected Visual Acuity",
                    "procedureType": "Assessment",
                    "code": {
                      "id": "3c15a44a-e7b7-4c40-8b67-dec4dd0ba2f5",
                      "code": "92015",
                      "codeSystem": "CPT",
                      "codeSystemVersion": "",
                      "decode": "Determination of refractive state",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "BCVA",
                    "description": "Assessment of visual acuity using ETDRS-like charts"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "744a444f-17cf-49f4-bc6c-3c2f4f5806f1",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "ed08aa17-5018-4a40-85f7-e84b8597a767",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "db8974ab-8d27-4de9-b027-105bbdfe04e2",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "f57dc500-305f-4a92-9cc7-614edab72c86",
                "name": "Brolucizumab 6 mg Injection",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "93fd77cb-cbe8-4bed-bfa1-4c55bcb9774b",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "8a3a5d04-0dec-48b4-833a-744136caf598",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "administration"
                  },
                  {
                    "id": "a4398dc9-f7c3-4261-808f-155e81787cf3",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "02d055a1-9ede-4538-9078-7cc44b787f2d",
                "name": "Color fundus photography",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "02d055a1-9ede-4538-9078-7cc44b787f2d",
                    "name": "Color fundus photography",
                    "procedureType": "Imaging Technique",
                    "code": {
                      "id": "f9379cb2-9ea9-4ee0-9330-30220cc30777",
                      "code": "92250",
                      "codeSystem": "CPT",
                      "codeSystemVersion": "",
                      "decode": "Fundus photography with interpretation and report",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "CFP",
                    "description": "Imaging of the retina using 7-field or wide field photography"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "82698471-a54a-4e99-b702-1cfb7dbfabe1",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "bbdf56a7-b0a4-4f9e-958f-515d7208238a",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "3e1b1995-a445-4ca6-9a46-df40762bec62",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "07cd1d20-b48c-4045-81e3-374bb56a2292",
                "name": "Demographics",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "71772434-8ddd-4a44-84b4-98426509bd0a",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "36c77fad-1de0-41ff-91d7-38cef5df1138",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "97a92acd-1ffe-4303-9523-687de9e9872d",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "4801cecb-d61e-41a3-a4c7-328942132ca2",
                "name": "Dilated Fundus Examination",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "3f5f23fb-aee7-43d8-8d7a-161d32faadc5",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "2310de09-a40b-4c36-898f-31e4832218f0",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "0bb3a693-d0c0-472c-bac3-c139234e513c",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "3cc4c6ef-f64e-40ee-84ee-8225667a3235",
                "name": "Disease Activity Assessment",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "ac53fa73-c9c1-42e4-8e13-a6cbb27abc74",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "235e12b4-113f-4cc2-bf66-cf9665095256",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "7537d34c-070a-445a-aacf-1aeaf18ebb4c",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "ac513318-abc5-4141-97c6-e922393ca390",
                "name": "FA",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "d191b915-4891-4c80-a45b-7f5c1ee218f8",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "a8300f0a-8f13-46a6-a31b-4f25500e1411",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "cd290092-c3b8-46cc-bb7b-c79943155e8a",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "f2708245-e9bc-47e5-b6f2-71c394102e16",
                "name": "Fluorescein angiography",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "f2708245-e9bc-47e5-b6f2-71c394102e16",
                    "name": "Fluorescein angiography",
                    "procedureType": "Imaging Technique",
                    "code": {
                      "id": "c2284d96-9f2b-4e9e-b655-98b71f3b8789",
                      "code": "92235",
                      "codeSystem": "CPT",
                      "codeSystemVersion": "",
                      "decode": "Fluorescein angiography with interpretation and report",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "FA",
                    "description": "Diagnostic imaging of retinal blood flow using fluorescein dye"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "352e2750-bdf7-4c1d-a9da-e265739e203a",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "53531bc3-3725-42ea-b02e-39cefd605d4c",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "887c40a2-36a4-44f4-9dde-7d03bbb04cf3",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "fb2bbbd7-5ddc-40fe-9829-940df3c9e047",
                "name": "IOP",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "86c24dc0-4173-499f-93c9-5b8d518ba2eb",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "0d446a37-b090-4251-8a8b-4df9ead67975",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "99ed9d9c-38a3-4f9a-a810-9d4ed8f3ebb8",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "a93b3967-4d03-4c22-b2ca-9268caa6d32c",
                "name": "Inclusion / Exclusion Criteria",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "b1b464a2-6082-4241-8f4d-a96fa7adafdb",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "462c6982-b099-450c-befc-6bb65756c572",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "1b1e8fe6-cfec-402c-ab57-84161188d47d",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "0f81063d-2fee-4aa3-9392-16ec686db9c1",
                "name": "Informed Consent",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "971f7635-9637-4d0e-b788-efb74393390c",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "e13e1267-f5aa-432b-9b4c-64b946f0c7ad",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "documentation"
                  },
                  {
                    "id": "70c66587-26cc-466b-b216-1f7e289744b0",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "faebc258-5b74-4378-8f7b-916e025ed1f8",
                "name": "Intraocular pressure measurement",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "faebc258-5b74-4378-8f7b-916e025ed1f8",
                    "name": "Intraocular pressure measurement",
                    "procedureType": "Monitoring",
                    "code": {
                      "id": "fe77b1a0-6ecc-4ba4-9975-9e52921da52c",
                      "code": "92100",
                      "codeSystem": "CPT",
                      "codeSystemVersion": "",
                      "decode": "Serial tonometry with medical interpretation and report",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "IOP Measurement",
                    "description": "Measurement of pressure within the eye post-injection"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "42a8f745-f84c-441a-bc6a-1020f70fbd4c",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "a3cb25f7-20ee-4eaf-97f6-bc62c950c71d",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "2eb9501d-0a0f-4d83-8abb-d80588499316",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "9145e8fd-8bc4-46aa-8f31-e694af06c7c9",
                "name": "Intravitreal injection",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "9145e8fd-8bc4-46aa-8f31-e694af06c7c9",
                    "name": "Intravitreal injection",
                    "procedureType": "Therapeutic Procedure",
                    "code": {
                      "id": "7ea64c00-8241-458a-af10-f25f281331ef",
                      "code": "67028",
                      "codeSystem": "CPT",
                      "codeSystemVersion": "",
                      "decode": "Intravitreal injection of a pharmacologic agent",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "IVT Injection",
                    "description": "Administration of brolucizumab into the vitreous of the eye"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "42f0423d-f62f-415a-9a94-b7a8d0a5ca94",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "1fbe5815-c188-4ab4-b9cb-17d553fe5368",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "1e60a1bf-3b01-4f39-993f-78b586cb23f7",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "7ed6b2dd-b9ac-4569-a332-b7c527e83e79",
                "name": "Laboratory evaluation",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "7ed6b2dd-b9ac-4569-a332-b7c527e83e79",
                    "name": "Laboratory evaluation",
                    "procedureType": "Biospecimen Collection",
                    "code": {
                      "id": "054278c5-8e3a-4fda-b967-c958c871589b",
                      "code": "C70793",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Biospecimen Collection",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Lab Tests",
                    "description": "Monitoring of hematology, clinical chemistry, and urinalysis"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "c0e648cf-a231-4787-bbf4-2f796261a985",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "752a0baf-2d1c-461c-89e1-01ad6fe04cf1",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "a86e1cbd-898c-45fb-97ea-d124f7c01d8b",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "e8583088-9dcd-4e47-93cd-3eaedfcc4d79",
                "name": "Medical History",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "8e082168-0405-462a-a6af-d6fdb2de2f10",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "18507f72-36f0-4203-974d-a549b0765b2d",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "7b516cf1-21f3-4a70-bb60-9d3de52780ad",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "a6b93991-ae32-4b7a-b202-4feca0790ead",
                "name": "PRP Treatment",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "3ea54627-9c85-4cb8-97c9-6b2d13c02395",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "930acf44-2ed5-4e77-b522-dac177abafb4",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "322a6035-fb3d-4bf5-872b-b3295b5e6b64",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "a6cd0afb-3977-4cef-acc8-4ae2aedb9453",
                "name": "Panretinal photocoagulation",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "a6cd0afb-3977-4cef-acc8-4ae2aedb9453",
                    "name": "Panretinal photocoagulation",
                    "procedureType": "Therapeutic Procedure",
                    "code": {
                      "id": "28333398-fb98-4f75-91e5-f204a06da7f4",
                      "code": "67228",
                      "codeSystem": "CPT",
                      "codeSystemVersion": "",
                      "decode": "Treatment of extensive or progressive retinopathy; photocoagulation",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "PRP",
                    "description": "Laser treatment to the retina to treat proliferative diabetic retinopathy"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "b7b541df-f4d3-4914-82f1-600cf4b2d8cb",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "0f41541f-7d4f-4415-9a3c-73c667a77fbf",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "e8721b8c-37cf-42c9-8ec8-10a00fbebe3c",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "06211281-bfd6-4df3-ae14-1737e96f567b",
                "name": "Prior / Concomitant Medications and Procedures",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "3bbbc691-ebde-4cb4-ad60-4ad5c1887a1a",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "8769cc10-6c56-48da-afbd-3d487faf0343",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "c55afb7a-f19c-46b5-8647-db243b7f0c10",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "bdf42c26-c7bc-4de3-bb70-685ff9cd9d69",
                "name": "Randomization / IRT",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "e29d20d1-f886-4bed-b4c9-dfef8a27873b",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "fbea2a4a-4ab1-4890-af76-3722834d360f",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "documentation"
                  },
                  {
                    "id": "79d95e66-4ffd-4c46-9bed-9ac96872e23e",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "5d1c5b41-cd18-4a78-b14a-4ef7f70bb526",
                "name": "SD-OCT",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "c76d307b-0e8c-4c3d-ba60-dd7826c57f82",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "3ec3cdf6-afc6-4450-9db2-87c1d78a4191",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "5deb59e0-a802-4d2f-b952-d625445a9b51",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "4f7e6d92-5d2c-4fac-89b6-9d7fabc509cf",
                "name": "Serious Adverse Events",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "d213a919-1271-44df-b3d5-495a3fbbecc1",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "df7ed799-0aa6-4b1f-a170-6d6c6ab13c7d",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "b502081f-f217-4429-8674-2a7dd3a7eef8",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "f9895782-769a-4286-8390-2de00ab9ded4",
                "name": "Slit-lamp Examination",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "11a25615-7eed-4593-a313-5c2341f6b345",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "a4ce09b9-e79a-44bb-b94b-ad17a01a312c",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "e731a4cc-b590-4d6b-b9f8-400771925439",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "5127d68d-6142-43d7-b920-c800817c689e",
                "name": "Spectral domain optical coherence tomography",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "5127d68d-6142-43d7-b920-c800817c689e",
                    "name": "Spectral domain optical coherence tomography",
                    "procedureType": "Imaging Technique",
                    "code": {
                      "id": "5db2239a-8fe2-447f-bb86-adc28bd59a4b",
                      "code": "92134",
                      "codeSystem": "CPT",
                      "codeSystemVersion": "",
                      "decode": "Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, retina",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "SD-OCT",
                    "description": "Imaging of the retina to assess anatomical markers"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "edd5c3a5-7118-4e4f-8318-a0a925857f94",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "8e29a720-b2b1-4a3c-ad2a-e512a5d82883",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "a0fcf4b7-89e8-47b5-b279-55457d5ffeb4",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "99549801-e757-4a91-b44f-0aa6fac8d1ca",
                "name": "Vital Signs",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "f1fbaa40-b2b5-4288-96cd-f07750577ace",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa,procedures"
                  },
                  {
                    "id": "0be9d207-2240-48a4-af5a-8922f87ec515",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "d56e2ab8-d351-41b2-a552-934dc02397d7",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "ed9ff8e4-1e23-4401-af71-3c34cb14064a",
                "name": "Vitrectomy",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "ed9ff8e4-1e23-4401-af71-3c34cb14064a",
                    "name": "Vitrectomy",
                    "procedureType": "Surgical Procedure",
                    "code": {
                      "id": "b6f72339-5851-406b-990c-127f27dcf2c1",
                      "code": "67036",
                      "codeSystem": "CPT",
                      "codeSystemVersion": "",
                      "decode": "Vitrectomy, mechanical, pars plana approach",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Vitrectomy",
                    "description": "Surgical removal of the vitreous gel from the eye"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "b0402e96-4887-4fe8-8da2-656fd98e5cc5",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "369022ec-3c27-4a49-9f12-335d3e126453",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "1689f207-6926-4af2-a1fb-64fa35e6a2ed",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              }
            ],
            "epochs": [
              {
                "id": "5164e538-0f16-463b-bed3-624da550c9dd",
                "name": "Screening period",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "b14bd9fd-fe1a-4c70-8d9d-45173bb65fb7",
                  "code": "C98779",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Screening Epoch",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "d69661dd-5098-4e26-b04d-95c04d6fdff4",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa,traversal"
                  },
                  {
                    "id": "4bf42260-028f-484d-8226-4cbb6c973960",
                    "url": "https://protocol2usdm.io/extensions/x-epochCategory",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "main"
                  },
                  {
                    "id": "e5c668f0-039c-49c9-81fc-21ec4d8f02ce",
                    "url": "https://protocol2usdm.io/extensions/x-epochSequenceOrder",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "1"
                  }
                ]
              },
              {
                "id": "fae44b45-d641-4d65-ae99-44b681ec569e",
                "name": "Single-Masked Treatment Period",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "60f11e91-712f-4a3a-95fb-3fc338149251",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "10db984f-5d1b-4d6c-95ce-938163b32230",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa,traversal"
                  },
                  {
                    "id": "b5b3156c-5619-48e9-9616-e0a2a2f57421",
                    "url": "https://protocol2usdm.io/extensions/x-epochCategory",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "main"
                  },
                  {
                    "id": "07ca5236-7a8d-480c-8046-5028455e4598",
                    "url": "https://protocol2usdm.io/extensions/x-epochSequenceOrder",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "2"
                  }
                ]
              },
              {
                "id": "93243f35-6c06-4826-af42-d53b369c07a4",
                "name": "Follow-up period",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "02e7c5e7-25ea-4cd4-9fb9-7f460297d271",
                  "code": "C98781",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Follow-up Epoch",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "552ef2c0-2898-44df-a81d-c37e5de4b7d2",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa,traversal"
                  },
                  {
                    "id": "e8c1f95d-c277-420d-a0de-fdc2c175558c",
                    "url": "https://protocol2usdm.io/extensions/x-epochCategory",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "main"
                  },
                  {
                    "id": "c0d44483-c3ce-4a5a-8618-bdc756e38ec5",
                    "url": "https://protocol2usdm.io/extensions/x-epochSequenceOrder",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "4"
                  }
                ]
              }
            ],
            "activityGroups": [
              {
                "id": "d24bd569-fe4c-474f-976c-953135104d0c",
                "name": "Administrative and Eligibility",
                "description": null,
                "childIds": [
                  "0f81063d-2fee-4aa3-9392-16ec686db9c1",
                  "a93b3967-4d03-4c22-b2ca-9268caa6d32c",
                  "07cd1d20-b48c-4045-81e3-374bb56a2292",
                  "e8583088-9dcd-4e47-93cd-3eaedfcc4d79",
                  "06211281-bfd6-4df3-ae14-1737e96f567b",
                  "bdf42c26-c7bc-4de3-bb70-685ff9cd9d69"
                ],
                "instanceType": "Activity",
                "activityNames": [
                  "Informed Consent",
                  "Inclusion / Exclusion Criteria",
                  "Demographics",
                  "Medical History",
                  "Prior / Concomitant Medications and Procedures",
                  "Randomization / IRT"
                ]
              },
              {
                "id": "f7048248-73d8-4c3e-9b5d-98b792be4acf",
                "name": "Safety Assessments",
                "description": null,
                "childIds": [
                  "99549801-e757-4a91-b44f-0aa6fac8d1ca"
                ],
                "instanceType": "Activity",
                "activityNames": [
                  "Vital Signs",
                  "Adverse Events",
                  "Serious Adverse Events"
                ]
              },
              {
                "id": "693cfb61-0ac3-4da7-879c-32ac796dac2d",
                "name": "Ocular Assessments",
                "description": null,
                "childIds": [
                  "a2af2a6b-8cb9-4630-9af0-8fbf4e0b1a69",
                  "fb2bbbd7-5ddc-40fe-9829-940df3c9e047",
                  "55a85e0c-efcd-4680-a788-a90f73bb4c24",
                  "ac513318-abc5-4141-97c6-e922393ca390",
                  "5d1c5b41-cd18-4a78-b14a-4ef7f70bb526",
                  "3cc4c6ef-f64e-40ee-84ee-8225667a3235"
                ],
                "instanceType": "Activity",
                "activityNames": [
                  "BCVA",
                  "IOP",
                  "Slit-lamp Examination",
                  "Dilated Fundus Examination",
                  "7-Field CFP",
                  "FA",
                  "SD-OCT",
                  "Disease Activity Assessment"
                ]
              },
              {
                "id": "7e1f7b61-1047-48ab-99ac-6527afdbe587",
                "name": "Study Treatment",
                "description": null,
                "childIds": [
                  "f57dc500-305f-4a92-9cc7-614edab72c86",
                  "a6b93991-ae32-4b7a-b202-4feca0790ead"
                ],
                "instanceType": "Activity",
                "activityNames": [
                  "Brolucizumab 6 mg Injection",
                  "PRP Treatment"
                ]
              }
            ],
            "notes": [
              {
                "id": "6ed87265-9f1c-4c36-8b4e-a8ee6c673105",
                "text": "a. Informed consent must be obtained prior to any study-specific procedures.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "3bb5d352-3dbe-4034-82cf-c934f1d15b3d",
                "text": "b. Includes history of primary diagnosis, including type of diabetes and PDR.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "35b10888-ba2e-46a3-a3bb-bb1d00517616",
                "text": "c. Vital signs include blood pressure and pulse rate.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "a6e2503b-1154-473a-8e48-22283a676183",
                "text": "d. BCVA to be assessed by masked certified personnel using ETDRS charts.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "802f9e0c-f137-49b3-b193-a55043e457a3",
                "text": "e. IOP measurement to be performed in both eyes; post-injection IOP measurement within 60 minutes for study eye.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "36916b1b-89c7-4e6e-abd4-f0343466bb96",
                "text": "f. 7-field CFP and FA images to be evaluated by the Central Reading Center (CRC).",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "8f3efde2-c58a-43c7-8394-1aafdad3c597",
                "text": "g. SD-OCT images to be evaluated by the CRC.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "afa16e9e-3407-4eb7-8e37-7203ad0b542b",
                "text": "h. Disease activity assessment (DAA) used to determine treatment interval extension or reduction.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "79942eaa-98d1-4396-aef7-39a4fc7038e5",
                "text": "i. PRP treatment may be split into 2-4 sessions as needed up to Week 12.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "d196f004-2cd9-4f72-95b9-a217c741587f",
                "text": "j. End of Study (EOS) visit to be performed at Week 96 or at early discontinuation.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "1dd4a3ae-9e7e-4f56-acdb-0ff92a61a6e4",
                "text": "2. Patients â‰¥ 18 years of age at Screening.",
                "instanceType": "Note"
              },
              {
                "id": "20e3ae24-d87a-4811-8648-0674533e7704",
                "text": "4. Patients diagnosed with type 1 or 2 DM, and HbA1c â‰¤ 12% at Screening.",
                "instanceType": "Note"
              }
            ],
            "model": {
              "id": "d124a5db-8292-45be-bcce-f70305d08a9a",
              "code": "C82639",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Parallel Study",
              "instanceType": "Code"
            },
            "indications": [
              {
                "id": "402889d4-05e2-4014-ba88-2b11158a00ec",
                "name": "Proliferative diabetic retinopathy",
                "isRareDisease": false,
                "instanceType": "Indication",
                "description": "Patients with proliferative diabetic retinopathy"
              }
            ],
            "procedures": [
              {
                "id": "9145e8fd-8bc4-46aa-8f31-e694af06c7c9",
                "name": "Intravitreal injection",
                "procedureType": "Therapeutic Procedure",
                "code": {
                  "id": "7ea64c00-8241-458a-af10-f25f281331ef",
                  "code": "67028",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "",
                  "decode": "Intravitreal injection of a pharmacologic agent",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "IVT Injection",
                "description": "Administration of brolucizumab into the vitreous of the eye"
              },
              {
                "id": "a6cd0afb-3977-4cef-acc8-4ae2aedb9453",
                "name": "Panretinal photocoagulation",
                "procedureType": "Therapeutic Procedure",
                "code": {
                  "id": "28333398-fb98-4f75-91e5-f204a06da7f4",
                  "code": "67228",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "",
                  "decode": "Treatment of extensive or progressive retinopathy; photocoagulation",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "PRP",
                "description": "Laser treatment to the retina to treat proliferative diabetic retinopathy"
              },
              {
                "id": "530993a4-e50d-4de8-9079-3a8f0d8b4057",
                "name": "Best Corrected Visual Acuity",
                "procedureType": "Assessment",
                "code": {
                  "id": "3c15a44a-e7b7-4c40-8b67-dec4dd0ba2f5",
                  "code": "92015",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "",
                  "decode": "Determination of refractive state",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "BCVA",
                "description": "Assessment of visual acuity using ETDRS-like charts"
              },
              {
                "id": "5127d68d-6142-43d7-b920-c800817c689e",
                "name": "Spectral domain optical coherence tomography",
                "procedureType": "Imaging Technique",
                "code": {
                  "id": "5db2239a-8fe2-447f-bb86-adc28bd59a4b",
                  "code": "92134",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "",
                  "decode": "Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, retina",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "SD-OCT",
                "description": "Imaging of the retina to assess anatomical markers"
              },
              {
                "id": "02d055a1-9ede-4538-9078-7cc44b787f2d",
                "name": "Color fundus photography",
                "procedureType": "Imaging Technique",
                "code": {
                  "id": "f9379cb2-9ea9-4ee0-9330-30220cc30777",
                  "code": "92250",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "",
                  "decode": "Fundus photography with interpretation and report",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "CFP",
                "description": "Imaging of the retina using 7-field or wide field photography"
              },
              {
                "id": "f2708245-e9bc-47e5-b6f2-71c394102e16",
                "name": "Fluorescein angiography",
                "procedureType": "Imaging Technique",
                "code": {
                  "id": "c2284d96-9f2b-4e9e-b655-98b71f3b8789",
                  "code": "92235",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "",
                  "decode": "Fluorescein angiography with interpretation and report",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "FA",
                "description": "Diagnostic imaging of retinal blood flow using fluorescein dye"
              },
              {
                "id": "faebc258-5b74-4378-8f7b-916e025ed1f8",
                "name": "Intraocular pressure measurement",
                "procedureType": "Monitoring",
                "code": {
                  "id": "fe77b1a0-6ecc-4ba4-9975-9e52921da52c",
                  "code": "92100",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "",
                  "decode": "Serial tonometry with medical interpretation and report",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "IOP Measurement",
                "description": "Measurement of pressure within the eye post-injection"
              },
              {
                "id": "7ed6b2dd-b9ac-4569-a332-b7c527e83e79",
                "name": "Laboratory evaluation",
                "procedureType": "Biospecimen Collection",
                "code": {
                  "id": "054278c5-8e3a-4fda-b967-c958c871589b",
                  "code": "C70793",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.01d",
                  "decode": "Biospecimen Collection",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Lab Tests",
                "description": "Monitoring of hematology, clinical chemistry, and urinalysis"
              },
              {
                "id": "ed9ff8e4-1e23-4401-af71-3c34cb14064a",
                "name": "Vitrectomy",
                "procedureType": "Surgical Procedure",
                "code": {
                  "id": "b6f72339-5851-406b-990c-127f27dcf2c1",
                  "code": "67036",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "",
                  "decode": "Vitrectomy, mechanical, pars plana approach",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Vitrectomy",
                "description": "Surgical removal of the vitreous gel from the eye"
              }
            ],
            "analysisPopulations": [
              {
                "id": "773b74d2-0f25-40f4-9381-17ec2898db34",
                "name": "All Enrolled Set",
                "text": "The All Enrolled Set includes all subjects who have signed informed consent and are assigned subject numbers.",
                "populationType": "Other",
                "instanceType": "AnalysisPopulation",
                "label": "All Enrolled",
                "populationDescription": "The All Enrolled Set includes all subjects who have signed informed consent and are assigned subject numbers.",
                "criteria": "Signed informed consent AND assigned subject number"
              },
              {
                "id": "604fc2d8-7013-42fa-92a9-dd2dad41f84e",
                "name": "Randomized Set",
                "text": "The Randomized Set will consist of all randomized subjects. Subjects are considered randomized when they have been deemed eligible for randomization by the investigator and given a randomization number. Subjects who were randomized but did not receive any study treatment at baseline and discontinued study per subject decision will be classified as screen failures.",
                "populationType": "Efficacy",
                "instanceType": "AnalysisPopulation",
                "label": "Randomized",
                "populationDescription": "The Randomized Set will consist of all randomized subjects. Subjects are considered randomized when they have been deemed eligible for randomization by the investigator and given a randomization number. Subjects who were randomized but did not receive any study treatment at baseline and discontinued study per subject decision will be classified as screen failures.",
                "criteria": "Deemed eligible AND assigned randomization number"
              },
              {
                "id": "b4a20f14-dea1-49de-9176-a982521ec209",
                "name": "Full Analysis Set",
                "text": "The Full Analysis Set (FAS) comprises all randomized subjects who receive at least one study treatment. Subjects in the FAS will be analyzed according to the treatment assigned to them at randomization.",
                "populationType": "Efficacy",
                "instanceType": "AnalysisPopulation",
                "label": "FAS",
                "populationDescription": "The Full Analysis Set (FAS) comprises all randomized subjects who receive at least one study treatment. Subjects in the FAS will be analyzed according to the treatment assigned to them at randomization.",
                "criteria": "Randomized AND received >=1 study treatment"
              },
              {
                "id": "02e0f7dc-aedc-4352-9ee2-749b3485a683",
                "name": "Safety Analysis Set",
                "text": "The Safety Analysis Set (SAF) includes all subjects who receive at least one study treatment. Subjects in the SAF will be analyzed according to the actual study treatment they received, where treatment received is defined as the randomized/assigned treatment if the subject took at least one dose of that treatment, or the first treatment received if the randomized/assigned treatment was never received.",
                "populationType": "Safety",
                "instanceType": "AnalysisPopulation",
                "label": "SAF",
                "populationDescription": "The Safety Analysis Set (SAF) includes all subjects who receive at least one study treatment. Subjects in the SAF will be analyzed according to the actual study treatment they received, where treatment received is defined as the randomized/assigned treatment if the subject took at least one dose of that treatment, or the first treatment received if the randomized/assigned treatment was never received.",
                "criteria": "Received >=1 study treatment"
              },
              {
                "id": "1ee7846c-b13f-4d3a-9c59-965f3983fbe6",
                "name": "Per Protocol Set",
                "text": "PPS is a subset of the FAS and will exclude or censor data from subjects with important protocol deviations (PDs) and analysis restrictions (ARs) that are expected to majorly affect the validity of the assessment of efficacy at Week 54.",
                "populationType": "Efficacy",
                "instanceType": "AnalysisPopulation",
                "label": "PPS",
                "populationDescription": "PPS is a subset of the FAS and will exclude or censor data from subjects with important protocol deviations (PDs) and analysis restrictions (ARs) that are expected to majorly affect the validity of the assessment of efficacy at Week 54.",
                "criteria": "Subset of FAS AND no important protocol deviations/analysis restrictions affecting efficacy validity"
              }
            ],
            "characteristics": [
              {
                "id": "6b4b59c0-0b2f-4831-ba06-905626f95104",
                "code": "AGE",
                "codeSystem": "http://www.cdisc.org/baseline-characteristics",
                "codeSystemVersion": "2024-03-29",
                "decode": "Age",
                "instanceType": "Code"
              },
              {
                "id": "b34e4b84-9f04-44d9-aeb1-648f2c8f82ec",
                "code": "SEX",
                "codeSystem": "http://www.cdisc.org/baseline-characteristics",
                "codeSystemVersion": "2024-03-29",
                "decode": "Sex",
                "instanceType": "Code"
              },
              {
                "id": "b6602e01-16d4-44a8-bb13-4bb0b84999da",
                "code": "BASELINE_BCVA",
                "codeSystem": "http://www.cdisc.org/baseline-characteristics",
                "codeSystemVersion": "2024-03-29",
                "decode": "Baseline BCVA",
                "instanceType": "Code"
              },
              {
                "id": "a7dc382b-cfb0-4481-9e8c-d87be5d06e7e",
                "code": "DIABETES_TYPE",
                "codeSystem": "http://www.cdisc.org/baseline-characteristics",
                "codeSystemVersion": "2024-03-29",
                "decode": "Diabetes type",
                "instanceType": "Code"
              },
              {
                "id": "5ce5726c-2c4e-4e42-a615-517b82e546a9",
                "code": "BASELINE_HBA1C",
                "codeSystem": "http://www.cdisc.org/baseline-characteristics",
                "codeSystemVersion": "2024-03-29",
                "decode": "Baseline HbA1c",
                "instanceType": "Code"
              },
              {
                "id": "1e5eb1e1-8e5d-418b-8b5d-474a5954cff6",
                "code": "BASELINE_DR_SEVERITY",
                "codeSystem": "http://www.cdisc.org/baseline-characteristics",
                "codeSystemVersion": "2024-03-29",
                "decode": "Baseline DR severity",
                "instanceType": "Code"
              },
              {
                "id": "218b8268-404d-4707-aa8c-d79c301fde2f",
                "code": "REGION",
                "codeSystem": "http://www.cdisc.org/baseline-characteristics",
                "codeSystemVersion": "2024-03-29",
                "decode": "Region",
                "instanceType": "Code"
              },
              {
                "id": "0dd409ee-30e1-480b-bce9-4a59efe96251",
                "code": "PRIOR_ANTI-VEGF_TREA",
                "codeSystem": "http://www.cdisc.org/baseline-characteristics",
                "codeSystemVersion": "2024-03-29",
                "decode": "Prior anti-VEGF treatment",
                "instanceType": "Code"
              },
              {
                "id": "0423f8c3-f17a-4bcb-a8d8-27c712d41ffb",
                "code": "BASELINE_CSFT",
                "codeSystem": "http://www.cdisc.org/baseline-characteristics",
                "codeSystemVersion": "2024-03-29",
                "decode": "Baseline CSFT",
                "instanceType": "Code"
              }
            ],
            "extensionAttributes": [
              {
                "id": "87c325bb-2f8d-4d8f-86ca-5c0b0f77ebbe",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-entityMaps",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"epochAliases\": {\"SCREENING PERIOD\": \"epoch_1\", \"SCREENING_PERIOD\": \"epoch_1\", \"SCREENING\": \"epoch_1\", \"SINGLE-MASKED TREATMENT PERIOD\": \"epoch_2\", \"SINGLE-MASKED_TREATMENT_PERIOD\": \"epoch_2\", \"TREATMENT\": \"epoch_2\", \"FOLLOW-UP PERIOD\": \"epoch_3\", \"FOLLOW-UP_PERIOD\": \"epoch_3\", \"FOLLOW_UP\": \"epoch_3\", \"BASELINE\": \"epoch_2\", \"END_OF_STUDY\": \"epoch_3\"}, \"visitAliases\": {\"SCREENING (DAY -21 TO DAY -1)\": \"enc_1\", \"SCREENING_(DAY_-21_TO_DAY_-1)\": \"enc_1\", \"DAY 1 (BASELINE)\": \"enc_2\", \"DAY_1_(BASELINE)\": \"enc_2\", \"WEEK 6\": \"enc_3\", \"WEEK_6\": \"enc_3\", \"WEEK 12\": \"enc_4\", \"WEEK_12\": \"enc_4\", \"WEEK 18\": \"enc_5\", \"WEEK_18\": \"enc_5\", \"WEEK 24\": \"enc_6\", \"WEEK_24\": \"enc_6\", \"WEEK 30\": \"enc_7\", \"WEEK_30\": \"enc_7\", \"WEEK 36\": \"enc_8\", \"WEEK_36\": \"enc_8\", \"WEEK 42\": \"enc_9\", \"WEEK_42\": \"enc_9\", \"WEEK 48\": \"enc_10\", \"WEEK_48\": \"enc_10\", \"WEEK 54 (PRIMARY ENDPOINT)\": \"enc_11\", \"WEEK_54_(PRIMARY_ENDPOINT)\": \"enc_11\", \"WEEK 60\": \"enc_12\", \"WEEK_60\": \"enc_12\", \"WEEK 66\": \"enc_13\", \"WEEK_66\": \"enc_13\", \"WEEK 72\": \"enc_14\", \"WEEK_72\": \"enc_14\", \"WEEK 78\": \"enc_15\", \"WEEK_78\": \"enc_15\", \"WEEK 84\": \"enc_16\", \"WEEK_84\": \"enc_16\", \"WEEK 90 (END OF TREATMENT)\": \"enc_17\", \"WEEK_90_(END_OF_TREATMENT)\": \"enc_17\", \"WEEK 96 (END OF STUDY)\": \"enc_18\", \"WEEK_96_(END_OF_STUDY)\": \"enc_18\", \"Screening\": \"enc_1\", \"baseline\": \"enc_2\", \"randomization\": \"enc_2\", \"Week 6\": \"enc_3\", \"Week 12\": \"enc_4\", \"Week 18\": \"enc_5\", \"Week 24\": \"enc_6\", \"Week 30\": \"enc_7\", \"Week 36\": \"enc_8\", \"Week 42\": \"enc_9\", \"Week 48\": \"enc_10\", \"Week 54\": \"enc_11\", \"Week 66\": \"enc_13\", \"Week 90\": \"enc_17\", \"Week 96\": \"enc_18\"}}"
              },
              {
                "id": "ext_conceptual_3b140b81-79a2-4ce1-970b-4810be30a812",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-conceptualAnchors",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"c7eb5cb1-bc06-460c-ba81-ad5625655bed\", \"name\": \"Treatment Administration Window\", \"classification\": \"Conceptual\", \"note\": \"Pure timing reference - no visit or activity instance\"}, {\"id\": \"931f056d-2e03-405b-89d0-cf4edc2ff23a\", \"name\": \"Minimum Brolucizumab Interval\", \"classification\": \"Conceptual\", \"note\": \"Pure timing reference - no visit or activity instance\"}]"
              },
              {
                "id": "20046227-8753-4054-966a-9e27a808ba98",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-promotionIssues",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"severity\": \"warning\", \"category\": \"timing_reference_remapped\", \"message\": \"Timing 'Screening Window' reference remapped: 22e0141f-db32-4e2f-a448-c8636b89278a \\u2192 anchor_inst_anchor_2\", \"affectedPath\": \"$.timings[?(@.id=='timing_1')]\"}, {\"severity\": \"info\", \"category\": \"visit_anchor_created\", \"message\": \"Created VISIT anchor instance: 3fba07a4-75a8-44a9-a43c-e766590a3f53 (encounter: enc_2)\", \"affectedPath\": \"$.scheduleTimelines[0].instances[-1]\"}, {\"severity\": \"info\", \"category\": \"conceptual_anchor_stored\", \"message\": \"CONCEPTUAL anchor 'Treatment Administration Window' stored as timing reference (no visit)\", \"affectedPath\": \"$.extensionAttributes[?(@.url contains 'conceptualAnchors')]\"}, {\"severity\": \"info\", \"category\": \"conceptual_anchor_stored\", \"message\": \"CONCEPTUAL anchor 'Minimum Brolucizumab Interval' stored as timing reference (no visit)\", \"affectedPath\": \"$.extensionAttributes[?(@.url contains 'conceptualAnchors')]\"}, {\"severity\": \"info\", \"category\": \"visit_anchor_created\", \"message\": \"Created VISIT anchor instance: 16cf7bd7-0dfa-4d22-b730-3b368bdf6eb6 (encounter: enc_2)\", \"affectedPath\": \"$.scheduleTimelines[0].instances[-1]\"}, {\"severity\": \"info\", \"category\": \"visit_anchor_created\", \"message\": \"Created VISIT anchor instance: f49b374a-a7e2-428c-a185-f65b5952b1f2 (encounter: enc_2)\", \"affectedPath\": \"$.scheduleTimelines[0].instances[-1]\"}]"
              },
              {
                "id": "ad42022c-bd86-4cd7-a074-3716d76ccb7b",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-timeAnchors",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"a97f64f6-5099-4cbd-9696-579387386113\", \"definition\": \"The point at which a subject is assigned to a treatment arm and is no longer considered a screen failure.\", \"anchorType\": \"Randomization\", \"classification\": \"Event\", \"timelineId\": null, \"dayValue\": 1, \"intraDayOrder\": 40, \"sourceText\": \"Screen Failure: A subject who is screened but is not treated or randomized\", \"encounterId\": null, \"activityId\": null}, {\"id\": \"a42cfc0d-424e-401c-b3b5-0dbd27bda01d\", \"definition\": \"Baseline visit/assessment\", \"anchorType\": \"Baseline\", \"classification\": \"Visit\", \"timelineId\": null, \"dayValue\": 1, \"intraDayOrder\": 50, \"sourceText\": \"Baseline visit\", \"encounterId\": null, \"activityId\": null}, {\"id\": \"5600f673-96e7-456b-ae49-b69140132e2d\", \"definition\": \"Screening visit\", \"anchorType\": \"Screening\", \"classification\": \"Visit\", \"timelineId\": null, \"dayValue\": 1, \"intraDayOrder\": 20, \"sourceText\": \"Screening visit\", \"encounterId\": null, \"activityId\": null}, {\"id\": \"8c418e62-3e92-4e03-beab-8da97df03dfd\", \"definition\": \"Informed consent obtained\", \"anchorType\": \"InformedConsent\", \"classification\": \"Event\", \"timelineId\": null, \"dayValue\": 1, \"intraDayOrder\": 10, \"sourceText\": \"Informed Consent\", \"encounterId\": null, \"activityId\": null}, {\"id\": \"f91d760a-c367-4107-9617-141483131bea\", \"definition\": \"procedure\", \"anchorType\": \"Custom\", \"classification\": \"Conceptual\", \"timelineId\": null, \"dayValue\": 1, \"intraDayOrder\": 100, \"sourceText\": \"procedure\", \"encounterId\": null, \"activityId\": null}]"
              },
              {
                "id": "687a4b47-0ad8-460a-8be0-2a384f3b9c9f",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-repetitions",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"d2268f3f-1a8a-4c3b-b258-58fd7b07058f\", \"type\": \"Daily\", \"interval\": \"P1D\", \"sourceText\": \"od\"}, {\"id\": \"ff9b97cc-3bb8-43de-95b6-dfbadeca3710\", \"type\": \"Continuous\", \"startOffset\": \"-P21D\", \"endOffset\": \"-P1D\", \"sourceText\": \"Days \\n-21 to -1\"}, {\"id\": \"116f89cb-ffa4-4f66-bf23-83912b0148fc\", \"type\": \"Continuous\", \"startOffset\": \"P18D\", \"endOffset\": \"P90D\", \"sourceText\": \"Week 18 to Week 90\"}, {\"id\": \"b8a0b239-50a4-4c23-aba1-dd5ea642b287\", \"type\": \"Continuous\", \"startOffset\": \"P90D\", \"endOffset\": \"P96D\", \"sourceText\": \"Week 90 to Week 96\"}, {\"id\": \"a31c06fb-a0e9-43bd-9032-b499fef091b4\", \"type\": \"Continuous\", \"startOffset\": \"P12D\", \"endOffset\": \"P96D\", \"sourceText\": \"Week 12 to Week 96\"}, {\"id\": \"882d1cbf-b465-4f90-b412-e299650d8142\", \"type\": \"Continuous\", \"startOffset\": \"P12D\", \"endOffset\": \"P96D\", \"sourceText\": \"from Week 12 to Week 96\"}, {\"id\": \"c5d6a08a-7194-479d-8a0f-ee7a4d5924de\", \"type\": \"Continuous\", \"sourceText\": \"screening period\"}, {\"id\": \"0080310e-a377-48ba-a233-8d27df667213\", \"type\": \"Continuous\", \"sourceText\": \"screening phase\"}, {\"id\": \"7f35e2d7-0d8e-4b0d-ac72-280b5fec1eb6\", \"type\": \"Continuous\", \"sourceText\": \"follow-up period\"}, {\"id\": \"ea2d3608-e994-44e7-845b-a2306dd6ca7a\", \"type\": \"Continuous\", \"sourceText\": \"3 days after\"}, {\"id\": \"34d0b03f-fe4c-47e2-89ba-95403e033d4b\", \"type\": \"Cycle\", \"startOffset\": \"P0D\", \"endOffset\": \"null\", \"interval\": \"P6W\", \"exitCondition\": \"null\", \"sourceText\": \"q6w Every 6 weeks\"}, {\"id\": \"2417e891-3cec-410a-a53f-e3d831b9b108\", \"type\": \"Cycle\", \"startOffset\": \"P0D\", \"endOffset\": \"null\", \"interval\": \"P8W\", \"exitCondition\": \"null\", \"sourceText\": \"q8w Every 8 weeks\"}, {\"id\": \"631b965f-dd45-4f8f-b74a-2748357e7dba\", \"type\": \"Cycle\", \"startOffset\": \"P0D\", \"endOffset\": \"null\", \"interval\": \"P12W\", \"exitCondition\": \"null\", \"sourceText\": \"q12w Every 12 weeks\"}, {\"id\": \"d9d47555-e2f6-4095-bea5-8535a2cf19a1\", \"type\": \"Continuous\", \"startOffset\": \"P0D\", \"endOffset\": \"null\", \"interval\": \"null\", \"exitCondition\": \"null\", \"sourceText\": \"Requirement to apply the same pregnancy testing in both arms, throughout the study\"}]"
              },
              {
                "id": "7d46dae1-3aa4-4153-b9ee-57c4d878c535",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-traversalConstraints",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"2619eed1-63e2-4107-aacb-fd50314febbf\", \"requiredSequence\": [\"epoch_1\", \"epoch_2\", \"epoch_2\", \"epoch_3\"], \"allowEarlyExit\": true, \"exitEpochIds\": [], \"mandatoryVisits\": [\"enc_1\", \"enc_2\", \"enc_2\", \"enc_18\"], \"sourceText\": \"[{'condition': 'Subject experiences AE requiring discontinuation', 'path': ['DISCONTINUATION_OF_STUDY_TREATMENT', 'EARLY_TERMINATION_VISIT']}, {'condition': 'Subject is lost to follow-up', 'path': ['LOST_TO_FOLLOW_UP_PROCEDURES']}, {'condition': 'Withdrawal of informed consent', 'path': ['WITHDRAWAL_OF_CONSENT_PROCEDURES']}]\"}]"
              },
              {
                "id": "02898cd0-08cf-4d94-a038-fb2e251a747d",
                "url": "https://protocol2usdm.io/extensions/x-footnoteConditions",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"6790365c-844b-451d-b094-30032a8a5bdd\", \"conditionType\": \"timing_before\", \"text\": \"a. Informed consent must be obtained prior to any study-specific procedures.\", \"footnoteId\": \"21e53e98-4fbc-43e3-989a-577e8cd47b8c\", \"structuredCondition\": \"sequence.must_precede(informed_consent, all_study_procedures)\", \"appliesToActivityIds\": [\"0f81063d-2fee-4aa3-9392-16ec686db9c1\", \"06211281-bfd6-4df3-ae14-1737e96f567b\", \"7e1f7b61-1047-48ab-99ac-6527afdbe587\"], \"sourceText\": \"a. Informed consent must be obtained prior to any study-specific procedures.\"}, {\"id\": \"e8f59106-e038-445f-8841-21c3086762ba\", \"conditionType\": \"general\", \"text\": \"b. Includes history of primary diagnosis, including type of diabetes and PDR.\", \"footnoteId\": \"e24484c0-ee43-4754-a22c-3bd66c86e1d4\", \"structuredCondition\": \"procedure.include(primary_diagnosis_history, [diabetes_type, PDR])\", \"appliesToActivityIds\": [\"e8583088-9dcd-4e47-93cd-3eaedfcc4d79\"], \"sourceText\": \"b. Includes history of primary diagnosis, including type of diabetes and PDR.\"}, {\"id\": \"f663ba38-37fa-4179-9956-7528a585136d\", \"conditionType\": \"general\", \"text\": \"c. Vital signs include blood pressure and pulse rate.\", \"footnoteId\": \"02b85f1c-10bb-4aa0-8e87-f6bbff80f424\", \"structuredCondition\": \"procedure.include(vital_signs, [blood_pressure, pulse_rate])\", \"appliesToActivityIds\": [\"99549801-e757-4a91-b44f-0aa6fac8d1ca\"], \"sourceText\": \"c. Vital signs include blood pressure and pulse rate.\"}, {\"id\": \"cafce793-6a8a-4cae-bbf8-e65f510264af\", \"conditionType\": \"general\", \"text\": \"d. BCVA to be assessed by masked certified personnel using ETDRS charts.\", \"footnoteId\": \"299f1746-bd0e-40a4-8a76-1aeab230a480\", \"structuredCondition\": \"procedure.method(BCVA, [masked_personnel, ETDRS_charts])\", \"appliesToActivityIds\": [\"a2af2a6b-8cb9-4630-9af0-8fbf4e0b1a69\"], \"sourceText\": \"d. BCVA to be assessed by masked certified personnel using ETDRS charts.\"}, {\"id\": \"e64b8e0d-8b50-447d-8207-09ae26b4f48d\", \"conditionType\": \"general\", \"text\": \"e. IOP measurement to be performed in both eyes; post-injection IOP measurement within 60 minutes for study eye.\", \"footnoteId\": \"2a51276b-b0c4-49d8-92ee-03a4eaf1f7e5\", \"structuredCondition\": \"timing.within(IOP_measurement, injection, PT60M)\", \"appliesToActivityIds\": [\"fb2bbbd7-5ddc-40fe-9829-940df3c9e047\"], \"sourceText\": \"e. IOP measurement to be performed in both eyes; post-injection IOP measurement within 60 minutes fo\"}, {\"id\": \"24909e87-18f1-40a5-87ce-81dcab0b0e45\", \"conditionType\": \"general\", \"text\": \"f. 7-field CFP and FA images to be evaluated by the Central Reading Center (CRC).\", \"footnoteId\": \"3bbd5710-9f63-4037-b9c2-1528b84c399b\", \"structuredCondition\": \"procedure.evaluator(CFP_FA_images, Central_Reading_Center)\", \"appliesToActivityIds\": [\"ac513318-abc5-4141-97c6-e922393ca390\", \"55a85e0c-efcd-4680-a788-a90f73bb4c24\"], \"sourceText\": \"f. 7-field CFP and FA images to be evaluated by the Central Reading Center (CRC).\"}, {\"id\": \"84e061c7-b382-444b-b346-067eb12e21bf\", \"conditionType\": \"general\", \"text\": \"h. Disease activity assessment (DAA) used to determine treatment interval extension or reduction.\", \"footnoteId\": \"24a79b58-ba6d-4041-abcd-30910070c87b\", \"structuredCondition\": \"decision.use(DAA, treatment_interval_adjustment)\", \"appliesToActivityIds\": [\"3cc4c6ef-f64e-40ee-84ee-8225667a3235\"], \"sourceText\": \"h. Disease activity assessment (DAA) used to determine treatment interval extension or reduction.\"}, {\"id\": \"21dda0d7-837e-4e07-a78a-58df21e00725\", \"conditionType\": \"general\", \"text\": \"i. PRP treatment may be split into 2-4 sessions as needed up to Week 12.\", \"footnoteId\": \"707ded92-7ed8-48c9-ab0e-d7943da0a4e4\", \"structuredCondition\": \"frequency.split(PRP_treatment, 2, 4).before(W12)\", \"appliesToActivityIds\": [\"a6b93991-ae32-4b7a-b202-4feca0790ead\"], \"sourceText\": \"i. PRP treatment may be split into 2-4 sessions as needed up to Week 12.\"}, {\"id\": \"b4db8d3b-da83-4d99-bf63-de38158200c1\", \"conditionType\": \"timing_at\", \"text\": \"j. End of Study (EOS) visit to be performed at Week 96 or at early discontinuation.\", \"footnoteId\": \"ccd4f795-d3c0-4afd-a6f9-6c182090ef68\", \"structuredCondition\": \"timing.at(EOS, [W96, early_discontinuation])\", \"appliesToActivityIds\": [\"7e1f7b61-1047-48ab-99ac-6527afdbe587\"], \"sourceText\": \"j. End of Study (EOS) visit to be performed at Week 96 or at early discontinuation.\"}, {\"id\": \"fcf89a44-5bc8-44c9-b494-1577e6433811\", \"conditionType\": \"timing_before\", \"text\": \"1. Signed informed consent must be obtained prior to participation in the study.\", \"footnoteId\": \"3c067d8e-5ba5-4ce2-bd7e-a7b8daaf7ea6\", \"sourceText\": \"1. Signed informed consent must be obtained prior to participation in the study.\", \"appliesToActivityIds\": [\"0f81063d-2fee-4aa3-9392-16ec686db9c1\", \"06211281-bfd6-4df3-ae14-1737e96f567b\", \"7e1f7b61-1047-48ab-99ac-6527afdbe587\"]}, {\"id\": \"be60087a-ae3a-4770-b5b6-c83bc5c94c03\", \"conditionType\": \"general\", \"text\": \"2. Patients \\u2265 18 years of age at Screening.\", \"footnoteId\": \"5e4f526e-0c6c-481b-a26a-40010b3e3b58\", \"structuredCondition\": \"eligibility.age >= 18\", \"appliesToActivityIds\": [\"Screening\"], \"sourceText\": \"2. Patients \\u2265 18 years of age at Screening.\"}, {\"id\": \"4a0d6922-f42d-4e5a-b00e-6a4cf786d165\", \"conditionType\": \"general\", \"text\": \"3. Participant cooperation sufficient for adequate fundus photographs and retinal images.\", \"footnoteId\": \"907859f7-b2a0-42e4-98d3-7af1860106e0\", \"sourceText\": \"3. Participant cooperation sufficient for adequate fundus photographs and retinal images.\", \"appliesToActivityIds\": [\"4801cecb-d61e-41a3-a4c7-328942132ca2\"]}, {\"id\": \"761b09d8-4bcf-4336-be40-41159f48d139\", \"conditionType\": \"general\", \"text\": \"4. Patients diagnosed with type 1 or 2 DM, and HbA1c \\u2264 12% at Screening.\", \"footnoteId\": \"cb3e99c8-48e8-402a-a6e0-444ab0f90bfb\", \"structuredCondition\": \"eligibility.and(diagnosis(DM_type_1_or_2), HbA1c <= 12)\", \"appliesToActivityIds\": [\"Screening\"], \"sourceText\": \"4. Patients diagnosed with type 1 or 2 DM, and HbA1c \\u2264 12% at Screening.\"}, {\"id\": \"9ee7aec8-34b1-4952-bc9c-8729209bac03\", \"conditionType\": \"timing_before\", \"text\": \"5. Any medication administered for the management of DM should be stable within 3 months prior to randomization and is expected to remain stable during the course of the study, as medically acceptable. Study eye\", \"footnoteId\": \"0397890e-65a3-4b9e-8cb8-11d812267bfb\", \"structuredCondition\": \"eligibility.stable_medication(DM, P3M)\", \"appliesToActivityIds\": [\"bdf42c26-c7bc-4de3-bb70-685ff9cd9d69\"], \"sourceText\": \"5. Any medication administered for the management of DM should be stable within 3 months prior to ra\"}, {\"id\": \"70a93fa1-d27e-401c-9c57-badc6960c4c0\", \"conditionType\": \"general\", \"text\": \"6. PDR as assessed by the investigator using standard or wide-field CFP and FA, with no evidence of previous PRP, and that requires treatment with either anti-VEGF or PRP in the opinion of the investigator.\", \"footnoteId\": \"e6d79e54-8150-4e60-85f2-c1de427f918a\", \"sourceText\": \"6. PDR as assessed by the investigator using standard or wide-field CFP and FA, with no evidence of \", \"appliesToActivityIds\": [\"ac513318-abc5-4141-97c6-e922393ca390\", \"7e1f7b61-1047-48ab-99ac-6527afdbe587\"]}, {\"id\": \"ed613f8a-1084-4f93-9c7e-00b5ac36d5d7\", \"conditionType\": \"general\", \"text\": \"7. BCVA \\u2265 34 ETDRS letters (Snellen equivalent 20/200) at Screening and Baseline.\", \"footnoteId\": \"b0fdb985-e3cb-442d-a348-51ad3f1ff817\", \"structuredCondition\": \"eligibility.BCVA >= 34\", \"appliesToActivityIds\": [\"a2af2a6b-8cb9-4630-9af0-8fbf4e0b1a69\"], \"sourceText\": \"7. BCVA \\u2265 34 ETDRS letters (Snellen equivalent 20/200) at Screening and Baseline.\"}, {\"id\": \"8dd6396d-9e95-472c-b3d5-a0a18203c373\", \"conditionType\": \"general\", \"text\": \"8. Presence of amblyopia, amaurosis, or ocular disorders in the fellow eye with BCVA < 20/200 at Screening (except when due to conditions for which treatment or surgery may improve VA, e.g. cataract). Ocular treatments in the study eye\", \"footnoteId\": \"1aa138a9-776b-4af7-ba62-9d1068154cc8\", \"sourceText\": \"8. Presence of amblyopia, amaurosis, or ocular disorders in the fellow eye with BCVA < 20/200 at Scr\", \"appliesToActivityIds\": [\"7e1f7b61-1047-48ab-99ac-6527afdbe587\", \"a2af2a6b-8cb9-4630-9af0-8fbf4e0b1a69\", \"693cfb61-0ac3-4da7-879c-32ac796dac2d\"]}]"
              },
              {
                "id": "cb4bc775-b192-45fa-bcb0-cc36bb2a7f7d",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-endpointAlgorithms",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"edecd821-b3e5-488a-a04c-775a3ebdc222\", \"name\": \"Primary: Change from Baseline in BCVA\", \"endpointType\": \"Primary\", \"inputs\": [\"BCVA at Week 54\", \"Baseline BCVA\", \"Alternative DR/DME treatment status\"], \"timeWindow\": {\"reference\": \"Baseline\", \"duration\": \"54 weeks\"}, \"algorithm\": \"BCVA_Week_54 - BCVA_Baseline (excluding data after confounding alternative DR/DME treatments)\", \"successCriteria\": \"Lower limit of the two-sided 95% CI for the least square mean difference (brolucizumab - PRP) > -4 letters\", \"sourceText\": \"The objective related to the primary endpoint is to demonstrate non-inferiority of brolucizumab versus PRP with respect to the change from Baseline in BCVA at Week 54, assuming a non-inferiority margi\"}, {\"id\": \"f89a855e-7968-45d1-945a-94eccb167877\", \"name\": \"First Key Secondary: Proportion of subjects with no PDR\", \"endpointType\": \"Secondary\", \"inputs\": [\"PDR status at Week 54\"], \"timeWindow\": {\"reference\": \"Baseline\", \"duration\": \"54 weeks\"}, \"algorithm\": \"(Count of subjects with no PDR at Week 54 / Total subjects in treatment arm)\", \"successCriteria\": \"Superiority of brolucizumab vs PRP via CMH test (one-sided p < 0.025) after primary non-inferiority is established\", \"sourceText\": \"The objective related to first key secondary endpoint is to demonstrate superiority of brolucizumab versus PRP with respect to increasing the proportion of subjects with no PDR at Week 54.\"}, {\"id\": \"51573948-eb72-42be-8804-024e145fd136\", \"name\": \"Other Key Secondary: Proportion of subjects with center-involved DME\", \"endpointType\": \"Secondary\", \"inputs\": [\"Center-involved DME status up to Week 54\"], \"timeWindow\": {\"reference\": \"Baseline\", \"duration\": \"Up to 54 weeks\"}, \"algorithm\": \"(Count of subjects with center-involved DME / Total subjects in treatment arm)\", \"successCriteria\": \"Superiority of brolucizumab vs PRP via CMH test (one-sided p < 0.025) after primary and first key secondary superiority are established\", \"sourceText\": \"The objective related to the other key secondary endpoint is to demonstrate superiority of brolucizumab versus PRP with respect to reducing the proportion of subjects with center-involved DME up to We\"}]"
              },
              {
                "id": "8fa8951c-9ac1-4955-82b8-0b3933c1a1e5",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-derivedVariables",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"dbe6a1d4-04e1-485d-9df8-599a0a2b867e\", \"name\": \"Change from Baseline in BCVA at Week 54\", \"variableType\": \"ChangeFromBaseline\", \"sourceVariables\": [\"BCVA\"], \"derivationRule\": \"Week 54 BCVA value - Baseline BCVA value\", \"baselineDefinition\": \"Last non-missing value prior to randomization/treatment\", \"baselineVisit\": \"Baseline\", \"analysisWindow\": \"Week 54\", \"imputationRule\": \"ANCOVA model (Primary estimand excludes confounding effect of alternative DR/DME treatments)\", \"unit\": \"ETDRS letters\"}, {\"id\": \"445c6d11-d68b-4397-a063-86927681db47\", \"name\": \"Proportion of subjects with no PDR at Week 54\", \"variableType\": \"Categorical\", \"sourceVariables\": [\"ETDRS DRSS score\"], \"derivationRule\": \"Count of subjects with DRSS score indicating no PDR / Total subjects in analysis set\", \"baselineDefinition\": \"Presence of PDR at Baseline as per inclusion criteria\", \"baselineVisit\": \"Baseline\", \"analysisWindow\": \"Week 54\", \"imputationRule\": \"Cochran-Mantel-Haenszel (CMH) test\", \"unit\": \"Percentage\"}, {\"id\": \"2874b8cc-1383-4169-a725-a9cff4843856\", \"name\": \"Proportion of subjects with center-involved DME up to Week 54\", \"variableType\": \"Categorical\", \"sourceVariables\": [\"SD-OCT anatomical markers\"], \"derivationRule\": \"Count of subjects developing center-involved DME at any point through Week 54 / Total subjects\", \"baselineDefinition\": \"Absence of center-involved DME at Baseline\", \"baselineVisit\": \"Baseline\", \"analysisWindow\": \"Up to Week 54\", \"imputationRule\": \"null\", \"unit\": \"Percentage\"}, {\"id\": \"40630d75-047a-49aa-8821-a1e035881291\", \"name\": \"Area under the curve in change from Baseline in BCVA\", \"variableType\": \"Composite\", \"sourceVariables\": [\"BCVA\"], \"derivationRule\": \"Area under the curve (AUC) calculation of change from baseline values across all visits up to Week 54 and Week 96\", \"baselineDefinition\": \"Last non-missing value prior to treatment\", \"baselineVisit\": \"Baseline\", \"analysisWindow\": \"Up to Week 54 and Week 96\", \"imputationRule\": \"null\", \"unit\": \"ETDRS letters * weeks\"}, {\"id\": \"08a7a25a-fb1b-4fa2-b6ad-b13311f2b43d\", \"name\": \"Change from Baseline in ETDRS DRSS score\", \"variableType\": \"ChangeFromBaseline\", \"sourceVariables\": [\"ETDRS DRSS score\"], \"derivationRule\": \"Visit_value - Baseline_value\", \"baselineDefinition\": \"Last non-missing score based on 7-field CFP prior to treatment\", \"baselineVisit\": \"Baseline\", \"analysisWindow\": \"Week 54 and Week 96\", \"imputationRule\": \"null\", \"unit\": \"DRSS score units\"}, {\"id\": \"1ed5c9b0-b579-4355-b114-cfa7b8969348\", \"name\": \"Proportion of subjects developing vision-threatening complications associated with DR\", \"variableType\": \"Categorical\", \"sourceVariables\": [\"Ocular complications\", \"BCVA\", \"CFP\"], \"derivationRule\": \"Count of subjects with one or more vision-threatening complications / Total subjects\", \"baselineDefinition\": \"Absence of complications at Baseline\", \"baselineVisit\": \"Baseline\", \"analysisWindow\": \"Up to Week 54 and Week 96\", \"imputationRule\": \"null\", \"unit\": \"Percentage\"}]"
              },
              {
                "id": "3ad80518-f78a-4acc-adc2-7e3fcc369be4",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-stateMachine",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"id\": \"f07bcaa5-c5b2-4c09-abbd-8af4c16a8f2c\", \"initialState\": \"Screening\", \"terminalStates\": [\"Early Termination\", \"Completed\"], \"states\": [\"Screening\", \"Baseline\", \"Treatment\", \"End Of Study\", \"Early Termination\"], \"transitions\": [{\"fromState\": \"Screening\", \"toState\": \"Baseline\", \"trigger\": \"Progress to Baseline\"}, {\"fromState\": \"Baseline\", \"toState\": \"Treatment\", \"trigger\": \"Progress to Treatment\"}, {\"fromState\": \"Treatment\", \"toState\": \"End Of Study\", \"trigger\": \"Progress to End Of Study\"}, {\"fromState\": \"Treatment\", \"toState\": \"Early Termination\", \"trigger\": \"Subject exits to Early Termination\"}], \"epochIds\": {\"Screening\": \"SCREENING\", \"Baseline\": \"BASELINE\", \"Treatment\": \"TREATMENT\", \"End Of Study\": \"END_OF_STUDY\", \"Early Termination\": \"EARLY_TERMINATION\"}}"
              },
              {
                "id": "953e5f49-f373-4f64-bca4-8dc5073a86f2",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-dosingRegimens",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"fbd9f4f0-ede2-4882-ac5f-b697c8c9c0e9\", \"treatmentName\": \"Brolucizumab\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 6.0, \"unit\": \"mg\"}], \"durationDescription\": \"6 weeks\", \"sourceText\": \"tients with proliferative diabetic retinopathy (PDR). Subjects who meet all the inclusion and none of the exclusion criteria will be randomized in a 1:1 ratio to one of the two treatment arms: \\u2022 Brolu\"}, {\"id\": \"91915040-dbf5-4313-8dcb-63b8d7794aea\", \"treatmentName\": \"RTH258\", \"frequency\": \"QD\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 6.0, \"unit\": \"mg\"}], \"sourceText\": \"Study treatment 6.1.1 Investigational drug Table 6-1 Investigational drug Investigational Drug Pharmaceutical Dosage Form Route of Administration Supply Type Sponsor Brolucizumab 6 mg (RTH258 6 mg/ 0.\"}, {\"id\": \"a94cf98b-356d-4b44-a714-e177db2a5745\", \"treatmentName\": \"Brolucizumab (RTH258)\", \"frequency\": \"Q4W\", \"route\": \"\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 6.0, \"unit\": \"mg\", \"description\": \"Intravitreal injection\"}], \"durationDescription\": \"96 weeks\", \"doseModifications\": [\"Dose modification and escalation details are located in Section 6.5 of the protocol.\"]}, {\"id\": \"06536de6-f985-48b1-81dc-9a75e3e7f553\", \"treatmentName\": \"Panretinal Photocoagulation (PRP) Laser\", \"frequency\": \"Single\", \"route\": \"\", \"startDay\": 1, \"durationDescription\": \"96 weeks (study duration)\"}]"
              },
              {
                "id": "c47dd9f5-b864-4af9-9a7b-719274c00e8a",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-visitWindows",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"5e8428ca-e82a-4d75-8a83-9481e48f887b\", \"visitName\": \"Screening\", \"targetDay\": -14, \"windowBefore\": 7, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 1, \"epoch\": \"Screening\", \"sourceText\": \"Screening ............................................................................................................... 43 8.1.1 Information to be collected on screening failures ...................\"}, {\"id\": \"427a6cba-7549-4fa5-85f1-bc022008d8bd\", \"visitName\": \"baseline\", \"targetDay\": 0, \"windowBefore\": 1, \"windowAfter\": 1, \"isRequired\": true, \"visitNumber\": 2, \"sourceText\": \"Subject demographics/other baseline characteristics ............................................. 43 8.3 Efficacy ......................................................................................\"}, {\"id\": \"6f7dbd4f-1cf0-4959-a2e5-46668f861301\", \"visitName\": \"Early Termination\", \"targetDay\": null, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 3, \"sourceText\": \"Safety ..................................................................................................................... 47 8.4.1 Vital sign assessments ...........................................\"}, {\"id\": \"6cbe50c9-9c41-40c3-b7ed-8ae55df2769a\", \"visitName\": \"EOS\", \"targetDay\": null, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 4, \"epoch\": \"Completion\", \"sourceText\": \"Baseline/Day 1 visit window and timing of EOS visit for early study discontinuation. \\u2022 Section 5.2 Exclusion Criteria: Protocol clarification regarding exclusion criteria Number 8, 13 and Number 20.\"}, {\"id\": \"7cc6f900-ee03-4742-b745-d98e1b4488c2\", \"visitName\": \"EOT\", \"targetDay\": null, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 5, \"sourceText\": \"16/EOT 17/EOS Days\"}, {\"id\": \"f07bdc7e-5057-47fd-8047-344d3221f0db\", \"visitName\": \"randomization\", \"targetDay\": 1, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 6, \"epoch\": \"Treatment\", \"sourceText\": \"stable within 3 months prior to randomization and is expected to remain stable during the course of the study, as medically acceptable. \\u2022\"}, {\"id\": \"85098902-3ab9-4319-9a1c-26341783f717\", \"visitName\": \"Week 6\", \"targetDay\": 36, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 7, \"targetWeek\": 6, \"sourceText\": \"every 6 weeks at Baseline, Week 6 and Week 12 during the loading phase. Maintenance phase (Week 18 to Week 90): Subjects will then receive q12w injections in the maintenance phase. Additional assessme\"}, {\"id\": \"c5939ee7-9e22-4685-a16e-16bec6123ee8\", \"visitName\": \"Week 12\", \"targetDay\": 78, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": false, \"visitNumber\": 8, \"targetWeek\": 12, \"sourceText\": \"PRP: initial treatment in 1-4 sessions up to Week 12, followed with additional PRP treatment (may split into 2-4 sessions) as needed up to Week 90.\"}, {\"id\": \"936a1137-6116-4469-982d-c7369d513094\", \"visitName\": \"Week 16\", \"targetDay\": 106, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 9, \"targetWeek\": 16, \"sourceText\": \"had disease activity at Week 16 in a head-to-head comparison based on matched dosing intervals, with a relative decrease of 30% versus aflibercept (P = 0.0022). Significantly fewer subjects on broluci\"}, {\"id\": \"5eb07367-b91a-4657-9c88-362e81b7aa03\", \"visitName\": \"Week 18\", \"targetDay\": 120, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 10, \"targetWeek\": 18, \"sourceText\": \"Maintenance phase (Week 18 to Week 90): Subjects will then receive q12w injections in the maintenance phase. Additional assessment visits are planned for disease monitoring, not for treatment administ\"}, {\"id\": \"ab3100ae-84cf-4b38-b6ec-f3222e14d1e3\", \"visitName\": \"Week 24\", \"targetDay\": 162, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 11, \"targetWeek\": 24, \"sourceText\": \"\\u2022 Subjects will receive q12w injections in the maintenance phase, i.e. at Week 24, Week 36, and Week 48 in the first year. \\u2022 During the maintenance phase, the additional visits (e.g. Week 30) are plan\"}, {\"id\": \"2e5d3a6a-ab6f-45b2-b7e6-644fa7377b17\", \"visitName\": \"Week 30\", \"targetDay\": 204, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 12, \"targetWeek\": 30, \"sourceText\": \"\\u2022 During the maintenance phase, the additional visits (e.g. Week 30) are planned for disease monitoring, not for treatment administration. However, additional injections may be administered at these v\"}, {\"id\": \"e8d3aba8-720c-4db9-a3aa-33b7555224f5\", \"visitName\": \"Week 36\", \"targetDay\": 246, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 13, \"targetWeek\": 36, \"sourceText\": \"e.g. no new or expanding retinal neovascularization, between Week 36 and Week 48 and there was no injection at Week 42. At Week 66, the investigator may elect to further extend the treatment interval \"}, {\"id\": \"3b92b152-62d4-487e-a616-05317bed71c5\", \"visitName\": \"Week 42\", \"targetDay\": 288, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 14, \"targetWeek\": 42, \"sourceText\": \"and there was no injection at Week 42. At Week 66, the investigator may elect to further extend the treatment interval from 18 weeks to 24 weeks, and treat the study eye at Week 90, if the disease did\"}, {\"id\": \"2dab6230-4f2f-4b16-b550-a8c2278f3420\", \"visitName\": \"Week 48\", \"targetDay\": 330, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 15, \"targetWeek\": 48, \"sourceText\": \"90, with the option from Week 48 onwards to extend the treatment interval by 6 weeks at a time up to 24 weeks. \\u2022\"}, {\"id\": \"fa63027f-88b0-4968-99f5-6f8c9eb23de5\", \"visitName\": \"Follow-up\", \"targetDay\": 365, \"windowBefore\": 7, \"windowAfter\": 7, \"isRequired\": true, \"visitNumber\": 16, \"sourceText\": \"Lost to follow-up ................................................................................... 53 9.1.4 Early study termination by the sponsor ................................................. \"}, {\"id\": \"4fdd7473-3189-4510-b85f-43db1be63d3c\", \"visitName\": \"Week 54\", \"targetDay\": 372, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 17, \"targetWeek\": 54, \"epoch\": \"Treatment\", \"sourceText\": \"change from Baseline in visual acuity at Week 54 by assessing the change from Baseline in best corrected visual acuity (BCVA) at Week 54 Secondary\"}, {\"id\": \"1ea15de5-5f75-46de-9878-ac54c868022b\", \"visitName\": \"Week 66\", \"targetDay\": 456, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 18, \"targetWeek\": 66, \"sourceText\": \"weeks to 18 weeks and treat the study eye at Week 66, if the disease did not worsen, e.g. no new or expanding retinal neovascularization, between Week 36 and Week 48 and there was no injection at Week\"}, {\"id\": \"b52a04a4-4215-4c40-90c9-1f61f04e8232\", \"visitName\": \"Week 90\", \"targetDay\": 624, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": false, \"visitNumber\": 19, \"targetWeek\": 90, \"sourceText\": \"PRP treatment (may split into 2-4 sessions) as needed up to Week 90.\"}, {\"id\": \"e3452f3e-f05c-4f55-b550-4d7edcf8928d\", \"visitName\": \"Week 96\", \"targetDay\": 666, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 20, \"targetWeek\": 96, \"epoch\": \"Treatment\", \"sourceText\": \"Week 96 To compare the effect of brolucizumab relative to PRP on ocular complications by assessing the proportion of subjects developing vision-threatening complications\"}]"
              },
              {
                "id": "a72fbe8f-209d-416f-bbf8-9943c4e4fcf2",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-randomizationScheme",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"id\": \"739da7e9-3f47-40dc-98ee-6cd07b77d0d4\", \"ratio\": \"1:1\", \"method\": \"Stratified block randomization\", \"centralRandomization\": true, \"blockSize\": \"Not specified\", \"stratificationFactors\": [{\"id\": \"6acca3d9-c016-417f-8c71-e91944fb66e0\", \"name\": \"Region\", \"categories\": [\"North America\", \"Europe\", \"Asia\", \"Rest of World\"], \"isBlocking\": false, \"sourceText\": \"region\"}, {\"id\": \"5ea80024-6999-40c4-ab20-b774736c055f\", \"name\": \"Baseline BCVA\", \"categories\": [\"73 to 78 letters\", \"72 letters or fewer\"], \"isBlocking\": false}, {\"id\": \"19fffbb4-096f-45a9-8f8f-2ebc404b5006\", \"name\": \"Prior anti-VEGF therapy for DME\", \"categories\": [\"Yes\", \"No\"], \"isBlocking\": false}], \"sourceText\": \"Novartis \\nConfidential \\nPage 2 \\nAmended Protocol Version No. 02 (Clean) \\n \\nProtocol No. CRTH258D2301 \\n \\nTable of contents \\nTable of contents ...........................................................\"}"
              },
              {
                "id": "ext_execution_model_e32450bd-5854-4cee-bbf6-0a5e23592411",
                "url": "https://protocol2usdm.io/extensions/x-executionModel",
                "instanceType": "ExtensionAttribute",
                "valueObject": {
                  "schemaVersion": "1.0.0",
                  "extractionTimestamp": "2026-01-23T04:53:37.367788",
                  "executionModel": {
                    "timeAnchors": [
                      {
                        "id": "a97f64f6-5099-4cbd-9696-579387386113",
                        "definition": "The point at which a subject is assigned to a treatment arm and is no longer considered a screen failure.",
                        "anchorType": "Randomization",
                        "classification": "Event",
                        "timelineId": null,
                        "dayValue": 1,
                        "intraDayOrder": 40,
                        "sourceText": "Screen Failure: A subject who is screened but is not treated or randomized",
                        "encounterId": null,
                        "activityId": null
                      },
                      {
                        "id": "a42cfc0d-424e-401c-b3b5-0dbd27bda01d",
                        "definition": "Baseline visit/assessment",
                        "anchorType": "Baseline",
                        "classification": "Visit",
                        "timelineId": null,
                        "dayValue": 1,
                        "intraDayOrder": 50,
                        "sourceText": "Baseline visit",
                        "encounterId": null,
                        "activityId": null
                      },
                      {
                        "id": "5600f673-96e7-456b-ae49-b69140132e2d",
                        "definition": "Screening visit",
                        "anchorType": "Screening",
                        "classification": "Visit",
                        "timelineId": null,
                        "dayValue": 1,
                        "intraDayOrder": 20,
                        "sourceText": "Screening visit",
                        "encounterId": null,
                        "activityId": null
                      },
                      {
                        "id": "8c418e62-3e92-4e03-beab-8da97df03dfd",
                        "definition": "Informed consent obtained",
                        "anchorType": "InformedConsent",
                        "classification": "Event",
                        "timelineId": null,
                        "dayValue": 1,
                        "intraDayOrder": 10,
                        "sourceText": "Informed Consent",
                        "encounterId": null,
                        "activityId": null
                      },
                      {
                        "id": "f91d760a-c367-4107-9617-141483131bea",
                        "definition": "procedure",
                        "anchorType": "Custom",
                        "classification": "Conceptual",
                        "timelineId": null,
                        "dayValue": 1,
                        "intraDayOrder": 100,
                        "sourceText": "procedure",
                        "encounterId": null,
                        "activityId": null
                      }
                    ],
                    "repetitions": [
                      {
                        "id": "d2268f3f-1a8a-4c3b-b258-58fd7b07058f",
                        "type": "Daily",
                        "interval": "P1D",
                        "sourceText": "od"
                      },
                      {
                        "id": "ff9b97cc-3bb8-43de-95b6-dfbadeca3710",
                        "type": "Continuous",
                        "startOffset": "-P21D",
                        "endOffset": "-P1D",
                        "sourceText": "Days \n-21 to -1"
                      },
                      {
                        "id": "116f89cb-ffa4-4f66-bf23-83912b0148fc",
                        "type": "Continuous",
                        "startOffset": "P18D",
                        "endOffset": "P90D",
                        "sourceText": "Week 18 to Week 90"
                      },
                      {
                        "id": "b8a0b239-50a4-4c23-aba1-dd5ea642b287",
                        "type": "Continuous",
                        "startOffset": "P90D",
                        "endOffset": "P96D",
                        "sourceText": "Week 90 to Week 96"
                      },
                      {
                        "id": "a31c06fb-a0e9-43bd-9032-b499fef091b4",
                        "type": "Continuous",
                        "startOffset": "P12D",
                        "endOffset": "P96D",
                        "sourceText": "Week 12 to Week 96"
                      },
                      {
                        "id": "882d1cbf-b465-4f90-b412-e299650d8142",
                        "type": "Continuous",
                        "startOffset": "P12D",
                        "endOffset": "P96D",
                        "sourceText": "from Week 12 to Week 96"
                      },
                      {
                        "id": "c5d6a08a-7194-479d-8a0f-ee7a4d5924de",
                        "type": "Continuous",
                        "sourceText": "screening period"
                      },
                      {
                        "id": "0080310e-a377-48ba-a233-8d27df667213",
                        "type": "Continuous",
                        "sourceText": "screening phase"
                      },
                      {
                        "id": "7f35e2d7-0d8e-4b0d-ac72-280b5fec1eb6",
                        "type": "Continuous",
                        "sourceText": "follow-up period"
                      },
                      {
                        "id": "ea2d3608-e994-44e7-845b-a2306dd6ca7a",
                        "type": "Continuous",
                        "sourceText": "3 days after"
                      },
                      {
                        "id": "34d0b03f-fe4c-47e2-89ba-95403e033d4b",
                        "type": "Cycle",
                        "startOffset": "P0D",
                        "endOffset": "null",
                        "interval": "P6W",
                        "exitCondition": "null",
                        "sourceText": "q6w Every 6 weeks"
                      },
                      {
                        "id": "2417e891-3cec-410a-a53f-e3d831b9b108",
                        "type": "Cycle",
                        "startOffset": "P0D",
                        "endOffset": "null",
                        "interval": "P8W",
                        "exitCondition": "null",
                        "sourceText": "q8w Every 8 weeks"
                      },
                      {
                        "id": "631b965f-dd45-4f8f-b74a-2748357e7dba",
                        "type": "Cycle",
                        "startOffset": "P0D",
                        "endOffset": "null",
                        "interval": "P12W",
                        "exitCondition": "null",
                        "sourceText": "q12w Every 12 weeks"
                      },
                      {
                        "id": "d9d47555-e2f6-4095-bea5-8535a2cf19a1",
                        "type": "Continuous",
                        "startOffset": "P0D",
                        "endOffset": "null",
                        "interval": "null",
                        "exitCondition": "null",
                        "sourceText": "Requirement to apply the same pregnancy testing in both arms, throughout the study"
                      }
                    ],
                    "samplingConstraints": [],
                    "traversalConstraints": [
                      {
                        "id": "2619eed1-63e2-4107-aacb-fd50314febbf",
                        "requiredSequence": [
                          "epoch_1",
                          "epoch_2",
                          "epoch_2",
                          "epoch_3"
                        ],
                        "allowEarlyExit": true,
                        "exitEpochIds": [
                          "443bc3e2-707c-43bb-9349-13e1bd28d55d"
                        ],
                        "mandatoryVisits": [
                          "Required Assessment",
                          "Screening",
                          "Baseline",
                          "Day 1",
                          "End of Study"
                        ],
                        "sourceText": "[{'condition': 'Subject experiences AE requiring discontinuation', 'path': ['DISCONTINUATION_OF_STUDY_TREATMENT', 'EARLY_TERMINATION_VISIT']}, {'condition': 'Subject is lost to follow-up', 'path': ['LOST_TO_FOLLOW_UP_PROCEDURES']}, {'condition': 'Withdrawal of informed consent', 'path': ['WITHDRAWAL_OF_CONSENT_PROCEDURES']}]"
                      }
                    ],
                    "executionTypes": [
                      {
                        "activityId": "Blood Sample",
                        "executionType": "Single",
                        "rationale": "No strong signals detected"
                      },
                      {
                        "activityId": "Vital Sign",
                        "executionType": "Single",
                        "rationale": "SINGLE signals: 1"
                      },
                      {
                        "activityId": "Pe",
                        "executionType": "Single",
                        "rationale": "EPISODE signals: 1; SINGLE signals: 2"
                      },
                      {
                        "activityId": "Adverse Events",
                        "executionType": "Single",
                        "rationale": "No strong signals detected"
                      },
                      {
                        "activityId": "Concomitant Medication",
                        "executionType": "Episode",
                        "rationale": "EPISODE signals: 2; SINGLE signals: 2"
                      },
                      {
                        "activityId": "Laboratory Assessments",
                        "executionType": "Single",
                        "rationale": "SINGLE signals: 1"
                      },
                      {
                        "activityId": "Pharmacodynamic",
                        "executionType": "Single",
                        "rationale": "No strong signals detected"
                      },
                      {
                        "activityId": "Drug Administration",
                        "executionType": "Single",
                        "rationale": "SINGLE signals: 4"
                      },
                      {
                        "activityId": "Imaging",
                        "executionType": "Recurring",
                        "rationale": "WINDOW signals: 1; EPISODE signals: 1; RECURRING signals: 4"
                      },
                      {
                        "activityId": "Epro",
                        "executionType": "Episode",
                        "rationale": "EPISODE signals: 2; SINGLE signals: 1"
                      },
                      {
                        "activityId": "Screening Assessment",
                        "executionType": "Single",
                        "rationale": "The screening phase is a one-time assessment period to determine eligibility prior to randomization."
                      },
                      {
                        "activityId": "Randomization",
                        "executionType": "Single",
                        "rationale": "Treatment assignment occurs as a single event at the start of the study."
                      },
                      {
                        "activityId": "Study Treatment Administration",
                        "executionType": "Single",
                        "rationale": "The protocol describes a 96-week study with scheduled doses of brolucizumab or laser at specific study visits."
                      },
                      {
                        "activityId": "Safety and Efficacy Assessments",
                        "executionType": "Single",
                        "rationale": "Assessments are scheduled to repeat at multiple study visits throughout the 96-week duration."
                      },
                      {
                        "activityId": "Dose Modification",
                        "executionType": "Single",
                        "rationale": "Section 6.5 indicates conditional workflows for adjusting treatment based on specific clinical criteria or safety findings."
                      }
                    ],
                    "footnoteConditions": [
                      {
                        "id": "6790365c-844b-451d-b094-30032a8a5bdd",
                        "conditionType": "timing_before",
                        "text": "a. Informed consent must be obtained prior to any study-specific procedures.",
                        "footnoteId": "21e53e98-4fbc-43e3-989a-577e8cd47b8c",
                        "structuredCondition": "sequence.must_precede(informed_consent, all_study_procedures)",
                        "appliesToActivityIds": [
                          "b5f7e7e4-e9d4-497e-a75a-63b72a089d30"
                        ],
                        "sourceText": "a. Informed consent must be obtained prior to any study-specific procedures."
                      },
                      {
                        "id": "e8f59106-e038-445f-8841-21c3086762ba",
                        "conditionType": "general",
                        "text": "b. Includes history of primary diagnosis, including type of diabetes and PDR.",
                        "footnoteId": "e24484c0-ee43-4754-a22c-3bd66c86e1d4",
                        "structuredCondition": "procedure.include(primary_diagnosis_history, [diabetes_type, PDR])",
                        "appliesToActivityIds": [
                          "Medical History"
                        ],
                        "sourceText": "b. Includes history of primary diagnosis, including type of diabetes and PDR."
                      },
                      {
                        "id": "f663ba38-37fa-4179-9956-7528a585136d",
                        "conditionType": "general",
                        "text": "c. Vital signs include blood pressure and pulse rate.",
                        "footnoteId": "02b85f1c-10bb-4aa0-8e87-f6bbff80f424",
                        "structuredCondition": "procedure.include(vital_signs, [blood_pressure, pulse_rate])",
                        "appliesToActivityIds": [
                          "Vital Signs"
                        ],
                        "sourceText": "c. Vital signs include blood pressure and pulse rate."
                      },
                      {
                        "id": "cafce793-6a8a-4cae-bbf8-e65f510264af",
                        "conditionType": "general",
                        "text": "d. BCVA to be assessed by masked certified personnel using ETDRS charts.",
                        "footnoteId": "299f1746-bd0e-40a4-8a76-1aeab230a480",
                        "structuredCondition": "procedure.method(BCVA, [masked_personnel, ETDRS_charts])",
                        "appliesToActivityIds": [
                          "BCVA"
                        ],
                        "sourceText": "d. BCVA to be assessed by masked certified personnel using ETDRS charts."
                      },
                      {
                        "id": "e64b8e0d-8b50-447d-8207-09ae26b4f48d",
                        "conditionType": "general",
                        "text": "e. IOP measurement to be performed in both eyes; post-injection IOP measurement within 60 minutes for study eye.",
                        "footnoteId": "2a51276b-b0c4-49d8-92ee-03a4eaf1f7e5",
                        "structuredCondition": "timing.within(IOP_measurement, injection, PT60M)",
                        "appliesToActivityIds": [
                          "IOP measurement"
                        ],
                        "sourceText": "e. IOP measurement to be performed in both eyes; post-injection IOP measurement within 60 minutes fo"
                      },
                      {
                        "id": "24909e87-18f1-40a5-87ce-81dcab0b0e45",
                        "conditionType": "general",
                        "text": "f. 7-field CFP and FA images to be evaluated by the Central Reading Center (CRC).",
                        "footnoteId": "3bbd5710-9f63-4037-b9c2-1528b84c399b",
                        "structuredCondition": "procedure.evaluator(CFP_FA_images, Central_Reading_Center)",
                        "appliesToActivityIds": [
                          "cfacdadb-2f92-4c19-8e1e-7bb2a1ecac1e",
                          "FA images"
                        ],
                        "sourceText": "f. 7-field CFP and FA images to be evaluated by the Central Reading Center (CRC)."
                      },
                      {
                        "id": "84e061c7-b382-444b-b346-067eb12e21bf",
                        "conditionType": "general",
                        "text": "h. Disease activity assessment (DAA) used to determine treatment interval extension or reduction.",
                        "footnoteId": "24a79b58-ba6d-4041-abcd-30910070c87b",
                        "structuredCondition": "decision.use(DAA, treatment_interval_adjustment)",
                        "appliesToActivityIds": [
                          "Disease activity assessment"
                        ],
                        "sourceText": "h. Disease activity assessment (DAA) used to determine treatment interval extension or reduction."
                      },
                      {
                        "id": "21dda0d7-837e-4e07-a78a-58df21e00725",
                        "conditionType": "general",
                        "text": "i. PRP treatment may be split into 2-4 sessions as needed up to Week 12.",
                        "footnoteId": "707ded92-7ed8-48c9-ab0e-d7943da0a4e4",
                        "structuredCondition": "frequency.split(PRP_treatment, 2, 4).before(W12)",
                        "appliesToActivityIds": [
                          "PRP treatment"
                        ],
                        "sourceText": "i. PRP treatment may be split into 2-4 sessions as needed up to Week 12."
                      },
                      {
                        "id": "b4db8d3b-da83-4d99-bf63-de38158200c1",
                        "conditionType": "timing_at",
                        "text": "j. End of Study (EOS) visit to be performed at Week 96 or at early discontinuation.",
                        "footnoteId": "ccd4f795-d3c0-4afd-a6f9-6c182090ef68",
                        "structuredCondition": "timing.at(EOS, [W96, early_discontinuation])",
                        "appliesToActivityIds": [
                          "End of Study visit"
                        ],
                        "sourceText": "j. End of Study (EOS) visit to be performed at Week 96 or at early discontinuation."
                      },
                      {
                        "id": "fcf89a44-5bc8-44c9-b494-1577e6433811",
                        "conditionType": "timing_before",
                        "text": "1. Signed informed consent must be obtained prior to participation in the study.",
                        "footnoteId": "3c067d8e-5ba5-4ce2-bd7e-a7b8daaf7ea6",
                        "sourceText": "1. Signed informed consent must be obtained prior to participation in the study."
                      },
                      {
                        "id": "be60087a-ae3a-4770-b5b6-c83bc5c94c03",
                        "conditionType": "general",
                        "text": "2. Patients â‰¥ 18 years of age at Screening.",
                        "footnoteId": "5e4f526e-0c6c-481b-a26a-40010b3e3b58",
                        "structuredCondition": "eligibility.age >= 18",
                        "appliesToActivityIds": [
                          "Screening"
                        ],
                        "sourceText": "2. Patients â‰¥ 18 years of age at Screening."
                      },
                      {
                        "id": "4a0d6922-f42d-4e5a-b00e-6a4cf786d165",
                        "conditionType": "general",
                        "text": "3. Participant cooperation sufficient for adequate fundus photographs and retinal images.",
                        "footnoteId": "907859f7-b2a0-42e4-98d3-7af1860106e0",
                        "sourceText": "3. Participant cooperation sufficient for adequate fundus photographs and retinal images."
                      },
                      {
                        "id": "761b09d8-4bcf-4336-be40-41159f48d139",
                        "conditionType": "general",
                        "text": "4. Patients diagnosed with type 1 or 2 DM, and HbA1c â‰¤ 12% at Screening.",
                        "footnoteId": "cb3e99c8-48e8-402a-a6e0-444ab0f90bfb",
                        "structuredCondition": "eligibility.and(diagnosis(DM_type_1_or_2), HbA1c <= 12)",
                        "appliesToActivityIds": [
                          "Screening"
                        ],
                        "sourceText": "4. Patients diagnosed with type 1 or 2 DM, and HbA1c â‰¤ 12% at Screening."
                      },
                      {
                        "id": "9ee7aec8-34b1-4952-bc9c-8729209bac03",
                        "conditionType": "timing_before",
                        "text": "5. Any medication administered for the management of DM should be stable within 3 months prior to randomization and is expected to remain stable during the course of the study, as medically acceptable. Study eye",
                        "footnoteId": "0397890e-65a3-4b9e-8cb8-11d812267bfb",
                        "structuredCondition": "eligibility.stable_medication(DM, P3M)",
                        "appliesToActivityIds": [
                          "Randomization"
                        ],
                        "sourceText": "5. Any medication administered for the management of DM should be stable within 3 months prior to ra"
                      },
                      {
                        "id": "70a93fa1-d27e-401c-9c57-badc6960c4c0",
                        "conditionType": "general",
                        "text": "6. PDR as assessed by the investigator using standard or wide-field CFP and FA, with no evidence of previous PRP, and that requires treatment with either anti-VEGF or PRP in the opinion of the investigator.",
                        "footnoteId": "e6d79e54-8150-4e60-85f2-c1de427f918a",
                        "sourceText": "6. PDR as assessed by the investigator using standard or wide-field CFP and FA, with no evidence of "
                      },
                      {
                        "id": "ed613f8a-1084-4f93-9c7e-00b5ac36d5d7",
                        "conditionType": "general",
                        "text": "7. BCVA â‰¥ 34 ETDRS letters (Snellen equivalent 20/200) at Screening and Baseline.",
                        "footnoteId": "b0fdb985-e3cb-442d-a348-51ad3f1ff817",
                        "structuredCondition": "eligibility.BCVA >= 34",
                        "appliesToActivityIds": [
                          "Screening",
                          "Baseline"
                        ],
                        "sourceText": "7. BCVA â‰¥ 34 ETDRS letters (Snellen equivalent 20/200) at Screening and Baseline."
                      },
                      {
                        "id": "8dd6396d-9e95-472c-b3d5-a0a18203c373",
                        "conditionType": "general",
                        "text": "8. Presence of amblyopia, amaurosis, or ocular disorders in the fellow eye with BCVA < 20/200 at Screening (except when due to conditions for which treatment or surgery may improve VA, e.g. cataract). Ocular treatments in the study eye",
                        "footnoteId": "1aa138a9-776b-4af7-ba62-9d1068154cc8",
                        "sourceText": "8. Presence of amblyopia, amaurosis, or ocular disorders in the fellow eye with BCVA < 20/200 at Scr"
                      }
                    ],
                    "endpointAlgorithms": [
                      {
                        "id": "edecd821-b3e5-488a-a04c-775a3ebdc222",
                        "name": "Primary: Change from Baseline in BCVA",
                        "endpointType": "Primary",
                        "inputs": [
                          "BCVA at Week 54",
                          "Baseline BCVA",
                          "Alternative DR/DME treatment status"
                        ],
                        "timeWindow": {
                          "reference": "Baseline",
                          "duration": "54 weeks"
                        },
                        "algorithm": "BCVA_Week_54 - BCVA_Baseline (excluding data after confounding alternative DR/DME treatments)",
                        "successCriteria": "Lower limit of the two-sided 95% CI for the least square mean difference (brolucizumab - PRP) > -4 letters",
                        "sourceText": "The objective related to the primary endpoint is to demonstrate non-inferiority of brolucizumab versus PRP with respect to the change from Baseline in BCVA at Week 54, assuming a non-inferiority margi"
                      },
                      {
                        "id": "f89a855e-7968-45d1-945a-94eccb167877",
                        "name": "First Key Secondary: Proportion of subjects with no PDR",
                        "endpointType": "Secondary",
                        "inputs": [
                          "PDR status at Week 54"
                        ],
                        "timeWindow": {
                          "reference": "Baseline",
                          "duration": "54 weeks"
                        },
                        "algorithm": "(Count of subjects with no PDR at Week 54 / Total subjects in treatment arm)",
                        "successCriteria": "Superiority of brolucizumab vs PRP via CMH test (one-sided p < 0.025) after primary non-inferiority is established",
                        "sourceText": "The objective related to first key secondary endpoint is to demonstrate superiority of brolucizumab versus PRP with respect to increasing the proportion of subjects with no PDR at Week 54."
                      },
                      {
                        "id": "51573948-eb72-42be-8804-024e145fd136",
                        "name": "Other Key Secondary: Proportion of subjects with center-involved DME",
                        "endpointType": "Secondary",
                        "inputs": [
                          "Center-involved DME status up to Week 54"
                        ],
                        "timeWindow": {
                          "reference": "Baseline",
                          "duration": "Up to 54 weeks"
                        },
                        "algorithm": "(Count of subjects with center-involved DME / Total subjects in treatment arm)",
                        "successCriteria": "Superiority of brolucizumab vs PRP via CMH test (one-sided p < 0.025) after primary and first key secondary superiority are established",
                        "sourceText": "The objective related to the other key secondary endpoint is to demonstrate superiority of brolucizumab versus PRP with respect to reducing the proportion of subjects with center-involved DME up to We"
                      }
                    ],
                    "derivedVariables": [
                      {
                        "id": "dbe6a1d4-04e1-485d-9df8-599a0a2b867e",
                        "name": "Change from Baseline in BCVA at Week 54",
                        "variableType": "ChangeFromBaseline",
                        "sourceVariables": [
                          "BCVA"
                        ],
                        "derivationRule": "Week 54 BCVA value - Baseline BCVA value",
                        "baselineDefinition": "Last non-missing value prior to randomization/treatment",
                        "baselineVisit": "Baseline",
                        "analysisWindow": "Week 54",
                        "imputationRule": "ANCOVA model (Primary estimand excludes confounding effect of alternative DR/DME treatments)",
                        "unit": "ETDRS letters"
                      },
                      {
                        "id": "445c6d11-d68b-4397-a063-86927681db47",
                        "name": "Proportion of subjects with no PDR at Week 54",
                        "variableType": "Categorical",
                        "sourceVariables": [
                          "ETDRS DRSS score"
                        ],
                        "derivationRule": "Count of subjects with DRSS score indicating no PDR / Total subjects in analysis set",
                        "baselineDefinition": "Presence of PDR at Baseline as per inclusion criteria",
                        "baselineVisit": "Baseline",
                        "analysisWindow": "Week 54",
                        "imputationRule": "Cochran-Mantel-Haenszel (CMH) test",
                        "unit": "Percentage"
                      },
                      {
                        "id": "2874b8cc-1383-4169-a725-a9cff4843856",
                        "name": "Proportion of subjects with center-involved DME up to Week 54",
                        "variableType": "Categorical",
                        "sourceVariables": [
                          "SD-OCT anatomical markers"
                        ],
                        "derivationRule": "Count of subjects developing center-involved DME at any point through Week 54 / Total subjects",
                        "baselineDefinition": "Absence of center-involved DME at Baseline",
                        "baselineVisit": "Baseline",
                        "analysisWindow": "Up to Week 54",
                        "imputationRule": "null",
                        "unit": "Percentage"
                      },
                      {
                        "id": "40630d75-047a-49aa-8821-a1e035881291",
                        "name": "Area under the curve in change from Baseline in BCVA",
                        "variableType": "Composite",
                        "sourceVariables": [
                          "BCVA"
                        ],
                        "derivationRule": "Area under the curve (AUC) calculation of change from baseline values across all visits up to Week 54 and Week 96",
                        "baselineDefinition": "Last non-missing value prior to treatment",
                        "baselineVisit": "Baseline",
                        "analysisWindow": "Up to Week 54 and Week 96",
                        "imputationRule": "null",
                        "unit": "ETDRS letters * weeks"
                      },
                      {
                        "id": "08a7a25a-fb1b-4fa2-b6ad-b13311f2b43d",
                        "name": "Change from Baseline in ETDRS DRSS score",
                        "variableType": "ChangeFromBaseline",
                        "sourceVariables": [
                          "ETDRS DRSS score"
                        ],
                        "derivationRule": "Visit_value - Baseline_value",
                        "baselineDefinition": "Last non-missing score based on 7-field CFP prior to treatment",
                        "baselineVisit": "Baseline",
                        "analysisWindow": "Week 54 and Week 96",
                        "imputationRule": "null",
                        "unit": "DRSS score units"
                      },
                      {
                        "id": "1ed5c9b0-b579-4355-b114-cfa7b8969348",
                        "name": "Proportion of subjects developing vision-threatening complications associated with DR",
                        "variableType": "Categorical",
                        "sourceVariables": [
                          "Ocular complications",
                          "BCVA",
                          "CFP"
                        ],
                        "derivationRule": "Count of subjects with one or more vision-threatening complications / Total subjects",
                        "baselineDefinition": "Absence of complications at Baseline",
                        "baselineVisit": "Baseline",
                        "analysisWindow": "Up to Week 54 and Week 96",
                        "imputationRule": "null",
                        "unit": "Percentage"
                      }
                    ],
                    "stateMachine": {
                      "id": "f07bcaa5-c5b2-4c09-abbd-8af4c16a8f2c",
                      "initialState": "Screening",
                      "terminalStates": [
                        "Early Termination",
                        "Completed"
                      ],
                      "states": [
                        "Screening",
                        "Baseline",
                        "Treatment",
                        "End Of Study",
                        "Early Termination"
                      ],
                      "transitions": [
                        {
                          "fromState": "Screening",
                          "toState": "Baseline",
                          "trigger": "Progress to Baseline"
                        },
                        {
                          "fromState": "Baseline",
                          "toState": "Treatment",
                          "trigger": "Progress to Treatment"
                        },
                        {
                          "fromState": "Treatment",
                          "toState": "End Of Study",
                          "trigger": "Progress to End Of Study"
                        },
                        {
                          "fromState": "Treatment",
                          "toState": "Early Termination",
                          "trigger": "Subject exits to Early Termination"
                        }
                      ],
                      "epochIds": {
                        "Screening": "SCREENING",
                        "Baseline": "BASELINE",
                        "Treatment": "TREATMENT",
                        "End Of Study": "END_OF_STUDY",
                        "Early Termination": "EARLY_TERMINATION"
                      }
                    },
                    "dosingRegimens": [
                      {
                        "id": "fbd9f4f0-ede2-4882-ac5f-b697c8c9c0e9",
                        "treatmentName": "Brolucizumab",
                        "frequency": "QD",
                        "route": "Oral",
                        "startDay": 1,
                        "doseLevels": [
                          {
                            "amount": 6.0,
                            "unit": "mg"
                          }
                        ],
                        "durationDescription": "6 weeks",
                        "sourceText": "tients with proliferative diabetic retinopathy (PDR). Subjects who meet all the inclusion and none of the exclusion criteria will be randomized in a 1:1 ratio to one of the two treatment arms: â€¢ Brolu"
                      },
                      {
                        "id": "91915040-dbf5-4313-8dcb-63b8d7794aea",
                        "treatmentName": "RTH258",
                        "frequency": "QD",
                        "route": "Oral",
                        "startDay": 1,
                        "doseLevels": [
                          {
                            "amount": 6.0,
                            "unit": "mg"
                          }
                        ],
                        "sourceText": "Study treatment 6.1.1 Investigational drug Table 6-1 Investigational drug Investigational Drug Pharmaceutical Dosage Form Route of Administration Supply Type Sponsor Brolucizumab 6 mg (RTH258 6 mg/ 0."
                      },
                      {
                        "id": "a94cf98b-356d-4b44-a714-e177db2a5745",
                        "treatmentName": "Brolucizumab (RTH258)",
                        "frequency": "Q4W",
                        "route": "",
                        "startDay": 1,
                        "doseLevels": [
                          {
                            "amount": 6.0,
                            "unit": "mg",
                            "description": "Intravitreal injection"
                          }
                        ],
                        "durationDescription": "96 weeks",
                        "doseModifications": [
                          "Dose modification and escalation details are located in Section 6.5 of the protocol."
                        ]
                      },
                      {
                        "id": "06536de6-f985-48b1-81dc-9a75e3e7f553",
                        "treatmentName": "Panretinal Photocoagulation (PRP) Laser",
                        "frequency": "Single",
                        "route": "",
                        "startDay": 1,
                        "durationDescription": "96 weeks (study duration)"
                      }
                    ],
                    "visitWindows": [
                      {
                        "id": "5e8428ca-e82a-4d75-8a83-9481e48f887b",
                        "visitName": "Screening",
                        "targetDay": -14,
                        "windowBefore": 7,
                        "windowAfter": 0,
                        "isRequired": true,
                        "visitNumber": 1,
                        "epoch": "Screening",
                        "sourceText": "Screening ............................................................................................................... 43 8.1.1 Information to be collected on screening failures ..................."
                      },
                      {
                        "id": "427a6cba-7549-4fa5-85f1-bc022008d8bd",
                        "visitName": "baseline",
                        "targetDay": 0,
                        "windowBefore": 1,
                        "windowAfter": 1,
                        "isRequired": true,
                        "visitNumber": 2,
                        "sourceText": "Subject demographics/other baseline characteristics ............................................. 43 8.3 Efficacy ......................................................................................"
                      },
                      {
                        "id": "6f7dbd4f-1cf0-4959-a2e5-46668f861301",
                        "visitName": "Early Termination",
                        "targetDay": null,
                        "windowBefore": 0,
                        "windowAfter": 0,
                        "isRequired": true,
                        "visitNumber": 3,
                        "sourceText": "Safety ..................................................................................................................... 47 8.4.1 Vital sign assessments ..........................................."
                      },
                      {
                        "id": "6cbe50c9-9c41-40c3-b7ed-8ae55df2769a",
                        "visitName": "EOS",
                        "targetDay": null,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 4,
                        "epoch": "Completion",
                        "sourceText": "Baseline/Day 1 visit window and timing of EOS visit for early study discontinuation. â€¢ Section 5.2 Exclusion Criteria: Protocol clarification regarding exclusion criteria Number 8, 13 and Number 20."
                      },
                      {
                        "id": "7cc6f900-ee03-4742-b745-d98e1b4488c2",
                        "visitName": "EOT",
                        "targetDay": null,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 5,
                        "sourceText": "16/EOT 17/EOS Days"
                      },
                      {
                        "id": "f07bdc7e-5057-47fd-8047-344d3221f0db",
                        "visitName": "randomization",
                        "targetDay": 1,
                        "windowBefore": 0,
                        "windowAfter": 0,
                        "isRequired": true,
                        "visitNumber": 6,
                        "epoch": "Treatment",
                        "sourceText": "stable within 3 months prior to randomization and is expected to remain stable during the course of the study, as medically acceptable. â€¢"
                      },
                      {
                        "id": "85098902-3ab9-4319-9a1c-26341783f717",
                        "visitName": "Week 6",
                        "targetDay": 36,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 7,
                        "targetWeek": 6,
                        "sourceText": "every 6 weeks at Baseline, Week 6 and Week 12 during the loading phase. Maintenance phase (Week 18 to Week 90): Subjects will then receive q12w injections in the maintenance phase. Additional assessme"
                      },
                      {
                        "id": "c5939ee7-9e22-4685-a16e-16bec6123ee8",
                        "visitName": "Week 12",
                        "targetDay": 78,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": false,
                        "visitNumber": 8,
                        "targetWeek": 12,
                        "sourceText": "PRP: initial treatment in 1-4 sessions up to Week 12, followed with additional PRP treatment (may split into 2-4 sessions) as needed up to Week 90."
                      },
                      {
                        "id": "936a1137-6116-4469-982d-c7369d513094",
                        "visitName": "Week 16",
                        "targetDay": 106,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 9,
                        "targetWeek": 16,
                        "sourceText": "had disease activity at Week 16 in a head-to-head comparison based on matched dosing intervals, with a relative decrease of 30% versus aflibercept (P = 0.0022). Significantly fewer subjects on broluci"
                      },
                      {
                        "id": "5eb07367-b91a-4657-9c88-362e81b7aa03",
                        "visitName": "Week 18",
                        "targetDay": 120,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 10,
                        "targetWeek": 18,
                        "sourceText": "Maintenance phase (Week 18 to Week 90): Subjects will then receive q12w injections in the maintenance phase. Additional assessment visits are planned for disease monitoring, not for treatment administ"
                      },
                      {
                        "id": "ab3100ae-84cf-4b38-b6ec-f3222e14d1e3",
                        "visitName": "Week 24",
                        "targetDay": 162,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 11,
                        "targetWeek": 24,
                        "sourceText": "â€¢ Subjects will receive q12w injections in the maintenance phase, i.e. at Week 24, Week 36, and Week 48 in the first year. â€¢ During the maintenance phase, the additional visits (e.g. Week 30) are plan"
                      },
                      {
                        "id": "2e5d3a6a-ab6f-45b2-b7e6-644fa7377b17",
                        "visitName": "Week 30",
                        "targetDay": 204,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 12,
                        "targetWeek": 30,
                        "sourceText": "â€¢ During the maintenance phase, the additional visits (e.g. Week 30) are planned for disease monitoring, not for treatment administration. However, additional injections may be administered at these v"
                      },
                      {
                        "id": "e8d3aba8-720c-4db9-a3aa-33b7555224f5",
                        "visitName": "Week 36",
                        "targetDay": 246,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 13,
                        "targetWeek": 36,
                        "sourceText": "e.g. no new or expanding retinal neovascularization, between Week 36 and Week 48 and there was no injection at Week 42. At Week 66, the investigator may elect to further extend the treatment interval "
                      },
                      {
                        "id": "3b92b152-62d4-487e-a616-05317bed71c5",
                        "visitName": "Week 42",
                        "targetDay": 288,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 14,
                        "targetWeek": 42,
                        "sourceText": "and there was no injection at Week 42. At Week 66, the investigator may elect to further extend the treatment interval from 18 weeks to 24 weeks, and treat the study eye at Week 90, if the disease did"
                      },
                      {
                        "id": "2dab6230-4f2f-4b16-b550-a8c2278f3420",
                        "visitName": "Week 48",
                        "targetDay": 330,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 15,
                        "targetWeek": 48,
                        "sourceText": "90, with the option from Week 48 onwards to extend the treatment interval by 6 weeks at a time up to 24 weeks. â€¢"
                      },
                      {
                        "id": "fa63027f-88b0-4968-99f5-6f8c9eb23de5",
                        "visitName": "Follow-up",
                        "targetDay": 365,
                        "windowBefore": 7,
                        "windowAfter": 7,
                        "isRequired": true,
                        "visitNumber": 16,
                        "sourceText": "Lost to follow-up ................................................................................... 53 9.1.4 Early study termination by the sponsor ................................................. "
                      },
                      {
                        "id": "4fdd7473-3189-4510-b85f-43db1be63d3c",
                        "visitName": "Week 54",
                        "targetDay": 372,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 17,
                        "targetWeek": 54,
                        "epoch": "Treatment",
                        "sourceText": "change from Baseline in visual acuity at Week 54 by assessing the change from Baseline in best corrected visual acuity (BCVA) at Week 54 Secondary"
                      },
                      {
                        "id": "1ea15de5-5f75-46de-9878-ac54c868022b",
                        "visitName": "Week 66",
                        "targetDay": 456,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 18,
                        "targetWeek": 66,
                        "sourceText": "weeks to 18 weeks and treat the study eye at Week 66, if the disease did not worsen, e.g. no new or expanding retinal neovascularization, between Week 36 and Week 48 and there was no injection at Week"
                      },
                      {
                        "id": "b52a04a4-4215-4c40-90c9-1f61f04e8232",
                        "visitName": "Week 90",
                        "targetDay": 624,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": false,
                        "visitNumber": 19,
                        "targetWeek": 90,
                        "sourceText": "PRP treatment (may split into 2-4 sessions) as needed up to Week 90."
                      },
                      {
                        "id": "e3452f3e-f05c-4f55-b550-4d7edcf8928d",
                        "visitName": "Week 96",
                        "targetDay": 666,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 20,
                        "targetWeek": 96,
                        "epoch": "Treatment",
                        "sourceText": "Week 96 To compare the effect of brolucizumab relative to PRP on ocular complications by assessing the proportion of subjects developing vision-threatening complications"
                      }
                    ],
                    "randomizationScheme": {
                      "id": "739da7e9-3f47-40dc-98ee-6cd07b77d0d4",
                      "ratio": "1:1",
                      "method": "Stratified block randomization",
                      "centralRandomization": true,
                      "blockSize": "Not specified",
                      "stratificationFactors": [
                        {
                          "id": "6acca3d9-c016-417f-8c71-e91944fb66e0",
                          "name": "Region",
                          "categories": [
                            "North America",
                            "Europe",
                            "Asia",
                            "Rest of World"
                          ],
                          "isBlocking": false,
                          "sourceText": "region"
                        },
                        {
                          "id": "5ea80024-6999-40c4-ab20-b774736c055f",
                          "name": "Baseline BCVA",
                          "categories": [
                            "73 to 78 letters",
                            "72 letters or fewer"
                          ],
                          "isBlocking": false
                        },
                        {
                          "id": "19fffbb4-096f-45a9-8f8f-2ebc404b5006",
                          "name": "Prior anti-VEGF therapy for DME",
                          "categories": [
                            "Yes",
                            "No"
                          ],
                          "isBlocking": false
                        }
                      ],
                      "sourceText": "Novartis \nConfidential \nPage 2 \nAmended Protocol Version No. 02 (Clean) \n \nProtocol No. CRTH258D2301 \n \nTable of contents \nTable of contents ..........................................................."
                    }
                  }
                }
              },
              {
                "id": "128e03a9-d3d0-4d04-bd60-c81645d6b31d",
                "url": "https://protocol2usdm.io/extensions/x-soaFootnotes",
                "valueString": "[\"a. Informed consent must be obtained prior to any study-specific procedures.\", \"b. Includes history of primary diagnosis, including type of diabetes and PDR.\", \"c. Vital signs include blood pressure and pulse rate.\", \"d. BCVA to be assessed by masked certified personnel using ETDRS charts.\", \"e. IOP measurement to be performed in both eyes; post-injection IOP measurement within 60 minutes for study eye.\", \"f. 7-field CFP and FA images to be evaluated by the Central Reading Center (CRC).\", \"g. SD-OCT images to be evaluated by the CRC.\", \"h. Disease activity assessment (DAA) used to determine treatment interval extension or reduction.\", \"i. PRP treatment may be split into 2-4 sessions as needed up to Week 12.\", \"j. End of Study (EOS) visit to be performed at Week 96 or at early discontinuation.\", \"1. Signed informed consent must be obtained prior to participation in the study.\", \"2. Patients \\u2265 18 years of age at Screening.\", \"3. Participant cooperation sufficient for adequate fundus photographs and retinal images.\", \"4. Patients diagnosed with type 1 or 2 DM, and HbA1c \\u2264 12% at Screening.\", \"5. Any medication administered for the management of DM should be stable within 3 months prior to randomization and is expected to remain stable during the course of the study, as medically acceptable. Study eye\", \"6. PDR as assessed by the investigator using standard or wide-field CFP and FA, with no evidence of previous PRP, and that requires treatment with either anti-VEGF or PRP in the opinion of the investigator.\", \"7. BCVA \\u2265 34 ETDRS letters (Snellen equivalent 20/200) at Screening and Baseline.\", \"8. Presence of amblyopia, amaurosis, or ocular disorders in the fellow eye with BCVA < 20/200 at Screening (except when due to conditions for which treatment or surgery may improve VA, e.g. cataract). Ocular treatments in the study eye\", \"9. PRP any time prior to Baseline.\"]",
                "instanceType": "ExtensionAttribute"
              }
            ],
            "administrations": [
              {
                "id": "885d20b7-0671-4473-9ba7-44de572c285d",
                "name": "Brolucizumab Administration",
                "instanceType": "Administration",
                "dose": "6.0 mg",
                "doseFrequency": "QD",
                "route": {
                  "id": "5fff69b2-8464-441c-9005-6588ac080ff1",
                  "code": "Oral",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Oral",
                  "instanceType": "Code"
                },
                "duration": "6 weeks",
                "description": "tients with proliferative diabetic retinopathy (PDR). Subjects who meet all the inclusion and none of the exclusion criteria will be randomized in a 1:1 ratio to one of the two treatment arms: â€¢ Brolu"
              },
              {
                "id": "07b34fdb-536d-4b7a-aeae-0cb47b84f63b",
                "name": "RTH258 Administration",
                "instanceType": "Administration",
                "dose": "6.0 mg",
                "doseFrequency": "QD",
                "route": {
                  "id": "3f7a1483-da55-47c0-b207-5a3e70b4bcf5",
                  "code": "Oral",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Oral",
                  "instanceType": "Code"
                },
                "description": "Study treatment 6.1.1 Investigational drug Table 6-1 Investigational drug Investigational Drug Pharmaceutical Dosage Form Route of Administration Supply Type Sponsor Brolucizumab 6 mg (RTH258 6 mg/ 0."
              },
              {
                "id": "a88dfa20-d404-49e8-87e8-7d1cf8136bee",
                "name": "Brolucizumab (RTH258) Administration",
                "instanceType": "Administration",
                "dose": "6.0 mg",
                "doseFrequency": "Q4W",
                "route": {
                  "id": "d1389a61-beec-4c45-9a89-8cb34626516b",
                  "code": "",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "",
                  "instanceType": "Code"
                },
                "duration": "96 weeks"
              },
              {
                "id": "052d3315-ae22-4cd0-a799-c64f3f2b90ae",
                "name": "Panretinal Photocoagulation (PRP) Laser Administration",
                "instanceType": "Administration",
                "doseFrequency": "Single",
                "route": {
                  "id": "740090a0-01c6-40b2-afb6-5dfafda44776",
                  "code": "",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "",
                  "instanceType": "Code"
                },
                "duration": "96 weeks (study duration)"
              }
            ]
          }
        ],
        "titles": [
          {
            "id": "5e873cfc-aafa-4873-bd31-ee4b996ee1c3",
            "text": "A 96-week, two-arm, randomized, single-masked, multi-center, phase III study assessing the efficacy and safety of brolucizumab 6 mg compared to panretinal photocoagulation laser in patients with proliferative diabetic retinopathy (CONDOR)",
            "type": {
              "id": "9a014b6b-0254-4f65-b7c9-a30d50f17db0",
              "code": "Official Study Title",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Official Study Title",
              "instanceType": "Code"
            },
            "instanceType": "StudyTitle"
          },
          {
            "id": "4f6e92cc-1c13-4d22-8d68-5fd06b73463c",
            "text": "CONDOR",
            "type": {
              "id": "507bf544-83c9-4777-aadf-3fad4a064971",
              "code": "Study Acronym",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Study Acronym",
              "instanceType": "Code"
            },
            "instanceType": "StudyTitle"
          }
        ],
        "studyIdentifiers": [
          {
            "id": "b2d7e1a7-2924-4a74-94af-2f765d335c2b",
            "text": "NCT04278417",
            "instanceType": "StudyIdentifier",
            "scopeId": "b6118ca2-1c1c-4d3c-88c5-ccae19001ad8",
            "type": {
              "code": "C172240",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Clinicaltrials.gov Identifier",
              "instanceType": "Code"
            }
          },
          {
            "id": "b0a98db8-9212-4c39-b382-8d91a269ab98",
            "text": "CRTH258D2301",
            "instanceType": "StudyIdentifier",
            "scopeId": "56656b34-b618-4d0d-b6e0-3d49a001aca1",
            "type": {
              "code": "C132351",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Sponsor Protocol Identifier",
              "instanceType": "Code"
            }
          },
          {
            "id": "4932f891-33b2-49c7-8b00-74823f96ce3d",
            "text": "N/A",
            "instanceType": "StudyIdentifier",
            "scopeId": "8cb32710-e13d-4d41-8f9a-78b0256be938",
            "type": {
              "code": "C132351",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Sponsor Protocol Identifier",
              "instanceType": "Code"
            }
          }
        ],
        "organizations": [
          {
            "id": "56656b34-b618-4d0d-b6e0-3d49a001aca1",
            "name": "Novartis",
            "type": {
              "id": "463bd902-a42c-4a6f-97b2-2492d630d5a4",
              "code": "C54086",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Pharmaceutical Company",
              "instanceType": "Code"
            },
            "identifier": "Novartis",
            "identifierScheme": "DUNS",
            "instanceType": "Organization"
          },
          {
            "id": "b6118ca2-1c1c-4d3c-88c5-ccae19001ad8",
            "name": "ClinicalTrials.gov",
            "type": {
              "id": "5e2eb04a-ef5d-40a9-ae1b-99d56f6bc07d",
              "code": "C19326",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Healthcare Facility",
              "instanceType": "Code"
            },
            "identifier": "ClinicalTrials.gov",
            "identifierScheme": "DUNS",
            "instanceType": "Organization"
          },
          {
            "id": "56656b34-b618-4d0d-b6e0-3d49a001aca1",
            "name": "Retina Associates SW",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "1",
            "type": {
              "id": "83adbe46-c01c-4192-9fad-100581a218dc",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "b6118ca2-1c1c-4d3c-88c5-ccae19001ad8",
            "name": "Retina-Vitreous Assoc Medical Group",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "2",
            "type": {
              "id": "f77a9f89-ecbb-48ae-92c4-ea11b1c7e012",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "e4ac2ba9-7228-46e9-ba11-20674d5ad6d4",
            "name": "Retina Consultants of Orange County",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "3",
            "type": {
              "id": "1311faad-46e5-4784-8d06-fed4a5b8f4b2",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "cbef61c5-db95-4716-a507-28150ce0dc29",
            "name": "Salehi Retina Institute",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "4",
            "type": {
              "id": "05b96a94-71bc-4f12-8b3f-9cfb5448938f",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "7f37b583-bda1-41b2-96f6-2c2a4fd8c4d2",
            "name": "Retina Consultants of Southern California",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "5",
            "type": {
              "id": "6db17fc1-fe4e-405f-ab2e-c5bb1aeffbba",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "749d3a8a-7c09-46de-bd5a-9a0dd87f42a6",
            "name": "Premiere Practice Management LLC",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "6",
            "type": {
              "id": "71a50bea-46d7-48a0-9a91-5beea714af21",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "670ec56c-7cac-432a-ba00-d7b191c35781",
            "name": "Lundquist Inst BioMed at Harbor",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "7",
            "type": {
              "id": "57d8255f-4ce1-476b-b0bd-28d5c271393a",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "d3f01810-ebc2-4be1-9804-6b8d50a56e93",
            "name": "Miramar Eye Specialists",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "8",
            "type": {
              "id": "b1a8c9cf-153a-4a32-9fbf-c61979223ac2",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "81f24f69-a45b-40f4-b07e-86e910b42998",
            "name": "Advanced Research LLC",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "9",
            "type": {
              "id": "f919e858-2c5f-48a2-92dc-0bbcc742575b",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "facb677a-88c3-459c-9aa3-adf45d11073e",
            "name": "Rand Eye Institute",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "10",
            "type": {
              "id": "ecf8f89a-7a4e-4f76-8701-d07e5fb1bba3",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "2e9297be-0ff9-4728-a167-f400613d3ca5",
            "name": "Pinnacle Research Institute",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "11",
            "type": {
              "id": "a1abb935-8fd5-4350-ae47-f7c4af46b1c8",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "ff75a3c8-e9c5-4823-8d0a-7fb190d9ef0f",
            "name": "National Ophthalmic Research Institute",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "12",
            "type": {
              "id": "32b5517c-a7f4-4929-8853-2f0931f0a8c8",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "acd45b27-3ebb-4354-996c-a0d384352fbf",
            "name": "Florida Retina Institute",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "13",
            "type": {
              "id": "79ba0530-c669-4914-9e95-c649b2123de6",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "25d06997-73b0-43ae-8274-6667f5310e4e",
            "name": "Blue Oc Clin Res at Palm Bch Eye Ct",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "14",
            "type": {
              "id": "29e6c234-5b5b-43c0-9399-182334a14ee3",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "cf4dff4d-ea19-46d9-a3f7-a0d42cd6a677",
            "name": "MedEye Associates",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "15",
            "type": {
              "id": "617f246e-1b15-48da-9f49-aa78dd00abf8",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "392ab664-ee8c-47b2-8713-73a18689e430",
            "name": "Florida Retina Institute",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "16",
            "type": {
              "id": "ad5dbfea-6a16-44ce-959f-836a17f8073a",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "f2cbdf49-a974-447b-b84f-83bc95969f86",
            "name": "Eye Center of North Florida",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "17",
            "type": {
              "id": "4facb120-4e8e-4cfc-9ad4-bc38370aaeef",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "a7fb4d5b-a264-4c25-804f-b5ac8bb98042",
            "name": "Fort Lauderdale Eye Institute",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "18",
            "type": {
              "id": "45162cf2-bf30-439d-855c-9a577343e860",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "a0d053ab-c809-4f6d-b85b-ef65eece7370",
            "name": "Retina Associates",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "19",
            "type": {
              "id": "e12cb8b6-02fe-450c-93f0-73f2a8261842",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "9f0c4af2-0cee-463e-a899-e58808cce4fe",
            "name": "Midwest Eye Institute",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "20",
            "type": {
              "id": "355ceddc-deed-428b-a0db-99ce4f2308da",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "14087b92-8ac0-4cb3-915b-856b43448fb2",
            "name": "John-Kenyon American Eye Institute PC",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "21",
            "type": {
              "id": "60969638-e15a-4f20-acda-bc5a90e754eb",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "9f2dc7a1-22bb-490b-9efc-655bc2f65caa",
            "name": "Retina Associates PA",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "22",
            "type": {
              "id": "6b3748d8-db82-40bd-823f-876921f4a037",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "b3d41b49-e342-4871-b6d3-1f02e02f202c",
            "name": "Cumberland Valley Retina Consultants",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "23",
            "type": {
              "id": "0264ca9e-31c6-4339-af20-e6a95909e993",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "53d265f6-7c22-485a-ac08-ca43bd7d49b8",
            "name": "University of Mississippi Med Ctr",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "24",
            "type": {
              "id": "117aaf0c-1b84-44c0-a1fd-a5c618682ad6",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "093e521f-1c73-4e18-a201-a5a2580fb88b",
            "name": "Retina Associates Of Cleveland",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "25",
            "type": {
              "id": "2149bd1c-0cb9-4f95-8c07-d28e0508b20c",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "88d9b6b7-f1a1-4ba5-a3ef-6daed158a0c4",
            "name": "Dean McGee Eye Institute",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "26",
            "type": {
              "id": "c254594d-dae9-4489-a8e5-e116928e10bc",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "46902002-77c3-4728-b13c-a9134590b205",
            "name": "Cascade Medical Research Institute",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "27",
            "type": {
              "id": "c199f7d4-4f91-4074-99fe-7a210a1c530c",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "1d19ca99-7ff2-4231-8f64-1639d33aac44",
            "name": "Erie Retinal Surgery",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "28",
            "type": {
              "id": "56d399aa-8ada-46e9-94b6-6f36d361476e",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "d9c6f4a0-4ce8-4b91-9c3c-673b214ddb8d",
            "name": "Charleston Neuroscience Institute",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "29",
            "type": {
              "id": "e71e7a4d-a9c4-4330-b3f7-75f2314dc8fc",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "85956e07-9950-4784-b20f-bb0b91dbe0ad",
            "name": "Southeastern Retina Associates P C",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "30",
            "type": {
              "id": "5514b47d-c09e-4a4d-90a4-ca81f8dbc223",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "75550dab-98e5-45c0-96c2-61f9c4b45d97",
            "name": "Austin Retina Associates",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "31",
            "type": {
              "id": "995f6219-460e-4906-a5c3-9e128bed59f0",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "7cc6c4c5-24ed-4f28-9e0d-fe093e758646",
            "name": "Texan Eye P A",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "32",
            "type": {
              "id": "0375b124-1e64-4524-86ed-acae6be4b263",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "58fcff7d-49bc-4d2f-8196-32eaba91d5af",
            "name": "Retina And Vitreous Of Texas",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "33",
            "type": {
              "id": "24b8aa35-54bc-4a7f-b25c-fa3562c21fcc",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "b75c6bff-d5a1-422c-a888-635edb6c7631",
            "name": "Retina Consultants TX Rsrch Ctr",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "34",
            "type": {
              "id": "3f2d2a99-b7ed-4c26-8379-fe390ffbb7f6",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "ede19e9e-24bf-4982-91d8-68a42cfd59f6",
            "name": "Texas Retina Associates",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "35",
            "type": {
              "id": "177537f0-d46d-4de8-9298-0cc7b207c49f",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "bdd79eca-403e-4ae0-a02c-6c4109d6f78e",
            "name": "Valley Retina Institute PA",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "36",
            "type": {
              "id": "537e7509-7784-44fd-8937-23b332ce08c6",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "d7fc6d68-bb3a-468d-babc-220a7010162b",
            "name": "Retina Consultants of Houston PA",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "37",
            "type": {
              "id": "abd4a171-289f-4a92-9aaf-d0a922355f82",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "1af5d50e-2742-46bb-94d6-ec632aad767a",
            "name": "Medical Center Opthamology Assoc",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "38",
            "type": {
              "id": "090b7774-42cc-4db2-b2c3-7d9976649a52",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "9fc36ecb-c547-4deb-95a1-78eb3ca02012",
            "name": "Retina Associates Of South Texas PA",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "39",
            "type": {
              "id": "d1c251c9-7bc8-4eb5-884c-f163a5fe8baa",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "4477bdb6-5968-4701-a581-c29fe3da621d",
            "name": "Virginia Eye Consultants",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "40",
            "type": {
              "id": "f19b57d0-2547-4d91-a4f0-aa8ae9f19de6",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "708b4dcd-b8a1-4254-bf95-d42510612e59",
            "name": "Novartis Investigative Site",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "41",
            "type": {
              "id": "9bf6097b-f361-4ad1-9be2-2b24b1ceb0bd",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "ee7369db-ebf6-4f4c-a31e-3e6aa1ad6989",
            "name": "Novartis Investigative Site",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "42",
            "type": {
              "id": "87bb91fe-e67d-4402-b3dd-28cac4e17507",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "06404675-e8e2-46e1-98f6-1e0478e8a97e",
            "name": "Novartis Investigative Site",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "43",
            "type": {
              "id": "e935af1d-0ec8-44e1-a663-cd604d1b06bc",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "93697bf0-0bf5-4ab5-8cf6-02fb14a273b5",
            "name": "Novartis Investigative Site",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "44",
            "type": {
              "id": "dc2eaf08-8e04-41e5-8b33-75d881e6be1d",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "a0e6ec16-e743-44f8-af0d-a579208ae7a8",
            "name": "Novartis Investigative Site",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "45",
            "type": {
              "id": "c4f294eb-53fa-4b7d-8aa1-1a84c4d3724e",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "c4d43fc3-792f-40b4-a284-abaeae574ff6",
            "name": "Novartis Investigative Site",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "46",
            "type": {
              "id": "d915d41d-eb40-4f67-8f69-76f4c785d7a7",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "b5254ed0-5745-468f-8dc9-1a11ad7dc942",
            "name": "Novartis Investigative Site",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "47",
            "type": {
              "id": "24d34de0-226e-471a-8cf8-638d6ac1fbf2",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "4a2c602d-37c8-43d8-a016-844fa988ae5c",
            "name": "Novartis Investigative Site",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "48",
            "type": {
              "id": "d3e24498-c72b-4c68-b2fb-e748c7dc116e",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "c748510a-0624-4b89-b971-ff3955acd9ea",
            "name": "Novartis Investigative Site",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "49",
            "type": {
              "id": "cacdcc92-3735-42f5-a08b-47bd9a00c588",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "435093fd-6d59-4f8d-99b8-1fb025d64355",
            "name": "Novartis Investigative Site",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "50",
            "type": {
              "id": "23a06f15-5ee0-4ec8-b3dd-060cab135d8f",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          }
        ],
        "studyPhase": {
          "id": "925c3025-a326-4462-bd64-1a2e81b48fb9",
          "code": "Phase3",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Phase3",
          "instanceType": "Code"
        },
        "eligibilityCriterionItems": [
          {
            "id": "801ca5a1-1309-49ed-be97-a7f860a24030",
            "name": "Informed Consent",
            "text": "Signed informed consent must be obtained prior to participation in the study.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "fa564fe5-b1c7-4bfb-9d32-fa2ae6dff957",
            "name": "Age Requirement",
            "text": "Patients â‰¥ 18 years of age at Screening.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "8358db14-fa05-42ae-9cb9-f0deb96f22e7",
            "name": "Participant Cooperation",
            "text": "Participant cooperation sufficient for adequate fundus photographs and retinal images.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "d7a5342f-db3f-41ba-a50e-56ebf7bdb2c9",
            "name": "Diabetes Diagnosis and HbA1c",
            "text": "Patients diagnosed with type 1 or 2 DM, and HbA1c â‰¤ 12% at Screening.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "ae7cc9f5-dbb2-481e-976b-bb5bc85218bb",
            "name": "Stable Diabetes Medication",
            "text": "Any medication administered for the management of DM should be stable within 3 months prior to randomization and is expected to remain stable during the course of the study, as medically acceptable.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "dbbc7db9-9e3b-491d-bdcb-c2e492f7eb96",
            "name": "PDR Diagnosis Study Eye",
            "text": "PDR as assessed by the investigator using standard or wide-field CFP and FA, with no evidence of previous PRP, and that requires treatment with either anti-VEGF or PRP in the opinion of the investigator.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "d418a177-46ad-457f-b2f9-db4cbc05f744",
            "name": "BCVA Requirement Study Eye",
            "text": "BCVA â‰¥ 34 ETDRS letters (Snellen equivalent 20/200) at Screening and Baseline.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "b2fa5285-288b-4bf4-8084-90570630c4fb",
            "name": "Concomitant Ocular Disorders",
            "text": "Concomitant conditions or ocular disorders in the study eye at Screening or Baseline as well as planned medical/surgical intervention during the first 54-week study period that could compromise functional or structural response to study treatment, in the opinion of the investigator.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "1076ddfa-02b2-47e9-ba66-415244111151",
            "name": "Center-involved DME",
            "text": "Presence of center-involved diabetic macular edema in the study eye at Screening or Baseline, as assessed by the investigator.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "ae05010b-184f-4d02-9195-3f3bf7f648b6",
            "name": "Active Infection or Inflammation",
            "text": "Any active intraocular or periocular infection or active intraocular inflammation (e.g. infectious conjunctivitis, keratitis, scleritis, infectious blepharitis, uveitis) in the study eye at Screening or Baseline.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "7a8837e9-879a-4c53-967d-712131c52339",
            "name": "Uncontrolled Glaucoma",
            "text": "Uncontrolled glaucoma in the study eye defined as IOP > 25 mmHg despite treatment with IOP-lowering medication, or according to investigatorâ€™s judgment, at Screening or Baseline.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "ffece53e-27cb-4136-9ed9-e028469c6e1a",
            "name": "Vitreous Hemorrhage",
            "text": "Moderate or dense pre-retinal or vitreous hemorrhage that prevents clear visualization of the macular and /or optic disc or prevents PRP treatment in the study eye at Baseline.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "ac6c1990-5f27-42c4-9d95-480732119ebd",
            "name": "Vitreoretinal Proliferation",
            "text": "Significant fibrovascular vitreoretinal proliferation or tractional retinal detachment of the study eye.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "8458b860-459c-4f86-99d5-0e79328c89d5",
            "name": "Neovascularization",
            "text": "Iris or anterior chamber angle neovascularization, or neovascular glaucoma in the study eye.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "6f57b856-4e64-45b2-a0e5-8fda06b858eb",
            "name": "Fellow Eye Condition",
            "text": "Presence of amblyopia, amaurosis, or ocular disorders in the fellow eye with BCVA < 20/200 at Screening (except when due to conditions for which treatment or surgery may improve VA, e.g. cataract).",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "23fc461f-ef85-4d86-a4d6-7cee150e8f5c",
            "name": "Prior PRP",
            "text": "PRP any time prior to Baseline.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "a0ce49be-2c41-4650-9a16-87062b8e691e",
            "name": "Prior Anti-VEGF",
            "text": "Intravitreal anti-VEGF treatment within 6 months prior to Baseline.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "757cda8d-6358-4055-af1c-55c9c7f1d04d",
            "name": "Vitreoretinal Surgery",
            "text": "Vitreoretinal surgery at any time prior to Baseline or anticipated need for vitreoretinal surgery within the next 12 months.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "1b06ca6a-fada-4861-b245-2ace242ab601",
            "name": "Macular Laser",
            "text": "Laser treatment of the macula within 3 months prior to Baseline.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "771f2a2d-ffc2-40b6-817c-efd7c47d2fac",
            "name": "Corticosteroid Implants",
            "text": "Treatment with fluocinolone acetonide intravitreal implant (e.g. ILUVIENÂ® or RETISERTÂ®) at any time prior to Baseline. Other intraocular or periocular corticosteroid injection within 6 months prior to Baseline.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "e3969fc0-56fc-4059-bcdd-b015bbdf9ae3",
            "name": "Aphakia",
            "text": "Aphakia with the absence of posterior capsule.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "13d33052-011e-4d39-a881-104f718b63c6",
            "name": "Intraocular Surgery",
            "text": "Intraocular surgery within 3 months prior to Baseline or anticipated need for cataract extraction within the next 12 months.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "59644ecb-2a92-4a9d-b93f-4819bb43ad2f",
            "name": "Stroke or MI",
            "text": "Stroke or myocardial infarction during the 6-month period prior to baseline.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "36c1363e-a5d4-40e1-8f0d-e1ff0d0539b7",
            "name": "Renal Disease",
            "text": "End stage renal disease requiring dialysis or renal transplant.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "83155406-a857-4e94-9940-8de01d932d76",
            "name": "Uncontrolled Blood Pressure",
            "text": "Uncontrolled blood pressure defined as a systolic value â‰¥ 180 mmHg or diastolic value â‰¥ 100 mmHg at screening or baseline. (In case there is an elevated blood pressure measurement, it should be repeated after approximately 20 minutes. If the repeat measurement is elevated, then the patient is not eligible to be enrolled into the study).",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "2ae12695-0378-41cc-8f04-fe10352c9e3b",
            "name": "Systemic Anti-VEGF",
            "text": "Systemic anti-VEGF therapy at any time.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "1092f6b5-34ca-451d-b857-dbaa0a844be3",
            "name": "Toxic Systemic Medications",
            "text": "Systemic medications known to be toxic to the lens, retina or optic nerve (e.g., deferoxamine, chloroquine/hydroxychloroquine, tamoxifen, phenothiazines and ethambutol) used during the 6â€‘month period prior to Baseline except temporary use for Coronavirus 19 (COVID-19) treatment.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "0240fe08-4453-4251-9ceb-98528d0a5387",
            "name": "Hypersensitivity",
            "text": "History of hypersensitivity to any of the study drugs or their excipients or to drugs of similar classes, or clinically relevant sensitivity to fluorescein dye as assessed by the investigator.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "a75064ff-fb75-4c0a-8647-92286325b106",
            "name": "History of Malignancy",
            "text": "History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within the past 5 years prior to Screening, regardless of whether there is evidence of local recurrence or metastases.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "a96d22bb-7edd-44a4-91cc-9e5f9bdc643d",
            "name": "General Medical Condition",
            "text": "History of a medical condition (e.g. metabolic dysfunction disease with exception of type 1 or 2 DM, or clinical laboratory finding) that, in the judgment of the investigator, would preclude scheduled study visits, completion of the study, or a safe administration of investigational product.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "fcf26105-865f-497e-abe2-b3425d2d7b1e",
            "name": "Investigational Drugs",
            "text": "Use of systemic investigational drugs within 5 half-lives of baseline, or within 30 days / until the expected pharmacodynamic effect has returned to baseline, whichever is longer; or longer if required by local regulations (observational clinical studies solely involving over-the-counter vitamins, supplements, or diets are not exclusionary).",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "11d668c1-025e-4b20-9d22-eb58097d8e43",
            "name": "Pregnancy and Nursing",
            "text": "Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin pregnancy test.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "2a7626b1-cd8c-4643-9e93-3bdf3a983169",
            "name": "Contraception Requirements",
            "text": "Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during the study drug administration and for at least one month after stopping the investigational medication.",
            "instanceType": "EligibilityCriterionItem"
          }
        ],
        "studyInterventions": [
          {
            "id": "10581c87-c0ef-4a13-be03-3287e72d9d64",
            "name": "Brolucizumab 6 mg",
            "type": {
              "id": "29500d69-e226-46bf-a277-dd3506850c97",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "role": {
              "id": "0d83275a-c80a-4e85-a302-193d553c9a43",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Anti-VEGF single-chain antibody fragment (scFv) for proliferative diabetic retinopathy",
            "productIds": [
              "a0120379-90d7-4a79-9fa3-e5c609e3532a"
            ],
            "administrationIds": [
              "ff76b957-e15b-474d-acaa-9e66086feff0",
              "10d4586c-5bbf-4781-9640-684573ddc68f"
            ]
          },
          {
            "id": "326373e7-062f-49b9-8c50-8fa33e95f026",
            "name": "Panretinal photocoagulation (PRP)",
            "type": {
              "id": "9de81ecf-7c64-4134-bbe9-4bdc8b89fcf7",
              "code": "C54129",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Comparator",
              "instanceType": "Code"
            },
            "role": {
              "id": "e85a5579-8f21-4154-843c-30d8ec757110",
              "code": "C54129",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Comparator",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Standard of care laser treatment for proliferative diabetic retinopathy",
            "administrationIds": [
              "8b34c842-91c1-42bb-be54-a0f01a41a216",
              "3fbe1598-5c10-46df-a87f-2b8b51eeaeb7"
            ]
          },
          {
            "id": "2cc2f964-c833-48e0-b218-ee9606dc6cba",
            "name": "Topical ocular medications",
            "type": {
              "id": "133e57ed-71b0-4db4-86f5-205202e0f8f6",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "5f21eeeb-0b37-4606-becd-5e07d17c20b5",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Permitted during the study, including corticosteroids",
            "administrationIds": [
              "209d6cfe-1e7b-4db8-8b98-09cbbf7bf331"
            ]
          },
          {
            "id": "6ce34975-fb01-4cfc-8586-15fb88c6a2cf",
            "name": "Corticosteroids (non-ocular)",
            "type": {
              "id": "83a4881e-015d-4c66-9aa0-275eda65a556",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "186b01b4-b5f7-4de1-96b2-c850df07bc0d",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Permitted via intra-nasal, inhaled, intra-articular, or non-extensive dermal routes",
            "administrationIds": [
              "fd3511ef-ed17-438f-918f-1818ca79c036"
            ]
          },
          {
            "id": "e432e7b1-5f07-46b3-8c8b-9b9e3b2297d2",
            "name": "Anti-VEGF therapy (other than study drug)",
            "type": {
              "id": "196a3bed-9010-4d0b-a54e-d9c5a054a68b",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "63b9b8bc-9ce9-4b4d-b3cb-d14bf91a78de",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Prohibited in the study eye and systemically",
            "administrationIds": [
              "681ed88e-00b8-42a3-84fc-687f879e4576"
            ]
          },
          {
            "id": "48902eef-c720-46d1-89b8-4906f20d44f7",
            "name": "Fluocinolone acetonide intravitreal implant",
            "type": {
              "id": "f4cf643b-164b-4e75-a3a3-62d83c172225",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "d858032c-75e2-41a4-9aab-0180072a665a",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Prohibited prior to baseline and during study"
          }
        ],
        "administrableProducts": [
          {
            "id": "a0120379-90d7-4a79-9fa3-e5c609e3532a",
            "name": "Brolucizumab",
            "administrableDoseForm": {
              "id": "e5eff975-bced-45ca-bc68-74b5fba82f77",
              "code": "C42986",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Solution",
              "instanceType": "Code",
              "standardCode": {
                "id": "568ded6b-6152-4a4d-b89e-fde872b842c7",
                "code": "C42986",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Solution",
                "instanceType": "Code"
              }
            },
            "productDesignation": {
              "id": "66778049-faea-4c06-a121-8a97b5d52c01",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "AdministrableProduct",
            "strength": "6 mg/0.05 mL",
            "substanceIds": [
              "49168bae-0358-4d82-bc19-d4b22f9b5532"
            ],
            "manufacturer": "Novartis"
          }
        ],
        "narrativeContents": [
          {
            "id": "611ea2f3-2e06-4218-add2-444599826182",
            "name": "Protocol summary",
            "text": "Protocol summary",
            "order": 0,
            "instanceType": "NarrativeContent",
            "sectionTitle": "Protocol summary",
            "sectionType": {
              "id": "d362b991-0041-41c6-a6cc-6ce8723c5c74",
              "code": "Synopsis",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Synopsis",
              "instanceType": "Code"
            }
          },
          {
            "id": "9e6e10b7-761c-4078-9579-68f8cbeb41ad",
            "name": "Introduction",
            "text": "Introduction",
            "order": 1,
            "instanceType": "NarrativeContent",
            "sectionNumber": "1",
            "sectionTitle": "Introduction",
            "sectionType": {
              "id": "56cdc665-9969-4784-b064-64341a1af999",
              "code": "Introduction",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Introduction",
              "instanceType": "Code"
            },
            "childIds": [
              "45c33c69-0c3a-4bf6-b90e-3f0910694c8d",
              "76b72d61-1de1-409d-9ae3-6f046477e09b"
            ]
          },
          {
            "id": "476cf560-9bae-488c-8ddb-948f4ea85feb",
            "name": "Objectives and endpoints",
            "text": "Objectives and endpoints",
            "order": 2,
            "instanceType": "NarrativeContent",
            "sectionNumber": "2",
            "sectionTitle": "Objectives and endpoints",
            "sectionType": {
              "id": "8df0c087-576c-44e1-887b-9a83cbcd3751",
              "code": "Objectives",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Objectives",
              "instanceType": "Code"
            }
          },
          {
            "id": "820da7ef-5f8c-44be-a98c-25d8f33ae801",
            "name": "Study design",
            "text": "Study design",
            "order": 3,
            "instanceType": "NarrativeContent",
            "sectionNumber": "3",
            "sectionTitle": "Study design",
            "sectionType": {
              "id": "3e250ec7-80e6-43ed-89d9-9ed98287dacf",
              "code": "Study Design",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Study Design",
              "instanceType": "Code"
            }
          },
          {
            "id": "4ff56bbc-a234-4244-97e8-d42c7b20ea3d",
            "name": "Rationale",
            "text": "Rationale",
            "order": 4,
            "instanceType": "NarrativeContent",
            "sectionNumber": "4",
            "sectionTitle": "Rationale",
            "sectionType": {
              "id": "42b52a4c-37cd-4f43-bc6b-ae92efb09111",
              "code": "Other",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Other",
              "instanceType": "Code"
            },
            "childIds": [
              "ec0b9f50-e5cb-47e0-8841-8b8fc100ab7f",
              "955c80a3-5fc2-4f2e-87f5-addb50eff77f",
              "c3054b35-727a-488c-b7d6-07eb83abaab4",
              "b4d1f879-d00f-4fe6-90c8-152f96aac49e",
              "a5843767-792c-4609-9c1f-c875bd7d4d13"
            ]
          },
          {
            "id": "69df091a-f999-453b-ba3c-9470b3c72b68",
            "name": "Population",
            "text": "Population",
            "order": 5,
            "instanceType": "NarrativeContent",
            "sectionNumber": "5",
            "sectionTitle": "Population",
            "sectionType": {
              "id": "00759bd1-a374-436a-a2f2-bb2549bdbd47",
              "code": "Study Population",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Study Population",
              "instanceType": "Code"
            },
            "childIds": [
              "0313cf13-3e7f-47e7-bc5c-caa4ba1166e0",
              "3f26f0a6-210a-414b-aedc-1bcafdfdf56f"
            ]
          },
          {
            "id": "c0433993-9ad7-4edb-a95f-4fd0bec4420b",
            "name": "Treatment",
            "text": "Treatment",
            "order": 6,
            "instanceType": "NarrativeContent",
            "sectionNumber": "6",
            "sectionTitle": "Treatment",
            "sectionType": {
              "id": "44f39e35-1c05-4f28-bcf3-5ec4d07451d4",
              "code": "Treatment",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Treatment",
              "instanceType": "Code"
            },
            "childIds": [
              "8a66d051-d18c-4714-bbe3-ece984abd473",
              "7bef3c0f-f1bf-4b6e-871c-9b3fdc1bceaa",
              "b499299c-def3-42fe-9680-ab87c28472b2",
              "4b962054-4281-420c-b15b-0d1353d7edff"
            ]
          },
          {
            "id": "60074cd9-4b80-4954-b3ad-8ce50b6211c6",
            "name": "Informed Consent procedures",
            "text": "Informed Consent procedures",
            "order": 7,
            "instanceType": "NarrativeContent",
            "sectionNumber": "7",
            "sectionTitle": "Informed Consent procedures",
            "sectionType": {
              "id": "7bf5de2b-3594-423e-8094-26b1634fb6e6",
              "code": "Ethics",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Ethics",
              "instanceType": "Code"
            }
          },
          {
            "id": "cc8b8f10-b337-4da7-962c-12c17a888455",
            "name": "Study Procedures and Assessments",
            "text": "Study Procedures and Assessments",
            "order": 8,
            "instanceType": "NarrativeContent",
            "sectionNumber": "8",
            "sectionTitle": "Study Procedures and Assessments",
            "sectionType": {
              "id": "3ee7cf12-1605-4447-afaf-4c0afbc27978",
              "code": "Study Procedures",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Study Procedures",
              "instanceType": "Code"
            },
            "childIds": [
              "7197793b-d02e-4a4f-acd6-ef7ce0998ffb",
              "15a1e4d4-a53d-44dc-9559-6dc0727da522",
              "58944059-8de5-469e-87a3-70c06ce187ad"
            ]
          },
          {
            "id": "9c4dc78f-ae40-4d78-a857-060a9e45f866",
            "name": "Discontinuation",
            "text": "Discontinuation",
            "order": 9,
            "instanceType": "NarrativeContent",
            "sectionNumber": "9",
            "sectionTitle": "Discontinuation",
            "sectionType": {
              "id": "a0317e32-0dca-4e47-87aa-b63b756973ca",
              "code": "Other",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Other",
              "instanceType": "Code"
            },
            "childIds": [
              "230011d7-d124-4ec4-a0f1-32110b2b0cf0",
              "6f782267-8a81-4e2c-8123-a0289d1e6fc7"
            ]
          },
          {
            "id": "e64c6c3e-c2f5-4306-ae69-347dd4c3758b",
            "name": "Safety Reporting",
            "text": "Safety Reporting",
            "order": 10,
            "instanceType": "NarrativeContent",
            "sectionNumber": "10",
            "sectionTitle": "Safety Reporting",
            "sectionType": {
              "id": "f872aa58-c18a-48c5-b375-7c97e24bccd9",
              "code": "Safety",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Safety",
              "instanceType": "Code"
            },
            "childIds": [
              "bea9cf9b-e10e-4b3c-b9bf-a998b4f1ce9d"
            ]
          },
          {
            "id": "906a1bc2-cb09-4d5f-aec4-9747cf168fdd",
            "name": "Data analysis and statistical methods",
            "text": "Data analysis and statistical methods",
            "order": 11,
            "instanceType": "NarrativeContent",
            "sectionNumber": "12",
            "sectionTitle": "Data analysis and statistical methods",
            "sectionType": {
              "id": "d6e52954-6e1d-4090-808d-0fa317458ab1",
              "code": "Statistics",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Statistics",
              "instanceType": "Code"
            }
          },
          {
            "id": "2abd357a-4c0a-4840-b815-269ddf5ff847",
            "name": "References",
            "text": "References",
            "order": 12,
            "instanceType": "NarrativeContent",
            "sectionNumber": "15",
            "sectionTitle": "References",
            "sectionType": {
              "id": "1082f167-e372-4366-998f-05edd2f9c7e5",
              "code": "References",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "References",
              "instanceType": "Code"
            }
          }
        ],
        "narrativeContentItems": [
          {
            "id": "45c33c69-0c3a-4bf6-b90e-3f0910694c8d",
            "name": "Background",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.1",
            "sectionTitle": "Background"
          },
          {
            "id": "76b72d61-1de1-409d-9ae3-6f046477e09b",
            "name": "Purpose",
            "text": "",
            "order": 1,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.2",
            "sectionTitle": "Purpose"
          },
          {
            "id": "ec0b9f50-e5cb-47e0-8841-8b8fc100ab7f",
            "name": "Rationale for study design",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "4.1",
            "sectionTitle": "Rationale for study design"
          },
          {
            "id": "955c80a3-5fc2-4f2e-87f5-addb50eff77f",
            "name": "Rationale for dose/regimen and duration of treatment",
            "text": "",
            "order": 1,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "4.2",
            "sectionTitle": "Rationale for dose/regimen and duration of treatment"
          },
          {
            "id": "c3054b35-727a-488c-b7d6-07eb83abaab4",
            "name": "Rationale for choice of comparator treatment",
            "text": "",
            "order": 2,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "4.3",
            "sectionTitle": "Rationale for choice of comparator treatment"
          },
          {
            "id": "b4d1f879-d00f-4fe6-90c8-152f96aac49e",
            "name": "Purpose and timing of interim analyses/design adaptations",
            "text": "",
            "order": 3,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "4.4",
            "sectionTitle": "Purpose and timing of interim analyses/design adaptations"
          },
          {
            "id": "a5843767-792c-4609-9c1f-c875bd7d4d13",
            "name": "Risks and benefits",
            "text": "",
            "order": 4,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "4.5",
            "sectionTitle": "Risks and benefits"
          },
          {
            "id": "0313cf13-3e7f-47e7-bc5c-caa4ba1166e0",
            "name": "Inclusion criteria",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "5.1",
            "sectionTitle": "Inclusion criteria"
          },
          {
            "id": "3f26f0a6-210a-414b-aedc-1bcafdfdf56f",
            "name": "Exclusion criteria",
            "text": "",
            "order": 1,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "5.2",
            "sectionTitle": "Exclusion criteria"
          },
          {
            "id": "8a66d051-d18c-4714-bbe3-ece984abd473",
            "name": "Study treatment",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "6.1",
            "sectionTitle": "Study treatment"
          },
          {
            "id": "7bef3c0f-f1bf-4b6e-871c-9b3fdc1bceaa",
            "name": "Other treatment(s)",
            "text": "",
            "order": 1,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "6.2",
            "sectionTitle": "Other treatment(s)"
          },
          {
            "id": "b499299c-def3-42fe-9680-ab87c28472b2",
            "name": "Subject numbering, treatment assignment, randomization",
            "text": "",
            "order": 2,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "6.3",
            "sectionTitle": "Subject numbering, treatment assignment, randomization"
          },
          {
            "id": "4b962054-4281-420c-b15b-0d1353d7edff",
            "name": "Treatment masking",
            "text": "",
            "order": 3,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "6.4",
            "sectionTitle": "Treatment masking"
          },
          {
            "id": "7197793b-d02e-4a4f-acd6-ef7ce0998ffb",
            "name": "Screening",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "8.1",
            "sectionTitle": "Screening"
          },
          {
            "id": "15a1e4d4-a53d-44dc-9559-6dc0727da522",
            "name": "Ophthalmic examination",
            "text": "",
            "order": 1,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "8.4",
            "sectionTitle": "Ophthalmic examination"
          },
          {
            "id": "58944059-8de5-469e-87a3-70c06ce187ad",
            "name": "Clinical Outcome Assessments (COAs)",
            "text": "",
            "order": 2,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "8.5.1",
            "sectionTitle": "Clinical Outcome Assessments (COAs)"
          },
          {
            "id": "230011d7-d124-4ec4-a0f1-32110b2b0cf0",
            "name": "Discontinuation of study treatment",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "9.1.1",
            "sectionTitle": "Discontinuation of study treatment"
          },
          {
            "id": "6f782267-8a81-4e2c-8123-a0289d1e6fc7",
            "name": "Withdrawal of Consent",
            "text": "",
            "order": 1,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "9.1.2",
            "sectionTitle": "Withdrawal of Consent"
          },
          {
            "id": "bea9cf9b-e10e-4b3c-b9bf-a998b4f1ce9d",
            "name": "SAE reporting",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "10.1.3",
            "sectionTitle": "SAE reporting"
          }
        ],
        "abbreviations": [
          {
            "id": "e156ff4e-9770-4483-b851-eb9b10753479",
            "abbreviatedText": "AE",
            "expandedText": "Adverse event",
            "instanceType": "Abbreviation"
          },
          {
            "id": "f5c22db0-77d4-4488-ac81-667d76c3288f",
            "abbreviatedText": "ANCOVA",
            "expandedText": "Analysis of covariance",
            "instanceType": "Abbreviation"
          },
          {
            "id": "1ca7acd9-2e77-4e15-b980-da6836257a63",
            "abbreviatedText": "AR",
            "expandedText": "Analysis restriction",
            "instanceType": "Abbreviation"
          },
          {
            "id": "06c22f1e-91b7-469d-b946-fd5023efbf42",
            "abbreviatedText": "ATC",
            "expandedText": "Anatomical therapeutic chemical",
            "instanceType": "Abbreviation"
          },
          {
            "id": "3b15ec59-330a-4d57-ae07-78aafd686b4b",
            "abbreviatedText": "BCVA",
            "expandedText": "Best corrected visual acuity",
            "instanceType": "Abbreviation"
          },
          {
            "id": "5641619b-b7c9-455d-97c7-866089905b06",
            "abbreviatedText": "CFP",
            "expandedText": "Color fundus photography",
            "instanceType": "Abbreviation"
          },
          {
            "id": "18b99750-5463-4a8f-8530-a29224594539",
            "abbreviatedText": "CFR",
            "expandedText": "Code of federal regulation",
            "instanceType": "Abbreviation"
          },
          {
            "id": "fdac9012-c70d-4e6d-a55e-4074e0c3d741",
            "abbreviatedText": "CI",
            "expandedText": "Confidence interval",
            "instanceType": "Abbreviation"
          },
          {
            "id": "086e1fb4-5e03-4261-8c02-5a839b601329",
            "abbreviatedText": "CMH",
            "expandedText": "Cochran-Mantel-Haenszel",
            "instanceType": "Abbreviation"
          },
          {
            "id": "26942972-f29e-4cb5-8073-1408d46f50f0",
            "abbreviatedText": "COA",
            "expandedText": "Clinical outcome assessment",
            "instanceType": "Abbreviation"
          },
          {
            "id": "1c8a83ea-105e-4097-9183-d07f4343abbb",
            "abbreviatedText": "COAs",
            "expandedText": "Clinical Outcome Assessments",
            "instanceType": "Abbreviation"
          },
          {
            "id": "d89837de-df1a-445c-a653-97d174e4b520",
            "abbreviatedText": "COVID-19",
            "expandedText": "Coronavirus disease-2019",
            "instanceType": "Abbreviation"
          },
          {
            "id": "3fa9b8cb-b737-42e1-9074-60dbf7bfc559",
            "abbreviatedText": "CRC",
            "expandedText": "Central reading center",
            "instanceType": "Abbreviation"
          },
          {
            "id": "a634b086-9bc6-4484-90ce-3000f531e9ab",
            "abbreviatedText": "CRO",
            "expandedText": "Contract Research Organization",
            "instanceType": "Abbreviation"
          },
          {
            "id": "56c72a56-c306-4010-beb0-888a1a7b7307",
            "abbreviatedText": "CSFT",
            "expandedText": "Central sub-field thickness",
            "instanceType": "Abbreviation"
          },
          {
            "id": "95991b42-497a-4ad0-a6ca-9f15c7745865",
            "abbreviatedText": "DM",
            "expandedText": "Diabetes mellitus",
            "instanceType": "Abbreviation"
          },
          {
            "id": "44c6ae29-70fb-4b6c-a1d9-9372bff307a0",
            "abbreviatedText": "DME",
            "expandedText": "Diabetic macular edema",
            "instanceType": "Abbreviation"
          },
          {
            "id": "3469bad8-3b4e-41bb-8da5-2ff46b679ff9",
            "abbreviatedText": "DR",
            "expandedText": "Diabetic retinopathy",
            "instanceType": "Abbreviation"
          },
          {
            "id": "bc5fed31-460f-46ea-a998-ee8b7b96d4a5",
            "abbreviatedText": "DRSS",
            "expandedText": "Diabetic retinopathy severity scale",
            "instanceType": "Abbreviation"
          },
          {
            "id": "ec6b14b8-d88a-4a41-a499-50807c6da978",
            "abbreviatedText": "eCRF",
            "expandedText": "Electronic case report/record form",
            "instanceType": "Abbreviation"
          },
          {
            "id": "127420b1-544a-4365-a249-26aab493aa2e",
            "abbreviatedText": "eCRFs",
            "expandedText": "Electronic Case Report Forms",
            "instanceType": "Abbreviation"
          },
          {
            "id": "4073d3a2-8eed-424b-9065-99bfd4c5f069",
            "abbreviatedText": "EDC",
            "expandedText": "Electronic data capture",
            "instanceType": "Abbreviation"
          },
          {
            "id": "a088dfb4-fb82-4d35-bfcb-c32a0b72dc13",
            "abbreviatedText": "EOS",
            "expandedText": "End of study",
            "instanceType": "Abbreviation"
          },
          {
            "id": "ebde85f9-a9a8-4603-a9c0-cf7057f335b1",
            "abbreviatedText": "EOT",
            "expandedText": "End of treatment",
            "instanceType": "Abbreviation"
          },
          {
            "id": "3714110d-8dea-4f36-8c10-ad5bf4198937",
            "abbreviatedText": "ETDRS",
            "expandedText": "Early Treatment Diabetic Retinopathy Study",
            "instanceType": "Abbreviation"
          },
          {
            "id": "4258f6ee-09b2-4e85-9a90-f31eb8b462ba",
            "abbreviatedText": "FA",
            "expandedText": "Fluorescein angiography",
            "instanceType": "Abbreviation"
          },
          {
            "id": "cbd6d25d-4478-46ca-b5c0-8c27fd363130",
            "abbreviatedText": "FAS",
            "expandedText": "Full analysis set",
            "instanceType": "Abbreviation"
          },
          {
            "id": "1bf8fb9c-33fa-4a63-8656-bf5d3e7e6b82",
            "abbreviatedText": "GCP",
            "expandedText": "Good Clinical Practice",
            "instanceType": "Abbreviation"
          },
          {
            "id": "b45a1114-c77f-424a-aeec-6c26d343e505",
            "abbreviatedText": "HbA1c",
            "expandedText": "Glycosylated hemoglobin A1c",
            "instanceType": "Abbreviation"
          },
          {
            "id": "23ac5517-4ae1-4d17-8ea9-61795e4aa6da",
            "abbreviatedText": "IB",
            "expandedText": "Investigator's brochure",
            "instanceType": "Abbreviation"
          },
          {
            "id": "3ae6958b-4f5e-443b-a736-a6af41dbe46b",
            "abbreviatedText": "ICF",
            "expandedText": "Informed consent",
            "instanceType": "Abbreviation"
          },
          {
            "id": "deba8a4b-71a4-4215-8c67-4bde71d9e647",
            "abbreviatedText": "ICH",
            "expandedText": "International Council for Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use",
            "instanceType": "Abbreviation"
          },
          {
            "id": "6e59f182-94ed-4b25-b302-37b343d392f0",
            "abbreviatedText": "IEC",
            "expandedText": "Independent ethics committee",
            "instanceType": "Abbreviation"
          },
          {
            "id": "61641f45-2aed-4af3-a54e-9545fda53ae8",
            "abbreviatedText": "IECs",
            "expandedText": "Independent Ethics Committee",
            "instanceType": "Abbreviation"
          },
          {
            "id": "4f3cfe3b-4b53-480b-840d-c0d2c259b397",
            "abbreviatedText": "IOI",
            "expandedText": "Intraocular inflammation",
            "instanceType": "Abbreviation"
          },
          {
            "id": "dce854dc-7811-4940-92e2-ffc44d793c7c",
            "abbreviatedText": "IOP",
            "expandedText": "Intraocular pressure",
            "instanceType": "Abbreviation"
          },
          {
            "id": "2fb20237-496e-4ba4-b9a7-acf38dc96d18",
            "abbreviatedText": "IRB",
            "expandedText": "Institutional review board",
            "instanceType": "Abbreviation"
          },
          {
            "id": "8f987d66-42fd-478f-9433-9531f158e070",
            "abbreviatedText": "IRBs",
            "expandedText": "Institutional Review Board",
            "instanceType": "Abbreviation"
          },
          {
            "id": "bdbe597d-f322-46ec-8d19-9081e850492c",
            "abbreviatedText": "IRT",
            "expandedText": "Interactive response technology",
            "instanceType": "Abbreviation"
          },
          {
            "id": "2ca97eba-f3a1-4280-9324-37fa293847b5",
            "abbreviatedText": "IVT",
            "expandedText": "Intravitreal",
            "instanceType": "Abbreviation"
          },
          {
            "id": "20bc664c-bbb6-4667-8217-ed015ac01815",
            "abbreviatedText": "LOCF",
            "expandedText": "Last observation carried forward",
            "instanceType": "Abbreviation"
          },
          {
            "id": "47df40ba-701d-43ee-ad93-fe83c2e74548",
            "abbreviatedText": "LPLV",
            "expandedText": "Last Patient Last Visit",
            "instanceType": "Abbreviation"
          },
          {
            "id": "ed949344-57e0-4d63-89c1-523f33f7e172",
            "abbreviatedText": "MedDRA",
            "expandedText": "Medical dictionary for regulatory activities",
            "instanceType": "Abbreviation"
          },
          {
            "id": "3e822952-70e8-482a-9cb5-b0bd51159340",
            "abbreviatedText": "mg",
            "expandedText": "milligram(s)",
            "instanceType": "Abbreviation"
          },
          {
            "id": "2de45ebe-4422-4cba-8610-3e4ee36822a7",
            "abbreviatedText": "mL",
            "expandedText": "milliliter(s)",
            "instanceType": "Abbreviation"
          },
          {
            "id": "2649c6b7-860b-4c45-8195-b14b684587f7",
            "abbreviatedText": "PDR",
            "expandedText": "proliferative diabetic retinopathy",
            "instanceType": "Abbreviation"
          },
          {
            "id": "1bc4fdc5-9161-4cdc-b684-75b01b69e70e",
            "abbreviatedText": "PRP",
            "expandedText": "panretinal photocoagulation laser",
            "instanceType": "Abbreviation"
          },
          {
            "id": "a97d5a63-74c2-413a-a57b-f307cb8f1f3b",
            "abbreviatedText": "RO",
            "expandedText": "retinal vascular occlusion",
            "instanceType": "Abbreviation"
          },
          {
            "id": "481598f4-c467-48fe-ba68-993eadcd2b62",
            "abbreviatedText": "RV",
            "expandedText": "retinal vasculitis",
            "instanceType": "Abbreviation"
          },
          {
            "id": "b6e07962-df8c-4f50-9ae1-4144a275e8c2",
            "abbreviatedText": "SAE",
            "expandedText": "Serious Adverse Event",
            "instanceType": "Abbreviation"
          },
          {
            "id": "961a8214-5312-4fe6-9ef6-6d6bf0c2cd9c",
            "abbreviatedText": "USM",
            "expandedText": "Urgent Safety Measures",
            "instanceType": "Abbreviation"
          },
          {
            "id": "5d7d1375-8043-40b7-a6fd-7c1cffe5a080",
            "abbreviatedText": "WoC",
            "expandedText": "Withdrawal of Consent",
            "instanceType": "Abbreviation"
          }
        ],
        "amendments": [
          {
            "id": "de51c45b-7066-4be3-bc4e-ab3be1c1ddcd",
            "number": "2",
            "name": "Amendment 2",
            "scope": {
              "id": "754d7c96-8599-473c-8eb4-7314edddea08",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "febc6ed4-6a07-4876-a8d6-b8a5b1eca3d0",
              "code": {
                "id": "8c7d6aca-8055-4100-8dc0-09a00b7d0c92",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "9badff4e-5572-4db9-837f-ab57786fa4e6",
                "type": {
                  "id": "8b551b1b-4a0b-4d7f-89a3-fb6d683ad0a9",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "The main purpose of this amendment is to implement the Urgent Safety Measures (USM) described in the 10-Aug-2021 Dear Investigator Letter (DIL) into the study protocol. The USM were implemented in response to the identification of a causal immune-mediated mechanism of the previously identified risk of retinal vasculitis (RV), and/or retinal vascular occlusion (RO), typically in the presence of intraocular inflammation (IOI) indicating a requirement to discontinue treatment in patients who develop events of RV and/or RO. This amendment also includes information on gender imbalance on IOI following brolucizumab treatment and recommendations on the time window for a study subject to receive the COVID-19 vaccine or vitrectomy.",
            "effectiveDate": "2021-09-28",
            "reasonIds": [
              "bdf11661-ba3d-45c8-bc96-89dccb508a53",
              "2f66d951-2b97-4ba4-b423-2bde641f3c2c",
              "a98bcc40-b979-4c76-85bc-52503e60300d"
            ],
            "previousVersion": "01",
            "newVersion": "02"
          },
          {
            "id": "0fe1166f-10fe-429e-bc1d-c7faca22a50e",
            "number": "1",
            "name": "Amendment 1",
            "scope": {
              "id": "ceecac60-3dc6-4480-b8a5-c5a6fa11083e",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "a237c391-ab4a-4329-83cb-cef5b50cb2ed",
              "code": {
                "id": "edaeca73-bd5f-4028-99f4-a175cedb4d82",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "3ecf496f-292a-401d-8b1c-1e5cd8f9dc0a",
                "type": {
                  "id": "3ac69331-694a-456d-ab2b-31f1a4e78516",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "The main purpose of this amendment is to provide clarification and guidance on safety assessments in accordance to the urgent safety measure regarding the post-marketing reports with brolucizumab (BeovuÂ®) in the treatment of nAMD, which were identified as retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, that may result in severe vision loss. In addition, the amendment includes the modifications due to COVID-19 pandemic.",
            "effectiveDate": "2020-06-05",
            "reasonIds": [
              "ea97e242-6ea6-40a0-9d2b-6c08e0ad2acd",
              "6ee93b6d-b969-47b0-a3b8-612b4eec806f",
              "e7c0a6fd-533c-4ef7-95ea-0b0ab6dfe82e"
            ],
            "previousVersion": "Original Protocol",
            "newVersion": "01"
          }
        ],
        "medicalDevices": [
          {
            "id": "160000ee-9951-425b-9c04-7ed0245241f3",
            "name": "Prefilled Syringe",
            "instanceType": "MedicalDevice",
            "label": "PFS",
            "description": "Single-use syringe containing brolucizumab for intravitreal injection",
            "deviceType": {
              "id": "b826f6b1-5edc-445b-8996-019940a92b37",
              "code": "Drug Delivery Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Drug Delivery Device",
              "instanceType": "Code"
            },
            "manufacturer": "Novartis"
          },
          {
            "id": "2d8bc9d0-489a-40ec-9a6a-685c028fd934",
            "name": "Glass vial",
            "instanceType": "MedicalDevice",
            "label": "Vial",
            "description": "Single-use, sterile glass vial for drug delivery",
            "deviceType": {
              "id": "9e5a4256-067a-4db8-9038-c8008faef1d6",
              "code": "Drug Delivery Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Drug Delivery Device",
              "instanceType": "Code"
            },
            "manufacturer": "Novartis"
          },
          {
            "id": "3afe50af-e22a-4492-8a74-ca3ecb2dec3d",
            "name": "Conventional laser",
            "instanceType": "MedicalDevice",
            "label": "Laser",
            "description": "Laser system used for panretinal photocoagulation"
          },
          {
            "id": "663ce9f0-a1b8-4b69-8c9c-c4a5aa684068",
            "name": "Automated pattern delivery system",
            "instanceType": "MedicalDevice",
            "label": "Pattern Laser",
            "description": "Automated laser system for PRP procedure"
          },
          {
            "id": "4fda043b-4dff-4931-abe8-2110ec945c99",
            "name": "ETDRS-like chart",
            "instanceType": "MedicalDevice",
            "label": "Vision Chart",
            "description": "Standardized chart for assessing visual acuity",
            "deviceType": {
              "id": "82100e63-8f96-4225-a390-885a70fdb258",
              "code": "Diagnostic Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Diagnostic Device",
              "instanceType": "Code"
            }
          },
          {
            "id": "7af755de-6cba-4f3f-b91f-6a981bae69b6",
            "name": "Spectral domain optical coherence tomography",
            "instanceType": "MedicalDevice",
            "label": "SD-OCT Device",
            "description": "Imaging equipment for retinal assessment",
            "deviceType": {
              "id": "e4a95d9b-5562-4cfe-a077-75b516b2c4cb",
              "code": "Diagnostic Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Diagnostic Device",
              "instanceType": "Code"
            }
          }
        ],
        "conditions": [
          {
            "id": "08261dcf-d2ae-4165-af8a-05de45f83985",
            "name": "Uncontrolled Blood Pressure",
            "instanceType": "Condition",
            "description": "Exclusion based on hypertension",
            "text": "Systolic â‰¥ 180 mmHg or diastolic â‰¥ 100 mmHg"
          },
          {
            "id": "4f2bb310-e7e1-46dc-9ef4-20511764c2ce",
            "name": "Brolucizumab Maintenance Extension",
            "instanceType": "Condition",
            "description": "Criteria for extending treatment interval",
            "text": "After Week 48, interval may be extended by 6 weeks up to 24 weeks based on DR disease activity"
          },
          {
            "id": "ecb670b8-f490-4632-ad09-54ac237d9c6c",
            "name": "IOI Safety Risk",
            "instanceType": "Condition",
            "description": "Intraocular inflammation signs",
            "text": "If any sign of intraocular inflammation is present, an IVT injection must not be performed"
          }
        ],
        "studySites": [
          {
            "id": "2ffb81ef-bfb2-493e-9ad2-274b9c11e6df",
            "name": "Retina Associates SW",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "1",
            "organizationId": "56656b34-b618-4d0d-b6e0-3d49a001aca1",
            "country": "United States"
          },
          {
            "id": "d68d2bc7-09e8-41f8-bd20-a26da2fa0834",
            "name": "Retina-Vitreous Assoc Medical Group",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "2",
            "organizationId": "b6118ca2-1c1c-4d3c-88c5-ccae19001ad8",
            "country": "United States"
          },
          {
            "id": "aa50eff3-f4d6-409b-a2fc-1e0ce039e2fd",
            "name": "Retina Consultants of Orange County",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "3",
            "organizationId": "e4ac2ba9-7228-46e9-ba11-20674d5ad6d4",
            "country": "United States"
          },
          {
            "id": "099dbe5c-7dc9-44a0-839d-96476e969bad",
            "name": "Salehi Retina Institute",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "4",
            "organizationId": "cbef61c5-db95-4716-a507-28150ce0dc29",
            "country": "United States"
          },
          {
            "id": "922b1ecb-31d7-43d4-8020-ca4f06d6d713",
            "name": "Retina Consultants of Southern California",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "5",
            "organizationId": "7f37b583-bda1-41b2-96f6-2c2a4fd8c4d2",
            "country": "United States"
          },
          {
            "id": "51018147-a2e7-4203-9ccc-29cc4479a927",
            "name": "Premiere Practice Management LLC",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "6",
            "organizationId": "749d3a8a-7c09-46de-bd5a-9a0dd87f42a6",
            "country": "United States"
          },
          {
            "id": "8bfb5127-e09e-45ee-9e0f-1c048a005b8f",
            "name": "Lundquist Inst BioMed at Harbor",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "7",
            "organizationId": "670ec56c-7cac-432a-ba00-d7b191c35781",
            "country": "United States"
          },
          {
            "id": "0cc6ab77-5769-4df2-8fd0-0d9180a53ba8",
            "name": "Miramar Eye Specialists",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "8",
            "organizationId": "d3f01810-ebc2-4be1-9804-6b8d50a56e93",
            "country": "United States"
          },
          {
            "id": "1125d1f4-e82a-4da0-b62b-573eed359c1b",
            "name": "Advanced Research LLC",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "9",
            "organizationId": "81f24f69-a45b-40f4-b07e-86e910b42998",
            "country": "United States"
          },
          {
            "id": "4f4d5a2b-9865-47a2-adf0-cdb76aa30798",
            "name": "Rand Eye Institute",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "10",
            "organizationId": "facb677a-88c3-459c-9aa3-adf45d11073e",
            "country": "United States"
          },
          {
            "id": "b4e8b0b6-c1f9-4ac8-a801-2925132f9be1",
            "name": "Pinnacle Research Institute",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "11",
            "organizationId": "2e9297be-0ff9-4728-a167-f400613d3ca5",
            "country": "United States"
          },
          {
            "id": "9169e042-40f7-46f1-aba1-b791da15c9e9",
            "name": "National Ophthalmic Research Institute",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "12",
            "organizationId": "ff75a3c8-e9c5-4823-8d0a-7fb190d9ef0f",
            "country": "United States"
          },
          {
            "id": "e552d329-7198-48da-809a-56e12e927a79",
            "name": "Florida Retina Institute",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "13",
            "organizationId": "acd45b27-3ebb-4354-996c-a0d384352fbf",
            "country": "United States"
          },
          {
            "id": "4401dba9-1bb7-4edd-947c-3ec178e04a3a",
            "name": "Blue Oc Clin Res at Palm Bch Eye Ct",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "14",
            "organizationId": "25d06997-73b0-43ae-8274-6667f5310e4e",
            "country": "United States"
          },
          {
            "id": "dfc4b0b5-c039-4996-986d-b44ccc518547",
            "name": "MedEye Associates",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "15",
            "organizationId": "cf4dff4d-ea19-46d9-a3f7-a0d42cd6a677",
            "country": "United States"
          },
          {
            "id": "0ac37ac2-97fd-4de9-b552-d7bb9edfa2f1",
            "name": "Florida Retina Institute",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "16",
            "organizationId": "392ab664-ee8c-47b2-8713-73a18689e430",
            "country": "United States"
          },
          {
            "id": "1b781618-2815-47bb-b756-72d3e904ff83",
            "name": "Eye Center of North Florida",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "17",
            "organizationId": "f2cbdf49-a974-447b-b84f-83bc95969f86",
            "country": "United States"
          },
          {
            "id": "44c09859-5343-4fe7-a886-218ba7bc08a3",
            "name": "Fort Lauderdale Eye Institute",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "18",
            "organizationId": "a7fb4d5b-a264-4c25-804f-b5ac8bb98042",
            "country": "United States"
          },
          {
            "id": "e5bc6784-673c-47bb-990d-003a6769b970",
            "name": "Retina Associates",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "19",
            "organizationId": "a0d053ab-c809-4f6d-b85b-ef65eece7370",
            "country": "United States"
          },
          {
            "id": "8095f714-dbde-4eb5-ad81-f9a14c79bf5e",
            "name": "Midwest Eye Institute",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "20",
            "organizationId": "9f0c4af2-0cee-463e-a899-e58808cce4fe",
            "country": "United States"
          },
          {
            "id": "ec5a435f-a3fc-4328-8900-6f9143e0b77d",
            "name": "John-Kenyon American Eye Institute PC",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "21",
            "organizationId": "14087b92-8ac0-4cb3-915b-856b43448fb2",
            "country": "United States"
          },
          {
            "id": "af7e95ee-3348-4713-b894-008842448d06",
            "name": "Retina Associates PA",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "22",
            "organizationId": "9f2dc7a1-22bb-490b-9efc-655bc2f65caa",
            "country": "United States"
          },
          {
            "id": "a78097b2-c81c-4a0a-adf1-0d97ecc62f84",
            "name": "Cumberland Valley Retina Consultants",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "23",
            "organizationId": "b3d41b49-e342-4871-b6d3-1f02e02f202c",
            "country": "United States"
          },
          {
            "id": "87784b53-fd34-4da4-bf52-7d29f7f0494d",
            "name": "University of Mississippi Med Ctr",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "24",
            "organizationId": "53d265f6-7c22-485a-ac08-ca43bd7d49b8",
            "country": "United States"
          },
          {
            "id": "d7811e5c-a6e6-46f9-a857-9cad75228eaa",
            "name": "Retina Associates Of Cleveland",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "25",
            "organizationId": "093e521f-1c73-4e18-a201-a5a2580fb88b",
            "country": "United States"
          },
          {
            "id": "c4457495-8256-437f-be76-bde12e6b689d",
            "name": "Dean McGee Eye Institute",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "26",
            "organizationId": "88d9b6b7-f1a1-4ba5-a3ef-6daed158a0c4",
            "country": "United States"
          },
          {
            "id": "bc35feb0-a75c-47cb-be20-a880a594a2ed",
            "name": "Cascade Medical Research Institute",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "27",
            "organizationId": "46902002-77c3-4728-b13c-a9134590b205",
            "country": "United States"
          },
          {
            "id": "8448e895-81fa-4da2-8ec3-faae8bbfa5e2",
            "name": "Erie Retinal Surgery",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "28",
            "organizationId": "1d19ca99-7ff2-4231-8f64-1639d33aac44",
            "country": "United States"
          },
          {
            "id": "79ac35f1-0ea8-4269-b096-eff787567cd0",
            "name": "Charleston Neuroscience Institute",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "29",
            "organizationId": "d9c6f4a0-4ce8-4b91-9c3c-673b214ddb8d",
            "country": "United States"
          },
          {
            "id": "97b60537-3f85-4729-8098-72ddc8720c70",
            "name": "Southeastern Retina Associates P C",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "30",
            "organizationId": "85956e07-9950-4784-b20f-bb0b91dbe0ad",
            "country": "United States"
          },
          {
            "id": "a2035fce-eb98-406d-b973-8abdaedf53c0",
            "name": "Austin Retina Associates",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "31",
            "organizationId": "75550dab-98e5-45c0-96c2-61f9c4b45d97",
            "country": "United States"
          },
          {
            "id": "383031cb-6e93-430b-a35d-877c967f650f",
            "name": "Texan Eye P A",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "32",
            "organizationId": "7cc6c4c5-24ed-4f28-9e0d-fe093e758646",
            "country": "United States"
          },
          {
            "id": "38decfc9-fa77-4eb7-9071-2c8c664d0b1e",
            "name": "Retina And Vitreous Of Texas",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "33",
            "organizationId": "58fcff7d-49bc-4d2f-8196-32eaba91d5af",
            "country": "United States"
          },
          {
            "id": "8e6771b1-a980-4043-8398-9b2e25763324",
            "name": "Retina Consultants TX Rsrch Ctr",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "34",
            "organizationId": "b75c6bff-d5a1-422c-a888-635edb6c7631",
            "country": "United States"
          },
          {
            "id": "73615afb-424a-40ff-86d1-fc46535d21a0",
            "name": "Texas Retina Associates",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "35",
            "organizationId": "ede19e9e-24bf-4982-91d8-68a42cfd59f6",
            "country": "United States"
          },
          {
            "id": "4cd81b42-5116-4781-9161-f02666394e5e",
            "name": "Valley Retina Institute PA",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "36",
            "organizationId": "bdd79eca-403e-4ae0-a02c-6c4109d6f78e",
            "country": "United States"
          },
          {
            "id": "81fe278f-1546-44f7-9eb6-af366403af50",
            "name": "Retina Consultants of Houston PA",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "37",
            "organizationId": "d7fc6d68-bb3a-468d-babc-220a7010162b",
            "country": "United States"
          },
          {
            "id": "5a04b97a-877a-4b0c-b23c-2d6805dccf88",
            "name": "Medical Center Opthamology Assoc",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "38",
            "organizationId": "1af5d50e-2742-46bb-94d6-ec632aad767a",
            "country": "United States"
          },
          {
            "id": "7d180e6e-9551-42a0-bff3-33b5b0b9ddbc",
            "name": "Retina Associates Of South Texas PA",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "39",
            "organizationId": "9fc36ecb-c547-4deb-95a1-78eb3ca02012",
            "country": "United States"
          },
          {
            "id": "8a9a73ac-1e2a-42c8-a876-308ab42428f5",
            "name": "Virginia Eye Consultants",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "40",
            "organizationId": "4477bdb6-5968-4701-a581-c29fe3da621d",
            "country": "United States"
          },
          {
            "id": "332b19a5-d44e-4261-bc45-286931019628",
            "name": "Novartis Investigative Site",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "41",
            "organizationId": "708b4dcd-b8a1-4254-bf95-d42510612e59",
            "country": "Argentina"
          },
          {
            "id": "944d5c48-bdb9-4b33-808d-95823efb0324",
            "name": "Novartis Investigative Site",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "42",
            "organizationId": "ee7369db-ebf6-4f4c-a31e-3e6aa1ad6989",
            "country": "Argentina"
          },
          {
            "id": "55d59caa-5084-4d1a-ba5f-f57d8d15c27e",
            "name": "Novartis Investigative Site",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "43",
            "organizationId": "06404675-e8e2-46e1-98f6-1e0478e8a97e",
            "country": "Argentina"
          },
          {
            "id": "2a7cdc97-5db4-4515-ad5f-accb94075688",
            "name": "Novartis Investigative Site",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "44",
            "organizationId": "93697bf0-0bf5-4ab5-8cf6-02fb14a273b5",
            "country": "Australia"
          },
          {
            "id": "5662b1e9-4f45-4218-8b75-7e72c3e7de9a",
            "name": "Novartis Investigative Site",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "45",
            "organizationId": "a0e6ec16-e743-44f8-af0d-a579208ae7a8",
            "country": "Australia"
          },
          {
            "id": "83d71a09-9903-4f77-8afc-4aac8944221c",
            "name": "Novartis Investigative Site",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "46",
            "organizationId": "c4d43fc3-792f-40b4-a284-abaeae574ff6",
            "country": "Australia"
          },
          {
            "id": "5b120ddb-3866-44b3-9d08-fd7f3ac2da72",
            "name": "Novartis Investigative Site",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "47",
            "organizationId": "b5254ed0-5745-468f-8dc9-1a11ad7dc942",
            "country": "Australia"
          },
          {
            "id": "94f58770-5b03-4522-a5ed-61d7be3019b1",
            "name": "Novartis Investigative Site",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "48",
            "organizationId": "4a2c602d-37c8-43d8-a016-844fa988ae5c",
            "country": "Brazil"
          },
          {
            "id": "1e702579-24fa-43ef-9b8b-21604b396fe4",
            "name": "Novartis Investigative Site",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "49",
            "organizationId": "c748510a-0624-4b89-b971-ff3955acd9ea",
            "country": "Brazil"
          },
          {
            "id": "18fc5ed2-0f4d-4196-9281-531f017a645e",
            "name": "Novartis Investigative Site",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "50",
            "organizationId": "435093fd-6d59-4f8d-99b8-1fb025d64355",
            "country": "Brazil"
          }
        ],
        "administrations": [
          {
            "id": "10d4586c-5bbf-4781-9640-684573ddc68f",
            "name": "Administration of Brolucizumab",
            "description": "RouteOfAdministration.ORAL DosingFrequency.ONCE_DAILY",
            "instanceType": "Administration",
            "route": {
              "id": "4c3bddbe-79a0-4807-825b-72f9ef4dbe5f",
              "code": "C38288",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "2024-09-27",
              "decode": "Oral",
              "instanceType": "Code"
            }
          },
          {
            "id": "a06bc367-de0b-4344-8f49-7ea076221e6b",
            "name": "Administration of RTH258",
            "description": "RouteOfAdministration.ORAL DosingFrequency.ONCE_DAILY",
            "instanceType": "Administration",
            "route": {
              "id": "2a0f8447-d0aa-4c7b-a846-688d14d28225",
              "code": "C38288",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "2024-09-27",
              "decode": "Oral",
              "instanceType": "Code"
            }
          },
          {
            "id": "38d952f7-6fe1-48d1-be64-e7d42b810190",
            "name": "Administration of Brolucizumab (RTH258)",
            "description": "RouteOfAdministration.UNKNOWN DosingFrequency.EVERY_FOUR_WEEKS",
            "instanceType": "Administration",
            "route": {
              "id": "a5c62c3b-1816-41ab-925b-9e623ef0f031",
              "code": "C38288",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "2024-09-27",
              "decode": "",
              "instanceType": "Code"
            }
          },
          {
            "id": "3fbe1598-5c10-46df-a87f-2b8b51eeaeb7",
            "name": "Administration of Panretinal Photocoagulation (PRP) Laser",
            "description": "RouteOfAdministration.UNKNOWN DosingFrequency.SINGLE_DOSE",
            "instanceType": "Administration",
            "route": {
              "id": "2f939e70-539a-468e-a599-efd397aa5e5e",
              "code": "C38288",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "2024-09-27",
              "decode": "",
              "instanceType": "Code"
            }
          }
        ],
        "rationale": "Protocol version"
      }
    ],
    "name": "A 96-week, two-arm, randomized, single-masked, multi-center, phase III study assessing the efficacy and safety of brolucizumab 6 mg compared to panretinal photocoagulation laser in patients with proliferative diabetic retinopathy (CONDOR)"
  },
  "administrations": [
    {
      "id": "ff76b957-e15b-474d-acaa-9e66086feff0",
      "name": "Brolucizumab Loading Phase",
      "instanceType": "Administration",
      "dose": "6 mg",
      "doseFrequency": "Every 6 weeks (3 doses)",
      "route": {
        "id": "9f8f0c07-702d-4360-8c90-ecd45c80cdee",
        "code": "Other",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Other",
        "instanceType": "Code"
      },
      "duration": "Baseline, Week 6, and Week 12"
    },
    {
      "id": "8b34c842-91c1-42bb-be54-a0f01a41a216",
      "name": "Brolucizumab Maintenance Phase",
      "instanceType": "Administration",
      "dose": "6 mg",
      "doseFrequency": "Every 12 weeks",
      "route": {
        "id": "1c377171-2ed5-45d9-bd18-7d3f3498391d",
        "code": "Other",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Other",
        "instanceType": "Code"
      },
      "duration": "Week 18 through Week 90"
    },
    {
      "id": "209d6cfe-1e7b-4db8-8b98-09cbbf7bf331",
      "name": "Brolucizumab Extension Phase",
      "instanceType": "Administration",
      "dose": "6 mg",
      "doseFrequency": "Extended by 6-week increments up to every 24 weeks",
      "route": {
        "id": "53fb5090-2106-4b56-bbd6-525562fed749",
        "code": "Other",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Other",
        "instanceType": "Code"
      },
      "duration": "From Week 48 onwards based on disease stability"
    },
    {
      "id": "fd3511ef-ed17-438f-918f-1818ca79c036",
      "name": "PRP Initial Treatment",
      "instanceType": "Administration",
      "dose": "1500-5000 burns",
      "doseFrequency": "1 to 4 sessions",
      "route": {
        "id": "5a8c80df-456a-4633-a126-23b3cb8df517",
        "code": "Topical",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Topical",
        "instanceType": "Code"
      },
      "duration": "Up to Week 12"
    },
    {
      "id": "681ed88e-00b8-42a3-84fc-687f879e4576",
      "name": "PRP Maintenance (PRN)",
      "instanceType": "Administration",
      "dose": "As needed",
      "doseFrequency": "As needed (Pro re nata)",
      "route": {
        "id": "aafacf82-cbbe-4b2d-9413-5aef76358c6b",
        "code": "Topical",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Topical",
        "instanceType": "Code"
      },
      "duration": "From Week 18 to Week 90"
    }
  ],
  "substances": [
    {
      "id": "49168bae-0358-4d82-bc19-d4b22f9b5532",
      "name": "Brolucizumab",
      "instanceType": "Substance",
      "description": "Single-chain antibody fragment (scFv) inhibitor of vascular endothelial growth factor A (VEGF-A)"
    }
  ],
  "studyDefinitionDocument": {
    "id": "c0470807-9758-451a-9c07-91c7b132f8a0",
    "name": "A 96-week, two-arm, randomized, single-masked, multi-center, phase III study assessing the efficacy and safety of brolucizumab 6 mg compared to panretinal photocoagulation laser in patients with proliferative diabetic retinopathy (CONDOR)",
    "documentType": "Protocol",
    "language": "en",
    "instanceType": "StudyDefinitionDocument",
    "version": "02 (Clean)",
    "versionDate": "28-Sep-2021",
    "contentIds": [
      "611ea2f3-2e06-4218-add2-444599826182",
      "9e6e10b7-761c-4078-9579-68f8cbeb41ad",
      "476cf560-9bae-488c-8ddb-948f4ea85feb",
      "820da7ef-5f8c-44be-a98c-25d8f33ae801",
      "4ff56bbc-a234-4244-97e8-d42c7b20ea3d",
      "69df091a-f999-453b-ba3c-9470b3c72b68",
      "c0433993-9ad7-4edb-a95f-4fd0bec4420b",
      "60074cd9-4b80-4954-b3ad-8ce50b6211c6",
      "cc8b8f10-b337-4da7-962c-12c17a888455",
      "9c4dc78f-ae40-4d78-a857-060a9e45f866",
      "e64c6c3e-c2f5-4306-ae69-347dd4c3758b",
      "906a1bc2-cb09-4d5f-aec4-9747cf168fdd",
      "2abd357a-4c0a-4840-b815-269ddf5ff847"
    ]
  },
  "geographicScope": {
    "id": "d25f487f-ad94-4dca-9378-995486c92fe8",
    "name": "Study Geographic Scope",
    "scopeType": "Global",
    "instanceType": "GeographicScope"
  },
  "ingredients": [
    {
      "id": "3d4a4941-c2f7-473a-8792-c02e7d4979f0",
      "name": "Brolucizumab",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "RTH258"
    }
  ],
  "strengths": [
    {
      "id": "eee93311-900f-404e-89dc-7295285e94b0",
      "instanceType": "Strength",
      "value": 6,
      "unit": "mg",
      "numerator": {
        "value": 6,
        "unit": "mg"
      },
      "denominator": {
        "value": 0.05,
        "unit": "mL"
      }
    }
  ],
  "transitionRules": [
    {
      "id": "515a7478-5267-4a76-9ef9-55f445133448",
      "name": "Screening to Randomization",
      "instanceType": "TransitionRule",
      "transitionType": "Epoch Transition",
      "fromElementId": "23f15d87-c981-4e1d-9021-e7700076deb1",
      "toElementId": "d289d1f9-4543-4aaa-86a1-6fecaf0cf5ad",
      "text": "Confirmation of eligibility at Baseline/Day 1"
    },
    {
      "id": "0e00ff48-7722-4885-abd9-43456bf64af7",
      "name": "Discontinuation for RV/RO",
      "instanceType": "TransitionRule",
      "transitionType": "Discontinuation",
      "text": "Subject develops retinal vasculitis (RV) and/or retinal vascular occlusion (RO)"
    },
    {
      "id": "d3f76db7-107b-4462-98b2-0c233793376f",
      "name": "Dose Modification Restriction",
      "instanceType": "TransitionRule",
      "transitionType": "Dose Modification",
      "text": "No dose modification or deviation to dose intervals during loading phase allowed"
    }
  ],
  "documentContentReferences": [
    {
      "id": "f5e7d887-d0ad-401f-b1cf-645c5ccaf622",
      "name": "Rescreening Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "8.1",
      "sectionTitle": "Screening",
      "description": "Reference to screening procedures for subjects who were screen failures but are rescreened."
    },
    {
      "id": "cca7fbf4-39a7-473c-a392-d5f6f7bbdb98",
      "name": "Prohibited Treatment Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "6.2.2",
      "sectionTitle": "Prohibited medication",
      "description": "Cross-reference regarding the use of prohibited treatments and study discontinuation."
    },
    {
      "id": "07e1ec26-b8ee-4a03-9d56-247dac195f4a",
      "name": "Imaging Analysis Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "8.3.2",
      "sectionTitle": "Color fundus photography and fluorescein angiography",
      "description": "Reference to independent review of images at predefined time-points."
    },
    {
      "id": "8e68ece3-1ecc-42c5-8064-28ce286d0500",
      "name": "OCT Assessment Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "8.3.3",
      "sectionTitle": "Optical coherence tomography",
      "description": "Reference to independent review of SD-OCT images."
    },
    {
      "id": "9cd9e8c7-c740-4b61-99d1-690e41e521bf",
      "name": "IOI Safety Evaluation Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "8.4.5",
      "sectionTitle": "Ophthalmic examination",
      "description": "Reference for additional ophthalmic examination and imaging to evaluate intraocular inflammation."
    },
    {
      "id": "e3c21669-c01d-47d5-adc6-d903d9ec8434",
      "name": "Pregnancy Reporting Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "8.4.3",
      "sectionTitle": "Pregnancy",
      "description": "Reference to pregnancy reporting requirements."
    },
    {
      "id": "6b417c18-7245-40bf-b3f1-cd8baa420328",
      "name": "SAE Reporting Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "10.1.3",
      "sectionTitle": "SAE reporting",
      "description": "Reference for reporting details of serious adverse events during screening."
    },
    {
      "id": "cf16ca70-0a5d-42c0-9971-b3d63b44cc58",
      "name": "Table Reference - Assessment Schedule",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Table 8-1",
      "sectionTitle": "Assessment Schedule",
      "description": "Internal link to the list of all assessments and visit schedules."
    }
  ],
  "commentAnnotations": [
    {
      "id": "445c9655-9f6b-4a5e-aaeb-905f37dda292",
      "text": "Two consecutive injections should be at least 21 days apart.",
      "annotationType": "Note",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Visit schedule and assessments",
      "pageNumber": 38
    },
    {
      "id": "dd1dffe8-0038-4383-8c08-fd7eff101372",
      "text": "PRP performed as a day case hospitalization should not be recorded as a serious adverse event (SAE) despite hospitalization.",
      "annotationType": "Clarification",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Arm 2: PRP",
      "pageNumber": 36
    },
    {
      "id": "016fb074-f1e3-4a31-b082-8c09a7d93543",
      "text": "If any signs of intraocular inflammation are present, then an IVT injection must not be performed.",
      "annotationType": "Note",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Instruction for administering study treatment",
      "pageNumber": 36
    },
    {
      "id": "d605201c-3a1c-4f0f-a68a-36d26590eb13",
      "text": "It is recommended to receive the COVID-19 vaccine at least 7 days before or after the study treatment visit.",
      "annotationType": "Clarification",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Other treatment(s)",
      "pageNumber": 31
    }
  ],
  "studyDefinitionDocumentVersions": [
    {
      "id": "0e266c3f-8d89-40aa-bbdc-49bc20603206",
      "versionNumber": "02 (Clean)",
      "status": "Approved",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2021-09-28",
      "description": "Implementation of Urgent Safety Measures (USM) regarding retinal vasculitis and retinal vascular occlusion.",
      "amendmentNumber": "Amendment 2"
    },
    {
      "id": "53243eed-854f-4cab-a324-c9c911d2eb85",
      "versionNumber": "01",
      "status": "Approved",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2020-06-05",
      "description": "Clarification on safety assessments and modifications due to COVID-19 pandemic.",
      "amendmentNumber": "Amendment 1"
    }
  ],
  "studyAmendmentImpacts": [
    {
      "id": "b26ffa26-b249-4acd-9fa0-f39add209723",
      "amendmentId": "0fe1166f-10fe-429e-bc1d-c7faca22a50e",
      "affectedSection": "Section 6.7.2, 8.4.5, 9.1.1",
      "impactLevel": "Major",
      "instanceType": "StudyAmendmentImpact",
      "description": "Mandatory treatment discontinuation requirement for subjects developing retinal vasculitis (RV) and/or retinal vascular occlusion (RO)."
    },
    {
      "id": "37eff5c3-fa66-4dac-a670-817997ad9632",
      "amendmentId": "0fe1166f-10fe-429e-bc1d-c7faca22a50e",
      "affectedSection": "Section 6.2.1.1",
      "impactLevel": "Minor",
      "instanceType": "StudyAmendmentImpact",
      "description": "Added guidance for COVID-19 vaccination and vitrectomy timing."
    },
    {
      "id": "e324c0bb-c89b-4cba-9216-4f082e904df5",
      "amendmentId": "de51c45b-7066-4be3-bc4e-ab3be1c1ddcd",
      "affectedSection": "Section 6.7.2",
      "impactLevel": "Major",
      "instanceType": "StudyAmendmentImpact",
      "description": "Instruction to withhold IVT injection if any sign of intraocular inflammation (IOI) is present."
    },
    {
      "id": "928ec97b-fd85-4820-a15e-29bc2ab1350e",
      "amendmentId": "0fe1166f-10fe-429e-bc1d-c7faca22a50e",
      "affectedSection": "Section 8.4.3 - Pregnancy",
      "impactLevel": "Administrative",
      "instanceType": "StudyAmendmentImpact",
      "description": "Standardization of pregnancy testing across both study arms."
    }
  ],
  "studyAmendmentReasons": [
    {
      "id": "cfd01505-054a-459a-98ce-cf31e0547e21",
      "amendmentId": "0fe1166f-10fe-429e-bc1d-c7faca22a50e",
      "reasonText": "Implementation of Urgent Safety Measures (USM) following identification of causal immune-mediated mechanism for RV and RO.",
      "category": "Safety",
      "isPrimary": true,
      "instanceType": "StudyAmendmentReason"
    },
    {
      "id": "c469cadb-4a38-4d78-bb91-499b7739f804",
      "amendmentId": "0fe1166f-10fe-429e-bc1d-c7faca22a50e",
      "reasonText": "Address gender imbalance observations in IOI following brolucizumab treatment.",
      "category": "Scientific",
      "isPrimary": false,
      "instanceType": "StudyAmendmentReason"
    },
    {
      "id": "9473e9a3-0607-4485-a384-0896f9d7af95",
      "amendmentId": "de51c45b-7066-4be3-bc4e-ab3be1c1ddcd",
      "reasonText": "Modifications due to the COVID-19 pandemic and post-marketing safety reports of RV/RO in nAMD patients.",
      "category": "Operational",
      "isPrimary": true,
      "instanceType": "StudyAmendmentReason"
    }
  ],
  "studyChanges": [
    {
      "id": "368ad66d-01e9-4bb3-a775-fc83317652e0",
      "amendmentId": "0fe1166f-10fe-429e-bc1d-c7faca22a50e",
      "changeType": "Modification",
      "instanceType": "StudyChange",
      "sectionNumber": "9.1.1",
      "beforeText": "Not specified",
      "afterText": "Requirement of treatment discontinuation was added if subject developed RV and/or RO.",
      "summary": "Mandated treatment cessation for specific retinal safety events."
    },
    {
      "id": "f054dae2-9435-47ff-9c22-8043d6549b67",
      "amendmentId": "0fe1166f-10fe-429e-bc1d-c7faca22a50e",
      "changeType": "Addition",
      "instanceType": "StudyChange",
      "sectionNumber": "6.2.1.1",
      "beforeText": "null",
      "afterText": "Recommendations on the time window for a study subject to receive the COVID-19 vaccine or vitrectomy.",
      "summary": "Added concomitant therapy guidance for vaccines and surgery."
    },
    {
      "id": "a36d7546-98d9-434d-8e87-fe7c44c1228e",
      "amendmentId": "de51c45b-7066-4be3-bc4e-ab3be1c1ddcd",
      "changeType": "Clarification",
      "instanceType": "StudyChange",
      "sectionNumber": "3",
      "beforeText": "Not specified",
      "afterText": "Window definition of the Baseline/Day 1 visit window and timing of EOS visit for early study discontinuation.",
      "summary": "Refined visit window definitions."
    },
    {
      "id": "c4c2e59d-d41e-4358-844d-57fb53f83de7",
      "amendmentId": "de51c45b-7066-4be3-bc4e-ab3be1c1ddcd",
      "changeType": "Modification",
      "instanceType": "StudyChange",
      "sectionNumber": "6.7.2",
      "beforeText": "Not specified",
      "afterText": "If any sign of intraocular inflammation is present, an IVT injection must not be performed.",
      "summary": "Safety-driven modification to injection administration rules."
    }
  ],
  "computationalExecution": {
    "ready": true,
    "supportedSystems": [
      "EDC",
      "ePRO",
      "CTMS",
      "RTSM"
    ],
    "validationStatus": "complete"
  }
}